

1 UNITED STATES NUCLEAR REGULATORY COMMISSION

2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

PUBLIC MEETING
ON MEDICAL ISSUES PAPER AND OTHER
REGULATION ISSUES

Sheraton Baltimore North Hotel
903 Dulaney Valley Road
Towson, Maryland

October 29, 1992
8:04 a.m.

ANN RILEY & ASSOCIATES, Ltd.
Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

9403230039 930617
PDR FDIA
R09E92-533 PDR

H.4

I N D E X

	AGENDA ITEM	PAGE NO.
1		
2		
3	Opening Remarks	3
4	Chairman Vandy Miller	
5	Presentation by Dr. Donald Cool	4
6	Presentation by Paul H. Lohaus	37
7	Presentation by Mark Haisfield	57
8	Medical Issues Paper	
9	Remarks by Larry Camper	62
10	Remarks by Dr. John Glenn	72
11	General Discussion	79
12	Closing Remarks	244
13	Chairman Vandy Miller	
14		
15		
16		
17		
18		
19		
20		
21		
22		
23		
24		
25		

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

P R O C E E D I N G S

1
2 CHAIRMAN MILLER: Good morning again. It seems
3 that I was just here a few minutes ago. But this is our
4 public meeting for today, and for the public I am Vandy
5 Miller, the Assistant Director for the Agreement State
6 Program in the Office of State Programs, U.S. Nuclear
7 Regulatory Commission.

8 Now, today, our public meeting will probably last
9 all day. What we have managed to do initially is to include
10 the regulations that we want very early, early input into
11 initially, and there will be several of them being discussed
12 here this morning.

13 Then, about mid-morning we will have a break and
14 then finish up on the regulations, and then the rest of the
15 day will be spent on a special session lasting several
16 hours, and will be devoted to the upcoming medical issues.
17 We have several staff members from the U.S. Nuclear
18 Regulatory Commission who are sitting out in the audience
19 right now who will be handling that portion.

20 Now last evening, just before we ended up, I made
21 a mistake in that I did not recognize -- well, I will take
22 care of that later. Let's go on with the public meeting.

23 Now, we are going to have Dr. Donald Cool who
24 spoke to you yesterday to come up, and he will take care of
25 the first four items listed on your handout: one, 10 CFR

ANN RILEY & ASSOCIATES, Ltd.
Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 Part 20 clarification; two, 10 CFR Part 34 radiography;
2 three, PRM 20 CFR Part 20 and 35, releases of patients; and
3 four, 10 CFR Part 30, 40, and 70, timeliness of
4 decommissioning.

5 After he finishes with those four, then we will
6 call on Paul Lohaus, but first, let's hear from Dr. Donald
7 Cool from the Office of Research.

8 DR. COOL: I wanted to spend just a few moments
9 this morning to review where we are on several rule makings
10 which have been of interest to you before, a couple of
11 rulemakings which are very new and to get your early input
12 on those.

13 As in times past, this is an opportunity for us to
14 tell you some idea of what is going on and simultaneously to
15 get your input with regard to the directions, comments that
16 you may have.

17 As I go through each one of them, I will talk
18 about the status of where the rulemaking is, where we are in
19 that process, and what time constraints I may have in terms
20 of getting input from you after this meeting.

21 You can go ahead and put on the next slide.

22 The first of the rulemakings deals with 10 CFR
23 Part 20, and in particular some clarifications of
24 requirements.

25 You are probably saying why in the world would Don

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 Cool be standing up here talking about a rulemaking on Part
2 20, that ought to be the last thing that Don Cool ought to
3 be considering, given that the revision of Part 20 is not
4 even mandatory yet, that most of you have not yet had an
5 opportunity to put it into your state regulations, that the
6 SSR really isn't finished up yet, and all those other
7 things.

8 Well, there are a couple of reasons why craziness
9 dictates that we might look at a couple of items. As we
10 have gone around, developed the Regulatory Guides, done
11 training sessions, held meetings like this all across the
12 country in a w'de variety of settings, we have been asking
13 people to give us input on how they perceive the Rule is
14 going to work.

15 We have been trying to sort out exactly how it is
16 going to be implemented, and there have been questions that
17 have been raised. There have been situations that over the
18 course of time it has been clear to us that despite all of
19 our best efforts, some things maybe weren't as crystal clear
20 and golden as you might otherwise want them to be, that when
21 the reality of how it is going to work meets the little
22 printed letters in the Federal Register, that there were
23 some discrepancies.

24 Furthermore, just a couple of weeks ago, the
25 Nuclear Regulatory Commission published a Policy on

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 Metrication, and I am going to deal with how that may impact
2 Part 20 in just a minute.

3 The next slide.

4 The staff is at this moment considering -- and I
5 say considering, it has not been initiated, it has not been
6 an approved rulemaking activity by our executive director --
7 but we are considering whether or not to try and do a
8 limited rulemaking, purpose to have a proposed rule on the
9 street early in 1993, final by January 1, 1994, for obvious
10 reasons, to correspond to the implementation date for the
11 revised Part 20.

12 If we did such a thing, the changes would be only
13 to those sections where there is sufficient rationale --
14 meaning there is sufficient unclarity, confusion, or
15 otherwise to warrant trying to go in and surgically fix it. I
16 am not talking about opening up a wholesale Part 20
17 bandwagon for you all to come and give me whatever you don't
18 like. I know everybody has got their own favorite list of
19 things that they would like to change in Part 20, and the
20 list, if I had it on a computer paper and dropped it, it
21 would crash to the floor and just sort of pile up there,
22 because it is a very long list, everybody has got their own
23 pet things they would like to do.

24 I have my own list of pet things that I would like
25 to do. We are not talking about that. We are talking about

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 one, two, three, four particular items which, in order for
2 this to really work well, an amendment to the regulation to
3 improve the clarity, to improve the preciseness of what we
4 are talking about, to eliminate questions would be useful.

5 This is the first step in trying to solicit
6 Agreement State input into the process. It will not be the
7 only step. We are looking at the potential of trying to get
8 back together with you folks in another few months when we
9 have gotten some idea of what we really want to do and have
10 some proposals to talk about.

11 The other thing that I clearly recognize is that
12 you are in the process at this moment of trying to put
13 together your implementing state regs and that you have to
14 do that by January 1, 1994, so one of the other things that
15 the Office of Research will be developing the standard plan
16 to do is to work with the State Programs people and you
17 folks to try and come to some mechanism whereby if it looks
18 like we really are going to go in and try to correct or
19 clarify some requirements, that we have some sort of
20 mechanism to try and build that into your process of putting
21 your state regulations into place on the first pass.

22 I know that there is an incredible difficulty
23 every time the NRC goes in and changes something just about
24 the time you have managed to get it in the regulation and
25 you have to go back through the process again.

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 I don't know exactly how that will work, but that
2 is one of our goals, is to try and see if we can't help you
3 to integrate some of those in, perhaps by allowing some
4 flexibility on those particular items as we go through the
5 first pass or some other mechanism to try and get them in.

6 The next slide.

7 What are the sorts of things we are talking about?
8 This is one list. Maybe it is the right list, maybe it is
9 the wrong list.

10 The first one, and the one that has sort of caused
11 the most confusion, is the definition and use of a little
12 term called "Controlled Area" that came into the revised
13 Part 20.

14 This being an election year, my friends from
15 Illinois have gone on the campaign trail. They have
16 produced some buttons, which they gave me an honorary one.

17 Lloyd, why don't you put up that other one, just
18 so everybody knows what this thing says. Okay. Take it
19 back off.

20 [Laughter.]

21 DR. COOL: The question is whether or not to have
22 that term, and if so, how it should be used. The Commission
23 had originally put "Controlled Area" in to recognize the
24 fact that a lot of licensees have areas that they control
25 for some reason, not radiological, but they have got it

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 there because they want physical security in some cases,
2 because they just don't want people wandering around, or
3 whatever it happens to be.

4 Questions have arisen in times past, back in
5 history with the other Part 20, which had only "Restricted
6 Area" or "Unrestricted Areas." Licensees said, well, what
7 do I about this place, I am controlling it, what applies.

8 So, in the infinite wisdom we thought, well, okay,
9 we will call that a controlled area and we will try to make
10 it clear what works and doesn't work there.

11 Well, now we get the flip side. What is this
12 controlled area, what do I do with it, what applies? So,
13 the same sort of questions have been coming back from the
14 other side.

15 So, one of the items that we particularly believe
16 may need a re-look is whether or not we continue to use the
17 term and exactly how it should be applied.

18 Another one is where do the occupational dose
19 limits apply, where do the public dose limits apply. In
20 particular, we have had a lot of people who are very upset
21 at the prospect that if you have a member of the public walk
22 into a restricted area, under the regulation they would be
23 subject to occupational doses. That is the way it is
24 defined.

25 I don't think anybody in their right mind would

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 actually allow the school kids or the teachers association
2 who are going through their local facility on the tour for
3 the next hour to get anything measurable, let alone anything
4 close to the public dose limit, let alone anything close to
5 the occupational dose limit, but that is what the rule
6 provides at this time.

7 So, that has raised some serious questions and
8 hence, it is on our list as a potential thing to consider.

9 Another one: what is meant by dose from external
10 sources? That seems like it ought to be relatively simple,
11 but you would be amazed at the number of questions we have
12 got as what is that 50 millirems sitting in there.

13 The next slide.

14 Another one that we have gotten an amazing number
15 of questions on is at what point licensees can disregard
16 some radionuclides that are in a mixture of radioactive
17 materials in the air. 1204(g) has some words about that,
18 and there has continued to be some confusion. That one is a
19 little bit low on the priority list and may or may not need
20 to be fixed.

21 The last one deals with the use of SI units. Now,
22 some of you probably are shrinking in your seat at the
23 thought that you might have to use sieverts and becquerels,
24 but the Commission did publish a policy statement on October
25 7th in response to the Omnibus Trade bill of a couple of

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters

1612 K. Street, N.W., Suite 300

Washington, D. C. 20006

(202) 293-3950

1 years ago where federal agencies are supposed to do what
2 they can do to encourage the use of metric units to foster
3 international trade, and those sorts of things.

4 In response to that, the Commission's policy
5 statement says that things that the Commission publishes are
6 going to be in dual dimensions, with the SI units first,
7 sieverts, becquerels, and grays -- as much as you may not
8 like them -- followed by the special units, rads, rems,
9 curies.

10 It says that those things are going to be in place
11 on all future documents, that the Commission is going to go
12 back and look at existing documents to determine whether
13 changes are needed.

14 The one area that it would not apply to would be
15 areas involving event reporting and emergency response
16 communications. It was that exact reason, the emergency
17 response communications, that Part 20, when it came out in
18 final form, did not have a provision that would allow
19 licensees to use SI units.

20 You will remember perhaps that the revision was
21 dual dimensioned. We had special units first, SI in
22 parentheses, but they are both in there. But the rule in
23 2102 says you have to use the special units on records and
24 reports. So, effectively, you can only use rad, rem,
25 curies.

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 That was because of the great concern what if
2 somebody has something go wrong, and they report to the NRC,
3 and they report to the state, and they report to the local
4 authority, and something is happening, and they go one. One
5 what?

6 Well, one sievert would be one thing, and that
7 would be very bad. One millisievert would be something
8 different, that wouldn't be quite so bad. One rem, that
9 would be yet something different. One millirem would be
10 something a whole lot different yet.

11 So, there would be a great confusion if people
12 weren't being consistent in what they used, the State folks,
13 particularly the local authorities, of the concept of a
14 sievert or a millisievert or a microsievert or a
15 millicentisievert or one of those terms, totally confusing.
16 So, we wanted to limit the aggravation that that would cause
17 and stay with the special unit that everyone was used
18 to. The proposal that is being considered as part of this
19 revision would be to go back and to add some flexibility to
20 allow licensees to use the SI units or the special units, so
21 long as they were consistent. Don't give me microcuries and
22 sieverts on the same report.

23 I mean you are either going to be SI or you are
24 going to be special units with the exception that anything
25 that is reported related to events or emergency response

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 would have to be in the special units.

2 One of the considerations is that if you are going
3 to use SI, you have to have the special units in parentheses
4 behind it. So, those are the sorts of things that we are
5 particularly thinking about.

6 I am going to stop at that point just for a moment
7 as I work my way through these rulemakings to allow for any
8 questions on that particular topic before I move on to the
9 next one.

10 [No response.]

11 Next slide.

12 DR. COOL: Part 34. We have talked to you, at
13 least a couple of times I think, on doing a revision of Part
14 34. In fact, some folks from the Office of Nuclear Material
15 Safety and Safeguards were talking to you the other day
16 about a particular aspect of Part 34 dealing with
17 certification.

18 This rulemaking activity is a broader rulemaking
19 activity, to go back and look at the entire rule,
20 contemplating a revision. There are a couple of things that
21 are new on the status line here.

22 The first is last week we received a petition from
23 the International Union of Operating Engineers saying we
24 would like you to amend Part 34 to require two-man crews and
25 we are going to wrap the response to that petition into this

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 rulemaking revision. That was one of the issues that was
2 already very clearly on the table.

3 The second, for those of you who have not already
4 made your reservations, and Vandy has not already sent the
5 checks, there is a workshop scheduled the 16th and 18th of
6 this next month.

7 Notifications went out on that quite awhile ago,
8 to spend a couple days and talk particularly about the
9 issue, about the approaches that are going to be taken,
10 about how this might look and to get a more detailed input
11 during that session.

12 If I could have the next slide. All I am going to
13 do is give you a couple of really quick highlights.

14 The revision would be to attempt to bring Part 34
15 back up to speed, pull in the good stuff that the Agreement
16 States have put in, long since NRC's rule just sort of sat
17 there, some things the Canadians and other folks have done,
18 to try and change the rule in that process, so that we are
19 more consistent with things like Part 20, which have been
20 revised since that time, and, as a basis for that, to
21 consider the format and arrangement of the current 10 CFR
22 Part 39 as the basis for that revision.

23 One of the things that we looked at as we started
24 to go through 34, and we struggled with it and we looked at
25 this long list that you folks have given us about all these

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 things you would really like to fix, we looked at all that
2 and we said, you know, this really doesn't work very well in
3 this format, how can we do this.

4 We sort of looked around a little bit, and
5 somebody said, well, you know, a couple of these things
6 relate to Part 39. So, somebody went off and looked at Part
7 39.

8 The more we got looking at Part 39 and the
9 structure of that rule -- which is a lot more recent -- the
10 more it appeared to us that going with the format and
11 arrangement organization items that were in Part 39,
12 modified, so that they are for radiography, not for well
13 logging, would deal with, and it looks to be something on
14 the order of 90 percent or more of the items that people had
15 given us as ideas of things that needed to be fixed.

16 So, here is the heads-up, early warning of things
17 that we are going to talk about during that workshop in a
18 couple weeks. The staff is right now considering using the
19 Part 39 format as the basis and then taking the specific big
20 issues, like whether or not to use two-man crews, and to
21 hang it on that new framework as the basis for the revision
22 of the rule.

23 You can go ahead and put the next slide up. That
24 ends what I am going to say on Part 34.

25 Are there any questions on that before we go on?

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 MR. GODWIN: Godwin, Arizona.

2 Relative to the two-man crew, we would support
3 that. However, you might need to look at whether you want
4 to have that for a requirement in fixed operations. It is
5 probably real good for field operations, but for a fixed
6 facility it might not be quite as necessary.

7 DR. COOL: Thank you.

8 Anybody else?

9 [No response.]

10 DR. COOL: Under Parts 20 and 35, on the release
11 of patients, you may recall that the revision of Part 20
12 said that members of the public should have a dose limit or
13 shall now have a dose limit, Total Effective Dose Equivalent
14 not to exceed 1 millisievert, .1 of a rem.

15 It also had a provision to allow a licensee to
16 apply for approval up to 5 millisieverts under certain
17 specified conditions, program laid out, what they are going
18 to make sure things are allowed, limited time frames, the
19 variety of things that is in the rule.

20 Go ahead and have the next slide.

21 Part 35, as it currently exists, says that
22 licensees are not allowed to authorize the release of
23 patients from confinement until either the dose rate is less
24 than 5 millirem per hour or the in the patient is less than
25 30 millicuries.

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 Given those things we had several petitions for
2 rulemaking that were submitted over the last year or so.

3 Go ahead and put up the next slide.

4 Dr. Carol Marcus submitted a petition, which was
5 docketed as PRM-20-20, and the American College of Nuclear
6 Medicine submitted a couple of petitions. They actually
7 came in as part of the comment process on Dr. Marcus'
8 petition, docketed as PRM-35-10 and 35-10A.

9 If we can have the next slide.

10 PRM-20-20 requested that the NRC raise the dose
11 limit for members of the public for patients receiving
12 radiopharmaceuticals from 1 millisievert to 5 millisieverts,
13 and that we look at amending Part 35 to, one, retain the 30
14 millicuries for I-131, but otherwise allow the maximum
15 activity to vary around in accordance with the dose
16 calculation based on the NCRP Report 37.

17 If I could have the next slide.

18 The American College of Nuclear Medicine's
19 Petition 35-10 and 10-A asked us, first, to delete
20 35.75(a)(2), that is, delete 30 millicuries, just gone, and
21 furthermore, to allow an outpatient option instead of
22 mandating hospitalization.

23 They came in with an amended petition which
24 clarified it, did not really change the basic request, but
25 clarified it, saying we would like to have doses greater

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 than 30 millicuries in diagnostic types of activities, as
2 well as the therapies, and allow them to be released, and
3 getting a little more specific, we would like confinement to
4 be something like remaining in the hospital or a private
5 residence. Sort of an interesting concept.

6 The next slide.

7 There has been a lot of thinking. We had a
8 workshop with a lot of you folks that are here today from
9 the Agreement States in Atlanta, back in July. We spent a
10 whole afternoon talking about that.

11 Last week we spent several hours with our Advisory
12 Committee on Medical Uses of Isotopes. The proposal that
13 you see here reflects ACMUI. Now it is a week later and you
14 get your shot to comment on ACMUI and the medical community
15 thinks they might like.

16 Coming out of that meeting the proposal would
17 appear to be a two-pronged proposal. The second one, the
18 second bullet basically leaves in place what is there now.
19 It says, "Measured Dose Rates less than 5 millirem or
20 activity less than 30 millicuries," one or the other of
21 those.

22 Then, an "and" clause, go back up to the one above
23 it, that irrespective of either one of those, the Total
24 Effective Dose Equivalent to a maximum exposed individual,
25 less than 5 millisievert or 500 millirem.

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 To go along with that proposal would be to amend
2 Part 20.1301 to exclude the dose from patients that are
3 released under the provisions of Part 35 from the
4 requirements of the dose limit, so that the perception,
5 which was the driving force behind the petitions that if
6 patients were released in accordance with Part 35, the
7 licensee would nevertheless be in violation of Part 20 would
8 be removed.

9 The next slide.

10 This proposal would rely on a licensee calculation
11 of dose to the individual likely to receive the greatest
12 exposure, and would hopefully have built into it sufficient
13 flexibility to account for biological elimination, the fact
14 that the radionuclides decay -- a lot of the things in
15 nuclear medicine decay very rapidly, as a matter of fact --
16 the occupancy, all of those things that could affect the
17 actual dose to the individual, the significant other, wife,
18 spouse, kids, whatever that may be, when the patient is
19 released and goes back home, the basis behind that being
20 Part 20 already contained a provision that would allow you
21 to go to 500 on certain circumstances, so it is not a
22 different number.

23 That number was based on the fact that the
24 long-term dose rate ought not to exceed 100 millirem per
25 year, but variations above that were acceptable in short

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 circumstances.

2 Here, you have got certainly a justification. You
3 have got an individual who is not paying costs of staying in
4 the hospital, is with family receiving that care and comfort
5 which tends to be really beneficial for a patient's
6 well-being, mental if not physical, so it would rely on that
7 sort of calculation.

8 It would retain the two criterion that you had
9 already, the 5 millirem and the 30 millicuries, for the
10 practical ease of a nuclear medicine physician, knowing that
11 he was able to release the patient on the basis of a
12 measurement.

13 One of the things that the ACMUI came out very
14 strongly on was if I just have it be this total dose rate,
15 or I just use a dose rate 5 millirem or whatever it is,
16 suppose I have got a patient whose uptake is a little bit
17 different or who is thinner than the standard model, and so
18 I run my standard protocol and it's an outpatient I am all
19 ready to release, and I waive the meter, and whoops, now
20 what do I do.

21 So, the medical folks argued that it would help
22 them to retain those two criterion.

23 The third piece of that would be that the staff
24 would propose probably some type of Regulatory Guide which
25 would have some indication of some standard assumptions

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 which would be acceptable in terms of calculating the Total
2 Effective Dose Equivalent to a maximally exposed individual.

3 For example, we could live if you are assuming
4 occupancy, say, of a third or a quarter, some of those sorts
5 of things. Licensees would always have the ability to look
6 at the specifics of the case and do a specific calculation,
7 but once again, that would allow you to generate sort of a
8 standard set of numbers which would be relatively simple to
9 use in the Regulatory Guide sort of format, the use of a
10 Regulatory Guide rather than the rule in order to allow the
11 licensees to continue to have that flexibility associated
12 with the actual calculation.

13 That is where we are on that particular proposal.
14 I will stop and see if you want to give me any feedback on
15 that rule.

16 MS. MCBURNEY: Ruth McBurney, Texas.

17 In your current rule, and you have confinement for
18 medical care, is the intent of that hospitalized, and if so,
19 why can't you just use the word "hospitalized," or does that
20 mean in a clinical setting or what?

21 DR. COOL: Confinement -- and perhaps I am going
22 to let John Glenn or some one of those folks answer the
23 specific question -- the staff proposal at this point is not
24 to change with regard to confinement.

25 The problem that we had with the proposal that

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 came out was if you allow confinement or something like that
2 to mean someplace other than where you have control of the
3 individual, then you really don't have control of the
4 individual.

5 MS. MCBURNEY: That is correct.

6 DR. COOL: And that really didn't fit with the
7 ability to make this sort of calculation, know what sort of
8 doses were out there. So, the staff's proposal at this
9 point is not to change on that, hospitalization if they have
10 to be hospitalized. If you have got some sort of particular
11 clinic setting, where you have them in confinement and you
12 have them in control, that might or might not be acceptable
13 under the particular circumstances.

14 MS. MCBURNEY: But you still mean controlled, in a
15 controlled environment?

16 DR. COOL: A controlled environment where the
17 licensee still has a handle on what they are doing.

18 MS. MCBURNEY: That is correct. Thank you.

19 MR. KULIKOWSKI: Bob Kulikowski, New York City.

20 Just to follow up on what Ruth said, in our regs
21 we do say "confinement," however, we also have a provision
22 in our code that says it must be broadly interpreted.

23 We discussed this I think at the SR-6 committee
24 meeting back in May. We really bandied around whether
25 confinement indeed did mean hospitalization.

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 As far as our regs go, it would not mean solely
2 hospitalization. We could confine someone anyplace as long
3 as we were satisfied or the licensee could confine someone
4 as long as they were satisfied that the control was
5 maintained. It could be a private residence in some
6 circumstances.

7 I just had a second question. That was I think
8 also at the July meeting we talked about requesting NCRP to
9 update Report No. 37. Do you have any update on that, Don?

10 DR. COOL: Two contracts have been issued. One is
11 a relatively short-term grant to have NCRP provide us a
12 commentary, a relatively quick updating which we expect
13 within the year, hopefully next spring, and a second grant
14 which says NCRP, go back and look at it top to bottom,
15 inside-out, over the next two-year period to produce a
16 revised report.

17 Those two things are both now issued and NCRP
18 working on putting together the groups that are going to do
19 that.

20 Steve?

21 MR. COLLINS: Steve Collins from Illinois.

22 A personal conversation with the original author
23 of Part 35 indicated that Bob Kulikowski has the exact
24 interpretation that he intended when he put the word
25 "confinement" in the rule, that he did not intend it to be

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 limited to hospital, but as long as control was maintained,
2 wherever.

3 Also, I want to point out that the view you
4 expressed for the ACMUI was the majority view, but there was
5 a minority view that indicated we should get rid of the 30
6 millicuries -- I am sorry -- that you should keep the 30
7 millicuries, but that also you should allow even more than
8 that to the point of using strictly the basic statement in
9 NCRP-37, that said that as long as any individual would not
10 receive more than 500 millirem from the time of release
11 until total decay of the nuclide, as calculated at a meter
12 from that patient, that you could release, which in some
13 cases would allow up to even 80 millicuries even for Item
14 131.

15 MR. MERGES: Paul Merges from New York State.

16 There are other issues other than consideration of
17 the patient's needs when you talk about releasing a patient
18 at 30 millicuries. In this country, we have seen a
19 significant increase in instrumentation at the landfills and
20 resource recovery facilities, and we are seeing a
21 significant increase in the number of hits from people
22 discarding their diapers and what have you.

23 You need to look at other issues beyond just the
24 medical communities in the process of what you are going to
25 release, also, how that would impact the release of a

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 patient who passes away and is going to be cremated.

2 You do need to look at those issues before you
3 just decide on increasing that 30 millicurie level.

4 DR. COOL: I appreciate that. Thank you.

5 Any other questions or comments?

6 [No response.]

7 DR. COOL: If you do have thoughts afterwards -- I
8 know I tend to once I get away from the meeting to, oh, I
9 should have asked that question or that sort of thing -- in
10 the next week or two, if you want to send me specific
11 things, I think we can use them, but we are going to be
12 moving fairly rapidly at this point to try and put together
13 a proposal and get it out on the street.

14 One of our goals is to try and have this out, the
15 proposed rule, roughly the end of the year or very early
16 next year. Once again, the goal is to try and have this be
17 a final prior to the January 1, 1994 absolute implementation
18 date for Part 20 to avoid any potential difficulties with
19 regard to that implementation.

20 The last one that I am going to deal with is
21 timeliness of decommissioning. This gets back to what we
22 were talking about yesterday, decommissioning always comes
23 last. Here we go once again.

24 In this case, how long should it take for
25 timeliness to come last, and how long should licensees be

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 given in order to effectively clean up their site.

2 This is a rule which has been kicking around in
3 the staff for an untimely long time, a couple of years as a
4 matter of fact. The rule in its second incarnation
5 completed office concurrence just a week and a half or so
6 ago. The rule had been sent to the Commission back in
7 February of this year, the Commission had looked at it, sent
8 it back to the staff, basically approving it, but asking a
9 number of things to be done and for it to be resubmitted to
10 the Commission for approval prior to publication.

11 That is now in process. It has not yet gone to
12 the Commission. It has gone to our Executive Director for
13 Operations. I expect it to go back to the Commission very,
14 very shortly. In fact, it may make it to the Commission
15 within the next couple of days. I don't know about the
16 timing on that.

17 Once the Commission approves it and we get it
18 published in the Federal Register, a comment period, and
19 then onward to development of the final rule.

20 The next slide.

21 Applicability of the Proposal. I will emphasize
22 once again this is a proposal which the Commission has not
23 approved, so we are talking about things which are still
24 subject to change without notice, that it would apply to all
25 NCR licensees, that we are looking at a level 2 degree of

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 compatibility, something we think is important, but there is
2 no reason why you guys can't be more stringent if you folks
3 would like.

4 The Proposed Provisions. The first one, clarify
5 what license expiration means. This isn't so much tied to
6 timing, but rather some difficulties that we have had with
7 licensees in times past about when their licenses actually
8 expired and what it means if the Commission decides that
9 they are not going to renew the license, or some of those
10 sorts of things.

11 So, this is more a legal issue which is being
12 carried along by this rule, but there are some
13 clarifications to the expiration provisions.

14 A requirement for licensees to initiate the
15 decommissioning process -- put that in quotes if you would
16 like -- when notifying the Commission that it is ceasing its
17 principal activities, it is no longer doing things at the
18 entire site or in a particular building or outdoor area.

19 Now, the decommissioning process might be one of
20 two things. It might be get on with cleaning it up if you
21 have already got in place sufficient plans or if what you
22 need to do really doesn't change the sorts of provisions
23 that you need to live under, going ahead and doing that, or
24 the process may be start the preparation of the plan if
25 there are other procedures and activities which have to be

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 all planned out or if it is required by your license
2 condition or one of those sorts of things.

3 The timing would be established for two separate
4 things that I just mentioned. One, the end of the license,
5 where the licensee is no longer doing anything, or the
6 second one, what we are calling end of use, where you stop
7 doing things in some particular area. These are mostly the
8 very large sorts of facilities, sprawling buildings here and
9 there, where they are no longer going to use that particular
10 building on there.

11 That particular operation is no longer
12 economically feasible, viable, whatever it is, and we are
13 just not going to do that anymore. Well, if you are not
14 going to do it anymore, I believe you ought to go ahead and
15 get it cleaned up.

16 Another one is to try and provide some
17 clarification of an item which has been some source of
18 confusion, which is a description of the conditions of the
19 site when you submit the plan.

20 Logic tells you that if you are going to prepare a
21 plan to clean up your site, you have got to know what you
22 actually have on the site, where it is, how much of it you
23 have, and those sorts of things, but there has never really
24 been a requirement in the rule that says you have to know
25 what it is you have got before you start planning for it.

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 This is going to clarify that, at the same time
2 hopefully clarify that the final survey comes at the end.
3 So, those goes hand and hand as a pair of provisions which
4 hopefully will clarify the intent of that.

5 If I can have the next slide.

6 A couple of things related to Part 72, most of
7 which you are not directly influenced by, but for ISFSI'S
8 and some of those other facilities.

9 They already had some timing provisions in the
10 regulations. They were patterned more after the timing that
11 is in place for the reactors. Those will be changed with
12 this proposal or at least we are proposing to change them to
13 more model the pattern that is being used for the Part 30,
14 40, and 70's.

15 In particular, one of the things that is in this
16 proposal at this moment is for those licensees to tell us
17 two years before their expiration of their decision. Most
18 of the time the renewal provisions say that on such and such
19 a date you have to have submitted your request for a license
20 renewal.

21 This is sort of the other hand. If you aren't
22 going to renew it, we would like to know that, too, because
23 that means we need to start the process of cleaning it up,
24 so that when you actually get to the end of your license,
25 you will be able to release the license, it will be cleaned

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 up.

2 If I could have the next slide.

3 The specific provisions with regard to the timing,
4 a 24-month period allowed for cessation of the principal
5 activities, 24 months after the time you stop doing
6 something there to decide whether or not you are going to do
7 something again to allow businesses the opportunity in
8 varying economic cycles to decide if something really is or
9 is not viable, whether they are going to start it up again,
10 whether they are going to use it for some other purpose.

11 That allows the licensees flexibility, that the
12 day they stop something, they don't immediately have to do
13 things. A two-month period after that to provide for the
14 notification and the initiation of the decommissioning
15 process.

16 So, that means that from the time an activity
17 actually stopped in this building or at this site until the
18 time where something would have to be started, either the
19 formal preparation of the plan or the actual starting to
20 clean up would be 26 months.

21 There are provisions scattered all through the
22 proposal which would allow for extensions for good cause -
23 gee, I need a little longer to decide whether I am going to
24 use it or not, I need longer to prepare the plan because
25 this is really complex, I need really longer to clean it up

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 because I not in the compact and I haven't the foggiest idea
2 of where I am going to send the wastes or some of those
3 sorts of things.

4 A requirement for plans to be completed in 12
5 months if you have to prepare a plan, and finally, 18 months
6 to actually do the work. That assumes that most licensees
7 can probably complete the actual clean-up in 18 months. We
8 recognize that may not be right in all circumstances and
9 once again there are provisions built in to allow
10 alternative times for whatever reason.

11 If I can put up the last slide, just in sort of a
12 graphical form. These are little time lines with the dates
13 and months, where zero is when the activity stops at the
14 particular site. You can go 24 months before you have to
15 think about much of anything and a couple of months to tell
16 us, and then you have got one or two branches.

17 If you have to have a decommissioning plan, you
18 have got 12 months to prepare that, and then 18 months to
19 complete the work. If you didn't have to have a
20 decommissioning plan, then you have got the 18 months to
21 complete the work.

22 Now, the one thing that isn't on this time line, a
23 wonderful little variable in there, is called how long it
24 takes NRC or the state to act upon whatever request it was,
25 particularly things like decommissioning plans or approvals.

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 So, this sort of represents the licensee's time
2 blocks, but you can recognize that you can insert into there
3 variable times for the amount of time it takes the
4 regulatory agency to take action, and those would not be
5 charged to the licensee. It doesn't seem particularly fair
6 to say, licensee, you have got 18 months to clean up, but
7 oops, it took NRC a number of months to decide that your
8 plan was acceptable.

9 Are there comments or questions on the timeliness
10 provisions? That completes the discussion that I had
11 prepared.

12 MR. GODWIN: This is Godwin from Arizona again.

13 I believe that under your present provisions you
14 have, what, 60 days for bankruptcies, to be notified and all
15 of that kind of stuff, and I recognize that if one of your
16 licensees declares bankruptcy, you may have a problem with
17 this. The bankruptcy judge may not buy off on it.

18 Have you thought about any ways you can put either
19 in a rule or what approaches we could use if this concept
20 goes forward and deal with the bankruptcy? Although the
21 federal law requires them to take into consideration health
22 and safety, their interpretation of that is not always the
23 same as you and I may interpret it.

24 DR. COOL: Yes, that is very true. As I had
25 mentioned before, there are some things with regard to when

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 a license is expired. If you have got a circumstance like
2 that, the way this proposal would work, you don't have that
3 first 24 months, you are immediately into the process and
4 those timing provisions kick in.

5 Whether or not that will work in a particular
6 court case, we may have to wait and see what the lawyers say
7 about that.

8 MR. FLETCHER: Roland Fletcher, State of Maryland.

9 Speaking of interpretation, on page 22, when you
10 talk about, "Require those licensees that must prepare a
11 decommissioning plan to include a description of the
12 conditions of the site sufficient to evaluate the adequacy
13 of the plan," there are a lot of very conditional words in
14 there that I would interpret one way and a licensee might
15 interpret another way.

16 I would suggest that perhaps some specifics on
17 conditions that should be included in that plan might be
18 added as subparagraphs to that.

19 DR. COOL: I appreciate that input. We
20 deliberately wrote it in this form because this rule would
21 apply to an incredible variety of licensees, and what would
22 be an appropriate amount of information for a small licensee
23 who had sealed sources, and those sorts of things, would be
24 totally different from a large licensee, where there might
25 be ground water contamination and some of those sorts of

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 things.

2 So, we had perceived it difficult, although I am
3 always open to somebody giving me a new idea of how I could
4 get around this problem, how I could write a list and know
5 that I was right or know that I was wrong for a particular
6 set of licensees.

7 MS. ALLEN: Kathy Allen from Illinois.

8 I used to work for a licensee, and analogous to
9 this, we had a tank farm of chemicals. One process ended,
10 we actually stabilized the tank rather than decommission the
11 tank because of the expense involved. With the regulations
12 and things like that, it was easier just to stabilize that
13 particular tank a few years down the road than remove the
14 entire tank farm.

15 Would you be willing to accept just financial
16 reasons why they don't want to decommission a particular
17 area of their site, because I noticed in the handout it said
18 that the rulemaking is not expected to substantially affect
19 licensee costs?

20 There may be some circumstances where it would be
21 more expensive to decommission a particular area of a
22 facility rather than waiting and decommissioning the entire
23 facility at the same time, later down the road.

24 DR. COOL: I think that is certainly one of the
25 things the Commission would look at. These would be looked

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 at on a case-by-case basis, and certainly those sorts of
2 arguments would be an argument that you could put forward
3 and we would look at, yes.

4 MS. ALLEN: Someone yesterday had mentioned if
5 possible charge or repercussions for a facility that doesn't
6 decommission within the proper time frame, would possibly
7 require them to put money into a fund that would go towards
8 the decommissioning.

9 No one indicated whether or not they would be
10 allowed to reduce their surety amount by the amount that
11 they put into that fund.

12 DR. COOL: I can't answer that question. I really
13 don't know right now. What you are referring to in
14 yesterday's discussion as part of the Site Decommissioning
15 Management Plan, I would suspect that they would not because
16 if they were allowed to decrease it, it would not then be
17 any sort of penalty.

18 The thought that I believe Dr. Austin was talking
19 about was rather than them paying it to us and effectively
20 nothing getting done, trying to find financial mechanisms
21 where we are hitting the licensee, but we have the money in
22 a place where it can actually be used to do something about
23 the condition simultaneously.

24 I think there is still a lot of things there that
25 are going to have to be worked out as the staff continues to

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 move forward in experience with its sites on the Site
2 Decommissioning Management Plan, so that may yet have to be
3 worked out in court also.

4 MS. ALLEN: I just kind of think that some
5 licensees may have some problems. That is the whole reason
6 they put up their surety, and it is their facility, and they
7 feel that as long as there is no threat to public health and
8 safety, they may have a problem with this.

9 DR. COOL: Any other questions?

10 [No response.]

11 DR. COOL: If not, thank you very much.

12 CHAIRMAN MILLER: Let's give Don Cool a big hand.

13 [Applause.]

14 CHAIRMAN MILLER: I want to thank you, Don. By
15 the way, he did have a handout in the back, and the next
16 speaker, Paul Lohaus, does have a big handout back there, as
17 well, so if you didn't pick up one when you came in, you can
18 use this moment to do that.

19 Let me see if we have any members of the public
20 here today. Are there members of the public here today,
21 anybody? One, two. Well, you certainly can participate in
22 these proceedings. If you have a question, you may move to
23 the mike and ask it.

24 I also want to remind you now that Don did say to
25 you that if you don't have any comments today, if you think

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 of some after the meeting is over, just jot them down and
2 send them to Don Cool at Research of the Nuclear Regulatory
3 Commission as soon as possible. I am sure that holds true
4 for the other speakers to follow.

5 Now, we have the next three topics: Topic No. 5,
6 10 CFR Part 61, financial requirements for low-level waste
7 disposal; Item No. 6, 10 CFR Part 21, notification
8 requirements for defects in noncompliance; Item No. 7, 10
9 CFR Part 31, notification requests for generally license
10 devices.

11 The individual who is to come up and discuss those
12 with you is Paul Lohaus, who is on a rotation to Research at
13 the moment, and he is the Branch Chief of the Regulations
14 Development Branch of Research.

15 We will call on Paul Lohaus at this time.

16 MR. LOHAUS: Thank you very much, Vandy.

17 Given my long association with the Agreement
18 States, I am pleased to have an opportunity to meet with you
19 today and talk about three of our rulemaking actions.

20 Could I have the first viewgraph, Lloyd.

21 As Vandy mentioned, we would like to talk about
22 some changes that we are considering to Part 61 dealing with
23 the financial assurance requirements for the post-closure
24 institutional control period for low level waste facilities.

25 The second is Part 21 relating to reporting

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 defects in equipment by materials licensees.

2 The third relates to a final rulemaking action. I
3 want to talk to the status on where we are on the rulemaking
4 action dealing with the 31.5 generally licensed devices.

5 I asked the project managers within Research to
6 join me today, given the closeness of the meeting, and I
7 would like to introduce them. If there are specific
8 questions that you may have in the future, please feel free
9 to contact them on these rulemaking actions.

10 With respect to Part 61, let me introduce Brian
11 Rechter. Brian is project manager in the Regulations
12 Development Branch and has responsibility for Part 61.

13 Mark Au. Mark has responsibility for Part 21.
14 Joe Mate. Joe has responsibility for the Part 31 and 32
15 rulemaking action.

16 May I have the next viewgraph, please.

17 In looking at the Part 61 rulemaking action, as
18 you know, Part 61 does contain existing financial assurance
19 requirements. At the time we developed Part 61, we went as
20 far as we could in setting out a mechanism to try and ensure
21 that there would be an adequate base of funding to cover the
22 post-closure institutional control period.

23 We did not have a real hard statutory base for
24 that requirement, and when we developed the requirement it
25 was focused more on the lease or binding arrangement that

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 the operator might have with the landlord, and through that
2 mechanism try and ensure that there would be an adequate
3 base of funding.

4 With passage of Section 151 of the Nuclear Waste
5 Policy Act, NRC was given a much harder statutory basis to
6 establish a financial assurance requirement. So, in looking
7 at the intent of this rulemaking, it is really to meet the
8 statutory intent that we have within Section 151 and also to
9 strengthen the financial assuery requirements we have
10 within the existing rule to help provide a greater degree of
11 assurance that there will be funds to cover the monitoring
12 and surveillance and any requirement maintenance that is
13 going to be necessary during the institutional control
14 period.

15 Could I have the next slide, please.

16 Looking at the schedule, our next step in this
17 process is to prepare what we call an initiation package.
18 This basically lays out the concept for the rule, the draft
19 rule language, the bases, and goes forward to senior
20 management for review and approval to proceed.

21 We are looking to complete this package by the end
22 of November, and in addition to any discussion today, if
23 there are specific comments or specific points that you
24 think we should address, should cover in this rulemaking
25 action, it would be most helpful if we received them by the

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 end of November. That way we can focus and fold them into
2 the initiation package for the rulemaking.

3 That completes my comments on Part 61. Let me
4 stop at this point and see if there is any comments or
5 points of discussion on this rulemaking action.

6 MR. BAILEY: Ed Bailey from California.

7 One of the things I think that has at least caused
8 controversy and confusion and concern is that a state must
9 own the property while the waste is being deposited. At
10 least in California, that has been a major political issue.

11 If it could be clarified somehow that that waste
12 or the title to the land could transfer to the state after
13 close of operations, I think that would eliminate just one
14 of the issues that is often raised by the anti's regarding
15 the state accepting some unknown liability. That would
16 really help I think in some cases.

17 MR. LOHAUS: Thank you, Ed.

18 MS. DICUS: Greta Dicus representing the State of
19 Arkansas and also Chair of the Central Compact Commission.

20 I want to back up very strongly what Ed has said.
21 In fact, we may want to push for a change in that particular
22 part of Part 61.

23 MR. LOHAUS: Thank you, Greta.

24 MR. FRAZEE: Terry Frazee, State of Washington.

25 Just one point that our program manager wanted to

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 raise, and that was the parallel with the uranium mill
2 requirements where there is apparently a cap, an upper
3 limit, a financial limit. Ed is saying no?

4 MR. LOHAUS: Yes. There is for mills, yes.

5 MR. FRAZEE: Okay, for the mills. The point that
6 our program manager wants to make is don't put any kind of
7 financial lid on it, allow the states to require whatever
8 total surety they want to see.

9 One of the things that I think Gary Robertson
10 pointed out was that he would like to see included in the
11 post-closure funding enough money to actually replace the
12 entire cap in the event of a catastrophic failure of that
13 cover.

14 MR. LOHAUS: That latter point is an important
15 consideration in looking at the financial aspects and the
16 question of maintenance, how far do you go and what kinds of
17 contingencies should the applicant consider in looking at
18 establishing a fund and the kinds of activities, do you go
19 into contingencies, and if you do, what types of
20 contingencies.

21 You can get into a lot of different scenarios that
22 could occur, such as replacing the disposal unit cap or
23 taking other types of remedial action. I guess given the
24 focus of the requirements and given a lot of the focus on
25 design and operations, and the post-closure observation of

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 maintenance period, we would hope that we would not have the
2 situation develop.

3 You would have a high degree of confidence that
4 you wouldn't have to go in and take major types of remedial
5 action, but I think that is one of the issues that we will
6 need to address in looking at the question of how much money
7 should an applicant set aside.

8 Any other comments?

9 MR. MERGES: Paul Merges from New York State.

10 Third-party liability and financial assurance
11 specs. You need to closely at that and look specifically at
12 the issue of personal injury versus bodily injury in your
13 definitions and make sure your attorneys agree with what you
14 want to do with the regs there. Just an observation.

15 MR. LOHAUS: Thank you.

16 Okay. Let's move on to Part 21. This is a
17 rulemaking action that I really did not have a lot of
18 familiarity or understanding. It may be similar for some of
19 you, but in looking at Part 21, it was originally issued in
20 June of 1977 and was directed at implementing Section 206 of
21 the Energy Reorganization Act.

22 In looking at the intent here, it was really to
23 ensure that equipment defects, problems that would develop
24 both from the standpoint of a licensee or a vendor that
25 supplied equipment, that they would be evaluated and

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 reported to the NRC, such that their health and safety
2 significance could be assessed, and also, if it seemed to be
3 a generic issue, information could be provided to other
4 licensees and vendors to ensure that it was addressed.

5 So, the focus seemed to be primarily on power
6 reactor facilities, and the materials licensees, although
7 when you look at the scope of the rule, materials licensees
8 were encompassed within the scope of the rule, licensees
9 were not clear and it really wasn't entirely clear in the
10 staff in terms of the programs that were set up to deal with
11 Part 21, how Part 21 should apply to materials licensees.

12 The Office of the Inspector General did conduct an
13 audit in 1990 and looked at how the staff was implementing
14 the provisions of Part 21. One of the conclusions that was
15 reached was it is not clear whether Section 206 should apply
16 to materials licensees.

17 That recommendation really had two parts. One is
18 it asked that the Office of the General Counsel look at the
19 legislative history and look at Section 206 to see if there
20 was a clear statutory intent that it should apply to
21 materials licensees, and second, that based on that
22 determination and advice from counsel, that we proceed with
23 a rulemaking action to either eliminate materials licensees
24 from the scope of Part 21 or make it clear how Part 21
25 should apply to materials licensees.

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 Could I have the next slide, please.

2 What OGC determined is that Section 206 should
3 apply both to reactors, as well as materials licensees, and
4 the approach that staff is following in amending Part 21 is
5 to really divide licensees into two categories.

6 The first category would be those that would have
7 the capability and should have the knowledge to conduct
8 reviews of equipment defects and to file reports with the
9 NRC.

10 Licensees, all the major fuel cycle facilities,
11 waste disposal, larger irradiators, the medical therapy
12 device, radiography and spent fuel storage, those licensees
13 under the proposal would be required to develop and
14 implement procedures as a part of their license program to
15 evaluate any defects that they identify in equipment and
16 then to file reports with NRC.

17 Next viewgraph, please.

18 All other materials licensees would have the
19 option to either develop procedures that they would apply
20 within their program or they would have the option to notify
21 the manufacturer or distributor of the device who, in turn,
22 would be responsible for completing an evaluation and then
23 reporting that evaluation to the NRC.

24 Basically, what we are trying to do -- if we can
25 move on the next slide, please -- what we are trying to do

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 in terms of the rulemaking is to not only reduce the current
2 level of uncertainty relative to the application of Part 21
3 to materials licensees, as I mentioned, but also to try and
4 reduce the burden that would be faced by the smaller
5 licensees who may not have the same degree of capability to
6 conduct an evaluation and maybe properly place that burden
7 on the manufacturer and distributor, where they would have a
8 greater degree of knowledge and capability to do the
9 evaluation.

10 If I may have the next slide, please.

11 One of the questions that really seems to jump out
12 when you look at this -- again, I am not certain how many of
13 you are really familiar with this or may have reflected Part
14 21 in your programs -- but the question of compatibility and
15 the need for the states to adopt a similar requirement, I
16 think comes into focus very quickly.

17 That is one of the issues that we will be looking
18 at as a part of the rulemaking, as a part of the proposed
19 rule. We will ask for comments on that issue.

20 In terms of, say, the next steps that we have in
21 our process of preparation of the proposal rule, we are
22 targeting mid-November to have the proposed rule package
23 prepared and then to move that forward for management
24 concurrence.

25 So, within the next two weeks, if you have

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 specific views or thoughts relative to the question of
2 compatibility or the approach that we are planning to follow
3 in developing Part 21, we would very much appreciate
4 receiving that and give us a chance to factor that in at an
5 early time.

6 Let me stop at this point on Part 21 and ask if
7 there are any questions or comments.

8 MR. COLLINS: Steve Collins from Illinois.

9 What reasons did you have for putting radiography
10 licensees in the first option as opposed to the second since
11 a lot of these are very small companies where they obviously
12 wouldn't have the capability to do those evaluations on
13 their own, and which one of those options would well logging
14 licensees fit into?

15 MR. LOHAUS: Let me answer the first question.
16 Let me take back the question of well loggers, and we will
17 take that under discussion and see where they would fit. I
18 think given the fact that we have identified those specific
19 categories, Steve, I would say they would fall in the latter
20 category. They would be considered a small materials
21 licensee and would have the option to report to the
22 manufacturer/distributor.

23 You raise a good question relative to the
24 industrial radiographers. Probably the larger companies
25 should have capability to understand the equipment and

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 understand when there is a problem, take a look at it and do
2 an evaluation.

3 For your smaller operations, though, they may not
4 have the same degree of capability, and I guess the question
5 would be how would we maybe split those.

6 Do you feel there is a clear preference from your
7 standpoint of putting those into a category where they
8 should have the option of reporting or doing the evaluation
9 themselves as opposed to leaving them solely in the category
10 of do the evaluation?

11 MR. COLLINS: Yes.

12 MR. LOHAUS: Okay. Good point.

13 MR. GODWIN: Godwin, Arizona.

14 I would support Steve's comments relative to
15 radiographers. You might want to look at a division
16 relative to a small entity. That might be one way you could
17 look at that particular type division, if you wanted to
18 approach that, but I would raise the same question relative
19 to medical therapy device.

20 I suspect many of our smaller hospitals will also
21 be unable to really carry out what would be an efficient
22 investigation, particularly if you look at where some of
23 these teletherapy units are. We saw some problems one time
24 with a key, and nobody at the hospital had a metallurgical
25 expert. We didn't have one either.

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 MR. LOHAUS: Good point.

2 MR. GODWIN: This is the kind of thing you need to
3 look at. I would submit to you that you might want to
4 consider asking gauge manufacturers to be placed in this
5 first group, with the idea that the gauge user would be in
6 the second group, because there have been on occasion some
7 difficulties relative to gauges that have struck a cord of
8 interest.

9 MR. LOHAUS: Okay. Thank you.

10 MS. ALLEN: Kathy Allen from Illinois.

11 I would think that you would want most of the
12 manufacturers in the category one. There doesn't appear to
13 be any requirement that the manufacturers develop and
14 implement procedures for responding to the small entities.

15 How are we going to enforce the fact that these
16 manufacturers get comments or problems from the field, but
17 take two or three or four years to decide to investigate and
18 possibly implement procedures to prevent recurrence?

19 My second part of that is what do you do about
20 manufacturers from outside the country?

21 MR. LOHAUS: Very good points. On the first point
22 I may not have been entirely clear. There will be a
23 separate requirement as a part of the rulemaking that would
24 apply to the manufacturers and distributors, that they would
25 be responsible for completing the evaluation.

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 One other possible addition that we are
2 considering is that when the smaller materials licensee
3 would report to the manufacturer and distributor, that a
4 copy of that report should also go to NRC.

5 That would give us an opportunity to be aware that
6 there has been a defect identified and would provide an
7 opportunity to us to follow up with the manufacturer and
8 distributor if it did not appear that they were proceeding
9 to complete an evaluation.

10 With respect to manufacturers and distributors
11 outside the country, I don't have a clear answer for that,
12 but I will certainly take that issue back, take a look at
13 it, and see how we can address that as a part of the
14 rulemaking action.

15 MR. GODWIN: Godwin of Arizona again.

16 It occurred to me that maybe one other area that
17 may have some impact, but I am not sure, are you going to
18 look at auxiliary-supplied equipment and materials that may
19 affect the safety of the operations as part of this
20 reporting equipment?

21 For example, software associated with operation of
22 teletherapy units might be of some interest, electronic
23 equipment that turns equipment on and off may be of some
24 interest in gauging operations.

25 MR. LOHAUS: Good points. As I understand the

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 context of the rule, it does begin to move into areas such
2 as that, particularly in some cases the material vendor
3 suppliers or equipment suppliers, but that is a difficult
4 area because once you open that, how far do you go down into
5 the individuals that are involved up to the point where you
6 have a completed gauge or a completed device.

7 MS. ALDRICH: Rita Aldrich, New York State Health.

8 Since FDA regulates the manufacturers of medical
9 therapy devices, medical therapy devices seem to be the only
10 group among these that are already regulated by another
11 agency, isn't this either redundant or crossing regulatory
12 lines of authority with FDA? How does FDA feel about this,
13 are they involved in the rulemaking?

14 There is already a voluntary reporting program for
15 therapy device defects through the U.S. Pharmacopoeia. It
16 seems odd to have licensees use a voluntary program for the
17 agency that has regulatory jurisdiction over the devices
18 themselves and then impose a mandatory one under another
19 jurisdiction, which to me is not at all clear.

20 MR. LOHAUS: A very good point. We will take a
21 look at that and see what the relationship between FDA and
22 NRC should be in this area.

23 Are there other comments or questions?

24 [No response.]

25 MR. LOHAUS: The next viewgraph, please.

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 The final rulemaking action that I wanted to talk
2 about relates to changes to Parts 31 and 32. As you are
3 aware, the proposed rule was published in the Federal
4 Register December 27, 1991.

5 In principle, there is very good support for the
6 changes that are reflected here. I know that you very
7 actively participated in the development of this rulemaking
8 package.

9 I have included as a part of the handout three
10 viewgraphs at the end which go through the intent and the
11 major changes that are proposed in this rulemaking action.
12 I hadn't really planned to go through those in detail
13 because I think you are all familiar with that.

14 What I really wanted to focus on was really the
15 third bullet. We have the final rule prepared, and that is
16 moving forward in our concurrence process, and we will be
17 going to the Commission for their review and approval.

18 Relative to compatibility, the recommendation that
19 is likely to go forward from the staff in this area is that
20 this rulemaking action be a Division I matter of
21 compatibility. I think there is a number of obvious reasons
22 in looking at this.

23 Given the fact that there is need for some
24 consistency across the nation relative to the manufacturers
25 and distributors that are licensed both by NRC and the

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 Agreement States, the fact that this can help reduce some of
2 the burden that the manufacturers face in filing reports and
3 making sure that the general licensee gets a copy of the
4 general license, and also in helping ensure that the general
5 licensee has some clear guidance and clear instructions
6 relative to the requirements that they must follow under
7 their general license.

8 That is really the major point I wanted to make
9 here and make it clear that as this package is going
10 forward, it will likely contain a staff recommendation that
11 it be a Division I matter of compatibility.

12 That completes discussion on Part 31 and Part 32.
13 Any comments?

14 MR. GODWIN: Godwin of Arizona.

15 I have a question relative to which way you are
16 going relative to the final. I believe some comment was
17 made relative to not authorizing the general license to be
18 used on portable equipment and barges, and things like that,
19 that you all are making a decision relative to that,
20 particularly since you are asking for location as a part of
21 it.

22 MR. LOHAUS: That is a question I don't have a
23 clear answer on. Let me ask Joe Mate.

24 Joe, how will we handle that in the final package?

25 MR. MATE: Can I ask the gentleman to please

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 repeat the question, so that I understand it?

2 MR. GODWIN: There were some comments made at one
3 of these hearings relative to not allowing the general
4 license devices of this nature to be placed on portable
5 devices, such as barges or installment trucks, and things
6 like that.

7 I was wondering how you all finally handled it,
8 because there is still a requirement to report the location,
9 and if you report a location as a barge in Mobile Bay, it
10 suddenly may end up in California.

11 MR. MATE: I am trying to remember that portion,
12 and I don't believe that licensees would have the ability to
13 use it on portable mechanisms.

14 MR. BAILEY: Bailey from California.

15 That brings up the question of would you do away
16 with the existing general licenses for portable devices or
17 have you -- well, it gets rid of my other question, if that,
18 in fact, is true -- which was have you clarified the
19 requirements for reciprocity using GL devices.

20 Secondly, I would encourage that not all aspects
21 be a Division I item of compatibility since we intend to
22 have different reporting requirements for limit of size and
23 charge the manufacturer the registration fee rather than the
24 user, and we really don't think it makes any difference,
25 those kinds of aspects, on interstate commerce.

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 MR. LOHAUS: Thank you.

2 On the question of the location, I am not familiar
3 with the details on that. I am going to check and we will
4 give you a call and let you know how that is being handled.
5 I just don't recall.

6 MS. MCBURNEY: Ruth McBurney, Texas.

7 We had a discussion earlier in this meeting about
8 generally licensed devices, and I would also like to echo Ed
9 Bailey's last comment, in that there are several states that
10 are already or are intending to require some sort of
11 acknowledgement or registration of these devices in their
12 states, and the amount of information that these states may
13 require may vary.

14 So, please look at what parts of the rule might be
15 Division I compatibility, because some states may want to
16 require a little more information from those generally
17 licensed devices.

18 MR. LOHAUS: Okay. Thank you.

19 MS. HADEN: Robin Haden, North Carolina.

20 We already have a general license program in
21 effect, that has been in effect for a number of years. We
22 have found that it's -- at least we believe it to be, and
23 hope Dick does -- a pretty comprehensive program as far as
24 general licensing goes.

25 So, a Division I compatibility may cause a

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 complete rule change for us in a program that is already
2 very effective.

3 MR. LOHAUS: Okay. Thank you.

4 MR. FRAZEE: Terry Frazee, State of Washington.

5 This comment goes more to the specific licensees.
6 We are developing a rule for the general licensees because
7 there is concern for losing gauges, and you are going to
8 require periodic reporting from the general licensee as a
9 way of making sure that they still have the gauge.

10 With specific licensees, it is my understanding
11 that NRC's approach is to issue the specific license, do
12 initial inspection, and that is the last time they ever see
13 the licensee unless there is a problem, which of course they
14 would have to report.

15 Our experience has been in the State of
16 Washington, even though we do periodic inspections of
17 specific licensees on about a four-year cycle, we have in
18 fact lost the gauge of company, management changes,
19 ownership changes, and we come in four years later and the
20 gauge is long gone.

21 Have you considered, particularly for NRC where
22 you don't do periodic inspections, have you considered using
23 the same approach for your specific licensees, sending out a
24 notice, requiring them to report in on a certain frequency?

25 MR. KERR: Wayne Kerr from Illinois.

ANN RILEY & ASSOCIATES, Ltd.
Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 Paul, I can't let you get away. The discussion on
2 compatibility I think highlights the problem of the
3 application of compatibility and Division I. You know,
4 these things indicate that you need to apply the rule of
5 reason, is what the state proposes effectively the
6 equivalent of what you have rather than identical in terms
7 of some of the detailed provisions and wording.

8 MR. LOHAUS: Okay. Thank you.

9 Other comments or questions?

10 [No response.]

11 MR. LOHAUS: Thank you very much.

12 CHAIRMAN MILLER: Again, we want to give Paul
13 Lohaus a big hand here for his contribution here this
14 morning.

15 [Applause.]

16 CHAIRMAN MILLER: Again, if you come up with some
17 additional comments, be sure to get them to him as soon as
18 possible. He will be leaving Research at the end of
19 December, going back to his old job as the Branch Chief of
20 Low Level Waste Management Branch.

21 Now, we do have a couple more topics for this
22 morning before we take a break. However, I don't see Janet
23 Lambert in the room yet, and she was to talk a little bit
24 about Part 61, above-ground disposer, and this is probably
25 the first regulation that we mentioned under this early

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters

1612 K. Street, N.W., Suite 300

Washington, D. C. 20006

(202) 293-3950

1 involvement.

2 I think she has now brought it to closure. There
3 is not a lot to say because this was discussed with you some
4 two years ago, but if she comes in later, we will include
5 this.

6 However, let's move on and have Mark Haisfield to
7 come up quickly and talk about 10 CRF Parts 20 and 61,
8 Uniform Manifest.

9 Mark.

10 MR. HAISFIELD: The first thing I just wanted to
11 say is about Janet's rulemaking. It is with the Commission
12 and I don't really know what is particularly in there, but
13 it is supposed to come out final pretty soon. I don't think
14 you will see any surprises there.

15 Could I have the slide.

16 This rulemaking, which is commonly referred to as
17 the Uniform Manifest rulemaking, but that is the actual
18 title that it goes by, so if you ever see that title in
19 Uniform Manifest, it is really the same thing.

20 After this rule went out for comment, the
21 commenters almost universally liked the idea of a uniform
22 manifest, but an awful lot of them had problems with how the
23 NRC was going to implement that concept.

24 One of the first big problems that we have to
25 resolve is that our manifest would change how people are

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 filling out manifests right now for changing existing
2 practice.

3 The reason we did that is because we were trying
4 to meet DOT regulations as DOT explained it to us and as DOT
5 said that we had to do it that way, and as DOT said that
6 right now the manifests that are being done, are done
7 improperly, and they just haven't gotten around to citing
8 people.

9 They feel that the manifests that are currently
10 being used are wrong. After reviewing a lot of the
11 comments, however, we think the commenters made a really
12 good point that the existing practice makes a lot of sense,
13 and we are going back to DOT with those commenters' concerns
14 and with our proposals to them to see if they might want to
15 rethink it and if we can get some flexibility in how they
16 interpret their regulations.

17 That is pretty much where we are right now in that
18 rulemaking. We are just now going back to DOT. We have
19 provided them our concerns, the comments. They have gotten
20 back to us and wanted some additional information, and we
21 have provided that.

22 We have also been requested by the Low Level Waste
23 Forum to have a working public meeting about this
24 rulemaking. We think that is a really good idea except
25 until we can get things resolved with DOT, we think it is a

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 little premature.

2 So, we think it would be more effective if we wait
3 until we get some resolution with DOT about how these forms
4 are going to look like before we have that public meeting.

5 The last thing I wanted to mention is that DOT is
6 also being caught up with the President's regulatory
7 moratorium, and since our rule implements proposed rules of
8 DOT, it is very unlikely that we are going go out with a
9 final rule until they go out with their final rule.

10 At this point we haven't been able to get a very
11 good story as far as how that moratorium is going to affect
12 DOT. We know it is affecting them, but they seem to think
13 that they may be able to push forward anyway, but they
14 really can't commit to anything.

15 I think it would be very unlikely that we would go
16 out with the final rule until they do. To sum it all up,
17 basically, this rulemaking is going to be taking a step back
18 or two until we get some of these issues resolved and we see
19 where the moratorium is going. That is the status of this
20 rulemaking.

21 If there are any questions or comments, I would be
22 glad to help.

23 [No response.]

24 MR. HAISFIELD: Thank you.

25 CHAIRMAN MILLER: That gave us a good time for a

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 break now, and when we come back we will bring all of the
2 medical staff up for the rest of the day.

3 Let's take about a 20-minute break.

4 [Recess from 9:28 a.m. to 9:50 a.m.]

5 CHAIRMAN MILLER: Now, this next topic is the
6 Medical Issues Paper. It is a little bit different now. We
7 are not going to talk specifically about changing the
8 regulation at this time, but this is an all-encompassing
9 topic. They are going to talk about a little of everything
10 having to do with medical issues.

11 We have a distinguished panel that is going to do
12 that. This panel is headed up by their division director,
13 Dick Cunningham. Just raise your hand there, Dick, so
14 everybody can see you. He is the Division Director of NMSS
15 in the Office of Nuclear Material Safety and Safeguards.

16 Dick doesn't normally come to these, so I know
17 there is going to be some important things to take place
18 since we do have him in our audience this morning.

19 Now, we have also in the audience a member from
20 OGC, Marjorie Rothschild. Anytime we are going to talk
21 about medical issues, I expect to see her in the audience,
22 and she is there this morning.

23 We also have a representative from Research, John
24 Telford, who certainly would be helping out in the medical
25 area whenever there is a need for a regulation, so we

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 certainly want to recognize him this morning.

2 Is there anyone else that is out in the audience
3 that can add to this panel's discussion this morning? If
4 so, I want you to raise your hand here because I don't want
5 to skip anybody.

6 Okay. Seeing no others there, then let's talk
7 quickly about the panel which you see here before you.

8 The branch chief, as you all well know, is John
9 Glenn, Dr. John Glenn, who has been before you at least
10 twice this week. He is the branch chief, and the other
11 staff people you see here are members of his staff.

12 Everyone knows Larry Camper, who is the author of
13 most of these things that get written in the medical area.
14 He certainly has an able assistant in Dr. Patricia Holahan.

15 Then, we have a resident physician who works
16 directly in Dick's division, and works very closely with the
17 branch here that John Glenn heads up, and that is Dr.
18 Pollycove. You will remember he was with us last year at
19 the public meeting.

20 So, we have a very good panel here and I just want
21 you to know now we are talking specifically about one
22 specific regulation part of the medical issues. We are
23 going to talk about a lot of medical issues here. How well
24 it goes depends on how you contribute to this discussion
25 here today because there are no set answers yet. We are

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 just seeking some dialogue.

2 To start this out we are going to call on Larry
3 Camper at this time.

4 MR. CAMPER: Thank you, Vandy. Good morning.

5 Let me start off by saying that we have a lot of
6 work to do today and knowing that this group is not shy, we
7 are going to be getting a lot of input from you.

8 We don't have an ideal physical situation here.
9 We wish that we had a round table where we could talk, and
10 you all had microphones, and so forth. I know given the
11 nature of the topics that we are going to cover today, you
12 will have a lot to say.

13 So, I can only encourage you to stack up in line
14 and let's get your comments on the record. We will try to
15 make it work as well as we can. It will take several hours
16 to go through what we are going to go through.

17 I would also like to just reemphasize something
18 that Vandy was saying. That is, we are not here to discuss
19 rulemaking; we are here to discuss the Medical Use Program,
20 to a great degree in its entirety, if you will.

21 Each of you were provided a document identified as
22 a "Medical Issues Paper." Dr. Holahan of my staff and Dr.
23 Glenn's staff played a very large role as the primary author
24 of that document. Dr. Myron Pollycove, our medical visiting
25 fellow, one of two, was also very actively involved.

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 What I want to do is just kind of give you the
2 backdrop, make a few introductory comments, and then Dr.
3 Glenn will make a few comments about it.

4 What I would like to do is just share with you
5 briefly a certain excerpt from a memorandum from Mr.
6 Bernero, our office director, to Mr. James Taylor, of the
7 EDO.

8 It says in part the following: At the Office of
9 Nuclear Material Safety and Safeguards Management Conference
10 held on August 3 and 4, 1992, it was decided to prepare a
11 management plan for reassessment, guidance, and new
12 initiatives in the Medical Use Program.

13 The issues associated with the regulation of the
14 medical use and byproduct materials are complex, dynamic,
15 and controversial. During the last two years, the Advisory
16 Committee on the Medical Uses of Isotopes, the ACMUI, the
17 medical community, and the Agreement States have taken
18 strong exception to a number of aspects of our current
19 regulatory program for the medical use area.

20 As a result, the staff has commenced a
21 reassessment of the Medical Use Program and initiated a
22 number of actions to address the more pressing problems. In
23 a Commission paper identified as 92-175, the staff cited the
24 medical community's increasing concern about the extent of
25 the Nuclear Regulatory Commission's regulation and its

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 potential for interfering with the practices of medicine and
2 radiopharmacy and described current activities, including
3 rulemaking, to address some of those concerns.

4 The key component of the management plan which we
5 are going to discuss today is a continuation of the staff's
6 initiatives previously identified to senior management and
7 the Commission, as well as others which have emerged as a
8 result of continuing interaction with the regulated
9 community.

10 The staff believes that these efforts will
11 satisfactorily address many of the issues raised by the
12 medical community while improving the overall effectiveness
13 of the Medical Use Regulatory Program.

14 In addition to these initiatives, the staff has
15 identified other program areas which should be reviewed to
16 determine if substantial changes would improve the Medical
17 Use Program and further address concerns expressed by the
18 medical community.

19 Finally, there are likely to be other programmatic
20 issues and alternative approaches to regulation, not yet
21 identified by the staff, which should be evaluated and
22 possibly changed.

23 The first slide.

24 So, what we are talking about today in conceptual
25 terms is the development of a management plan for the

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 regulation of the medical uses of byproduct material. One
2 of the things that you have often said to us has come to us
3 early in the game, don't bring us a document that is
4 essential a fait accompli and ask us to comment on it.

5 So, what we are doing today is in the earliest
6 stage as possible, on a very aggressive time schedule, is
7 getting your input conceptually.

8 The next slide.

9 The planned development includes the issues paper,
10 which we will discuss at great length today, and you have
11 had an opportunity to read at this point, public meetings
12 with the Advisory Committee on the Medical Uses of Isotopes,
13 which took place last Thursday and Friday.

14 We went through the exact same questions that we
15 are going to go through with you today, the Agreement
16 States, of course. We are going to meet next month, in
17 November, with our regional counterparts to discuss the
18 medical issues. Finally, we are tasked with producing a
19 Commission paper in January of 1993.

20 With regard to the Medical Issues paper itself --
21 and I want to read this disclaimer for the record, so that
22 it will be clear:

23 The Medical Issues paper raises a variety of
24 issues in the NRC's Medical Use Program. The purpose of
25 this paper is to stimulate discussion on these and possibly

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 other issues as part of the development of a proposed
2 medical use management plan to be presented to the
3 Commission. The discussion of issues within this paper does
4 not necessarily represent official NRC policy.

5 The next slide.

6 The staff appreciates that there may not be an
7 ultimate resolution of some of these issues, but recognizes
8 a need to address them. Specific items that are beyond the
9 scope of the staff's management plan for the medical use
10 area have been excluded. Those were identified within the
11 text of the issues paper.

12 With regards to the issues in the medical use
13 area, we consider them to be four major categories. Under
14 each of these categories there are a number of subsets, and
15 then various questions within each subset.

16 The four major categories are: NRC's role in
17 regulating the use of byproduct material in medicine -- and
18 we are going to talk at great length about our medical
19 policy statement; operational flexibility -- and by that we
20 mean how on one hand can we have regulations that are
21 specific and clear, easily understood by the licensed
22 community, while on the other hand, providing flexibility
23 for a very dynamic area, that being the medical use area, so
24 that we don't restrict the practice of medicine and the
25 practice of radiopharmacy; regulatory relationships -- you

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 will notice I am not using the "C" word. What we are going
2 to be talking about, though, is the relationship that exists
3 between you as state regulators, and us as federal
4 regulators, and how we can take steps to work better
5 together, to better communicate to the licensed community
6 throughout the states to the extent that uniform criteria
7 can exist, and things of that nature.

8 Finally, professional relationships. The other
9 day I gave you an overview of the Quality Management
10 Program. At that time I mentioned that we were going to be
11 hearing from the American College of Nuclear Physicians
12 regarding its audit program.

13 We want to explore some questions about the
14 professional relationships and what we can do to enhance
15 that audit function that industry does for itself.

16 Next slide.

17 The formulation of the long-term objectives and
18 the umbrella policy. We will complete or reduce or perhaps
19 redirect certain ongoing activities. We are going to
20 continue to make assessments based upon periodic meetings
21 once we submit the Commission paper to the Commission in
22 January and receive direction from the Commission.

23 We do expect that in the future, we would continue
24 to hold meetings and receive additional input from the
25 Advisory Committee on the Medical Uses of Isotopes, from the

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 Agreement States, from organizations affected by the Quality
2 Management rule, and the public, as well.

3 We would need to continue to identify, evaluate,
4 and undertake new initiatives as a result of those periodic
5 assessments.

6 With regard to the things that are going on
7 currently, I want to take just a moment or two to go through
8 them quickly because we do think there is a great deal of
9 activity that is worthy of revisiting.

10 We won't discuss these very much today. Instead,
11 we are going to be asking you a lot of philosophical
12 questions, but just so you will be aware of the kinds of
13 things that are going on now, because we do think this is an
14 important part of improving the Medical Use Program.

15 The first is radiopharmacy rulemaking in response
16 to a petition filed by the ACNP/SNM. We are going to
17 propose to the Commission rather dramatic changes in the
18 language within Part 35.

19 For those of you that took part in the meeting
20 that we held with the Agreement States in Atlanta, I think
21 you will recall that was a very productive meeting and many
22 of the changes that were suggested during that meeting, we
23 are going to suggest in the language change of Part 35.

24 The idea is to relax the procurement possibilities
25 for obtaining radiopharmaceuticals in the practice of

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 medicine and to allow radiopharmacists to practice their
2 profession.

3 The preparation of inspection enforcement guidance
4 for the Quality Management rule. The other day I mentioned
5 that we are heavily involved currently in the inspection
6 guidance of performance-based inspections and that we are
7 going to propose a rather significant modification to the
8 enforcement policy for the QM rule. We will discuss that in
9 great detail during our November 9 public meeting.

10 We are currently seeking bids for a contract to
11 review the submitted QM programs, submitted to us by
12 licensees. We have approached three of the National Labs
13 and that process is currently underway.

14 We would hope to award a contract probably,
15 hopefully, before the end of this year, this calendar year.

16 We did complete guidance for broad-scope
17 licensees, including a standard review plan. There had been
18 some confusion as a result of the 1987 change of Part 35 by
19 some licensees as to what broad-scope licensees could and
20 could not do.

21 That confusion grew out of some comments that were
22 made in the statements of consideration, but the rule
23 language itself was inconsistent to some degree with what
24 the statements of consideration said.

25 So, we provided some guidance to our regions in

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 terms of a standard review plan to make sure that
2 broad-scope licensees indeed have the flexibility that we
3 intended for them to have and that they are licensed
4 consistently throughout our five regions.

5 The next slide.

6 We are going to hold a public meeting with
7 ACNP/SNM to explain the Quality Management rule, to seek
8 their input. It will be a highly participatory meeting, as
9 I explained the other day, and of course we are going to see
10 the ACNP audit program presentation.

11 Truncation of recordkeeping requirements for the
12 Interim Final Rule. You might recall that we had put in
13 place an Interim Final Rule that was designed to address, at
14 least in part, the petition that was filed by the ACNP/SNM.

15 The Interim Final Rule will allow physicians to
16 make departures to the manufacturer's packaged instructions
17 as long as they did certain recordkeeping requirements.

18 Well, on the 2nd of October we published a Federal
19 Register Notice in which we truncated the recordkeeping
20 requirements for those physician directed departures. They
21 may now make those departures and not maintain the
22 recordkeeping that was associated with the Interim Final
23 Rule. That has been very well received we think by the
24 medical community.

25 Review of modification of Abnormal Occurrence

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 Reporting Criteria for Medical Events. We believe, as a
2 result of having developed the Quality Management rule,
3 having made some fairly substantive changes in the
4 thresholds for misadministrations, it is time to take a look
5 at the reporting criteria for abnormal occurrences which get
6 reported to the Congress.

7 So, we are currently underway to do that and we
8 again think that we will propose some fairly dramatic
9 changes to the Commission, so that we capture big-ticket
10 items as opposed to the kinds of things we currently have in
11 the AO criteria.

12 The next slide.

13 Rulemaking to cover administration of byproduct
14 material to pregnant or breast-feeding women. We have
15 discussed this with you before. We are currently working
16 with Research to develop a rule whereby we would focus upon
17 having licensees notify patients of the potential
18 consequences of undergoing procedures in nuclear medicine
19 when they might be pregnant, particularly therapeutic
20 procedures, and to report incidents that involve unintended
21 exposures to a fetus or a breast-feeding infant.

22 Finally, we are working on release criteria for
23 patient undergoing nuclear medicine procedures, to make
24 changes in 35.75.

25 So, those kinds of things are going on currently,

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 a lot of activity, and what we really want to do today is to
2 explore and we want to ask you to think in broad
3 philosophical terms, paint with a very broad brush, try not
4 to the extent possible to get into specific things about
5 Part 35 that you take exception to, because if we find
6 ourselves debating the language in Part 35, we are not going
7 to make a lot of progress.

8 We have no preconceived position on this matter.
9 This is purely exploratory in nature. So, try to the extent
10 possible to make your responses and your comments as general
11 and as philosophical and conceptual in nature as possible.

12 With that, I would like to turn this over to Dr.
13 Glenn. He has a few comments that he wants to make about
14 the Management Plan.

15 DR. GLENN: Thank you, Larry.

16 I think for the rest of the presentation what we
17 would like to do is have the discussion occur from the
18 table, not be having formal presentations, try to overcome
19 the barrier of the formal setup of the room as much as
20 possible and invite an interactive discussion.

21 Based on some of the questions that were asked on
22 Tuesday morning when I was here earlier, I think I should
23 discuss a little bit about how these different meetings you
24 have been hearing about were scheduled and also to impress
25 upon you how much of an effort we are making to get you

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 involved as quickly as possible in this process.

2 We were tasked with the development of this
3 management plan in August of this year, and we had to
4 conceptually figure out, well, okay, how do we get the
5 necessary input to develop the management plan, what time
6 frames are reasonable, how can we both be responsive and
7 make sure that we touch all the bases before we go forward.

8 The only way we could do that was to make use of
9 existing mechanisms, meetings that already were scheduled,
10 and use those opportunities to help us go forward.
11 Fortunately, we had a string of meetings coming up in
12 October and November that were already scheduled, that were
13 kind of ideal for bringing up some of these ideas.

14 The first meeting we had was with the Advisory
15 Committee on the Medical Use of Isotopes which had been
16 scheduled for the 22nd of October, and so we did meet with
17 them last week, covered the same paper with them that we are
18 going to be covering with you today, have received some of
19 their comments.

20 The next meeting that we saw that was on the
21 agenda, and touched the groups that we feel we have to get
22 involved early in terms of any of any of this process was
23 the Agreement States meeting that we are at today, so we
24 intended from the first to have this discussion.

25 The meeting with the ACNP/SNM and the other

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 professional groups is a slightly different meeting. That
2 was scheduled mainly because of the problems associated with
3 the QM rule, the OMB override, and the sense of both the
4 staff and the Commission that a public meeting to discuss
5 the information collection requirements of the rule to
6 clarify misunderstandings that existed out there.

7 However, we also added onto that a discussion of
8 the ACNP audit program since they about that same time wrote
9 to the Commission wanting to discuss their program and how
10 that could be incorporated into our regulatory scheme.

11 The public meeting on November 9th will not be
12 specifically about this issues paper, and one thing I would
13 appreciate your commenting on today, we will have met with
14 the Advisory Group from the medical community, we will have
15 met with our co-regulators in the Agreement States, and we
16 will have discussed some specialized issues in an open forum
17 with the professional societies, but one thing we are
18 seeking is advice on whether before we proceed with the
19 development of this management plan, whether we need to have
20 a wider spectrum of public meetings where we try to solicit
21 comments from people other than the government and the
22 regulated community, and whether such groups actually exist
23 that we could hold a productive dialogue.

24 Our objectives in this management plan are to
25 develop the strategies to assure that we have the most

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 effective regulation of medical uses of radioactive
2 materials that we possibly can.

3 I think that the plan probably will be as much
4 about process as it is about content. The end product of
5 the plan and the process may be rulemaking on particular
6 issues, but we are really interested in how we arrive at
7 good decisionmaking in terms of the regulation of the
8 medical community.

9 One reason, of course, that we are working on this
10 management plan is that many contentious issues have arisen
11 in the last few years, and we have been criticized that we
12 are over-regulating or that we are not regulating correctly,
13 so we want to lay out a long-term plan strategy that will
14 resolve issues in a timely manner, assuring that we neither
15 over-regulate nor under-regulate, that the role of the
16 government regulator is appropriate in this area of medical
17 use of isotopes.

18 From this discussion we are not actually expecting
19 you to give us the answers. I think we are anticipating
20 that you are going to help us get the right questions, and
21 then together we will work out what the right answers may be
22 through this process.

23 Some of these, there is not going to a right
24 answer, this tension between precise requirements, so that
25 they are understood by everyone, so that the boundaries are

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 clear, and also that we have to allow the industry
2 flexibility to change, to grow, to go down the area of new
3 technologies, so we are always going to have that tension,
4 that challenge.

5 We want to eliminate the possibility of anything
6 going wrong, and yet, at the same time, we have to take the
7 risk of something going right, as well, so getting that
8 tension appropriately balanced in the way we do the
9 regulations is very important.

10 With that, I would like to get into the first area
11 of discussion. We have arranged the Issues Paper with sort
12 of a general discussion and then going into five areas of
13 particular concern.

14 Now, these were staff ideas from what we were
15 hearing from you and from the regulated community about what
16 some of the issues might be. The last appendix is Other
17 Issues, and we certainly are open to the idea that in our
18 brainstorming sessions, we may not have gotten to all of the
19 issues or maybe even the most important issues. So, we are
20 open to new ideas coming up.

21 But as the basis for the discussion, what we would
22 like to do is go through these five areas, these five
23 appendices to the paper, and have a discussion. We tried to
24 build into the discussions, questions, so as part of this,
25 we will pose these questions and invite your response.

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 If the consensus develops that in a particular
2 area there is no issue, and that is your consensus, let us
3 know early on, so we don't spend a lot of time discussing
4 something that you don't think is too important.

5 Appendix A involves the Medical Policy Statement.
6 In 1979, the Commission felt that it was important to make a
7 statement to the public as to what the role of the NRC would
8 be in the area of the regulation of the medical uses of
9 radioisotopes.

10 I don't think I have to tell you, but I will just
11 reiterate, that a policy statement of course in and of
12 itself carries no force. It is not a regulation, it is not
13 a law, it is a statement of intent. It is guidance that the
14 staff should consider in terms of rulemaking initiatives.

15 There were three points to that policy statement.
16 The first one was that the NRC will continue to regulate the
17 medical uses of radioisotopes as necessary to provide for
18 the radiation safety of workers and the general public.

19 Two, that the NRC will regulate the radiation
20 safety of patients where justified by the risk to patients
21 and where voluntary standards, or compliance with these
22 standards, are inadequate.

23 Third, that the NRC will minimize intrusion into
24 medical judgments affecting patients and into other areas
25 traditionally considered to be a part of the practice of

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 medicine.

2 Now, since this was published, we have had the
3 proposed rules on Medical Quality Assurance, the final
4 adopted rule on Quality Medical Management, and certainly
5 the regulated community has claimed that we have exceeded
6 the bounds of the policy statement and also there have been
7 criticisms that the policy itself is incorrect, that the
8 policy implies that the NRC should be more involved in the
9 regulation of the medical community than is justified.

10 So, what we would like to do is open up a
11 discussion in terms of the policy statement and whether it
12 is adequate or not.

13 I will give you a little bit of insight into what
14 the Advisory Committee told us last week. They essentially
15 said that Policy Statement No. 1 was fine as it stood. It
16 was their interpretation that that essentially referred to
17 Part 20 types of radiation safety concerns having to do with
18 workers and releases, they felt that the wording as it stood
19 is appropriate.

20 With respect to both 2 and 3, they felt that the
21 words might be okay, but that the way that staff had
22 interpreted them in the past was perhaps not correct, and
23 therefore, if we were to keep those, they proposed putting
24 in strong adjectives and adverbs that would limit the
25 involvement of the staff into certain areas, so it was to

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 limit the interpretation to make sure that the strength of
2 the words would be that we would stay out of the area except
3 where radiation safety was directly involved.

4 I would invite, at this point, comments from the
5 States as to whether you feel there is any need to change
6 the policy statement or if you have any specific
7 recommendations with regard to the policy statement.

8 MR. WHATLEY: Kirk Whatley from Arizona.

9 [Laughter.]

10 MR. WHATLEY: I may get you in trouble here. Kirk
11 Whatley from Alabama.

12 I would just like to comment directly on this, and
13 I prepared my statement on this before I came to the meeting
14 here.

15 It is very obvious that many people have different
16 opinions on this matter. I think that may be an
17 understatement of this meeting. But the question is why do
18 we have different opinions, and I want to address one of the
19 contributing factors or what I feel to be one of them, and
20 that is a Medical Policy Statement.

21 The three statements of the Medical Policy are
22 written in two terms that have come to be used every meeting
23 I go to, performance and prescriptive. They are written in
24 broad performance-based language.

25 They were even interpreted by the writer of this

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 document as that author viewed them, and that is not the
2 problem, but the problem occurs when we all attempt to put
3 our own words to what the Commission intended to mean by
4 each of these policy statements, and that is exactly what
5 was echoed by Dr. Glenn here.

6 Policy Statement 2 states, "The NRC will regulate
7 the radiation safety of patients," and Policy 3 states, in
8 part, that "The NRC will minimize intrusion into medical
9 judgment affecting patients traditionally considered to be a
10 part of medicine."

11 Is that the charge of NRC or is to protect public
12 health and safety even if it does intrude into the sacred
13 practice of medicine? There are differences of opinion on
14 that.

15 The problem is that we disagree what each of these
16 statements means. There is disagreements among NRC staff,
17 among Agreement States, among the medical community, et
18 cetera.

19 One question was asked, is it -- meaning the
20 Medical Policy Statement -- sufficient to keep the Medical
21 Use Program on track?

22 My answer to that is a resounding no because we
23 don't know where the tracks are, we don't know where they
24 are going, we don't know where they began, and sometimes a
25 new set of tracks seems to just begin at the whim of some

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 statement that somebody makes or somebody's idea.

2 Sometimes it appears impossible to know which
3 track the NRC is on, and the States also, and they do switch
4 tracks in the middle of a journey wherever we are going, and
5 depending on our own understanding, reasoning, and beliefs
6 and experience, it appears lately that many of us are going
7 in opposite ways, opposite directions on the same set of
8 tracks.

9 This was also states in a document provided to us.
10 These are not my words, but the authors of this document say
11 the same thing, when it is stated, "However, different
12 interpretations of the policy statement have led to
13 conflicting opinions between members of the NRC staff, the
14 Commission, and the medical community" -- and I would add
15 Agreement States also.

16 A statement also appears in the Discussion section
17 of Appendix A that was provided to us, that says, "A review
18 of the Medical Policy Statement should focus on whether the
19 prevailing rationale is different today."

20 I don't know what the prevailing rationale is
21 today. It is certainly different every meeting I go to. I
22 don't know what the prevailing rationale was back then. I
23 am not sure anybody knows. I am not sure anybody in this
24 room, here today, with the exception of a few, were even
25 around when Part 35 was being developed originally at that

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 time.

2 In fact, the only forum in which it has been
3 rationally discussed has been one in which each side was
4 forced to defend his position in a hostile atmosphere, and
5 to my knowledge, the Agreement States nor NRC staff have
6 ever been asked their opinion on this subject before.

7 There are significant differences of opinion on
8 medical licensing subjects and opposition is going to
9 continue until they are resolved. I don't believe that all
10 of Part 35 should be an item of compatibility in any way,
11 form, or fashion. I have no problem with parts of it being.

12 Let me tell you why. The prevailing thoughts of
13 NRC staff in the early 1980's, when this policy statement
14 was in effect, that all medical licensing should be
15 generally licensed, including therapy. Okay?

16 That is under the same policy statement that
17 exists today. A few years ago, the statement was
18 interpreted to mean that diagnostic nuclear medicine was so
19 hazardous they would have had to have a misadministration
20 rule for it under the same policy statement.

21 That is now being rescinded. It has been
22 determined that diagnostic nuclear medicine is not so
23 hazardous anymore, but all of a sudden, using the same
24 policy statement has determined that it is, and that we are
25 considering this to be an item of compatibility for all the

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 states.

2 Somebody used the word "waffling," and I think it
3 may be appropriate from my standpoint. Using the same
4 policy statement now it is my understanding that NRC wants
5 this to be an item of compatibility. I don't know what the
6 rationale for this is.

7 I don't want to leave the wrong impression. I go
8 back to my original statement, and that being that we simply
9 disagree on what the policy statement means and needs
10 clarification.

11 DR. GLENN: I think, Kirk, I hear fairly clearly
12 from you that in terms of that one question we asked, is the
13 policy statement adequate to keep us on a steady course, you
14 are giving us a resounding no on that one.

15 MR. WHATLEY: It has not kept us on anything.

16 MR. KERR: Wayne Kerr from Illinois.

17 The thrust of the policy statement as written now
18 revolves around doctor-patient-NRC relationship. Since we
19 are thinking today in broad terms, I would suggest that you
20 consider making a statement on regulatory relationships in
21 the policy statement, that is, what is the role of FDA, what
22 is the role of NRC, the role of Agreement States, and state
23 licensing boards, in particular.

24 It seems like if you would express that in the
25 policy statement -- and I think that is an issue I know you

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 are going to get to later, and I am going to be gone by then
2 -- but that is crying for a solution to state what those
3 relationships are.

4 DR. GLENN: I think, in 2, there was an attempt to
5 get at that, but I think again what I hear you saying is
6 that it is a little too broad and not specific enough,
7 doesn't really give guidance either to the staff or to
8 others.

9 It does say where, you know, other standards are
10 adequate that we won't regulate.

11 MR. FRAZEE: Terry Frazee from Washington.

12 With regard to the second statement, you might
13 consider specifying what risk, what level of risk you are
14 dealing with. That may be a little helpful to identify the
15 distinction between diagnostic and therapeutic patients.

16 DR. GLENN: You bring up a good point. I guess
17 one of the questions that we may want to discuss here, be it
18 now or later, is what are good measures of risk for the NRC
19 and for the Agreement States to consider in making these
20 decisions.

21 MR. GODWIN: Godwin, Arizona, really.

22 [Laughter.]

23 MR. GODWIN: I think that I would more or less
24 echo what Kirk said in that I think if you read out the
25 policy statement and said how many can support it, probably

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 everybody would, but then when you ask what it meant, we
2 would have the darndest fight you ever wanted to see.

3 It is a good policy statement as a general, broad
4 scope of things, but standing on its own, it doesn't quite
5 get there. It's the interpretations and defining where the
6 track is or putting the fence up. There is an expression
7 that good fences make good neighbors, and that is true. We
8 really need to know where you are going to put that fence
9 line down before we can really make an informed judgment of
10 where you are going here.

11 I think that is probably the key item missing.
12 You can either modify the statement or put out a
13 supplemental interpretation section saying where it is. I
14 am not really sure which way would be the best to go, but I
15 it really needs a good, clear definition of what risk you
16 are talking about, what do you mean by intrusion into the
17 relationship.

18 I can give you my opinion all day long, and
19 probably most everybody here would disagree. So, we really
20 need to get down and try to build a consensus on where the
21 fence is.

22 DR. GLENN: Any more comments on whether the
23 principles are appropriate?

24 [No response.]

25 DR. GLENN: One of the next question was, is it

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 specific enough to keep the Medical Use Program on track
2 while allowing accommodation of technological development?

3 I guess a corollary question to that, do you think
4 that in fact -- Kirk pointed out that he has seen some
5 lurches, go one way, then go the other way -- what is the
6 sense of the group as to whether actions that have been
7 taken in the last decade have been consistent with the
8 policy statement as it is written?

9 [No response.]

10 DR. GLENN: Maybe a show of hands. How many feel
11 that as you see the three principles, that there has been a
12 consistent application of this in the last decade of
13 regulation? How many say yes? How many say no? Okay. I
14 have a consensus.

15 That gets us into the next area that we posed a
16 question, and that is, in order to make that process more
17 visible and perhaps as discipline to the NRC staff, should a
18 line item be put into any rulemaking, into the statements of
19 consideration, describing the relationship of this rule,
20 whatever it happens to be, to the policy statement?

21 Could I have some statements on that?

22 MR. KERR: Wayne Kerr, Illinois.

23 Probably so. I think, if for nothing else, it
24 would help you to explain, if you will, the kind of things
25 that Kirk pointed out, you know, eight, 10 years down the

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 road there may still be some deviations, but at least it
2 forces you to sit and say I have thought about it, and here
3 is what we think today, and it is consistent presumably or
4 else you wouldn't issue it.

5 MR. GODWIN: Godwin from Arizona.

6 I think what I would like to see is some way to
7 know that whenever you decide that is time for a change,
8 that a real informed decision is made by whatever group is
9 going to make that decision -- and I think that may be a
10 little vague depending on what decision you are making -- of
11 at least looking at what had been said in the way of policy
12 up to that point, and we have a clear switch-over to another
13 track

14 I think what we see now is we come to a change
15 point and the track suddenly disappears for a while, and
16 then the cars end up somewhere else. This is what is a
17 large part of the problem.

18 If we had a clear decision basis for the change
19 and why we are changing, and all of that, I think it would
20 help us ease our way through there.

21 For example, Part 35, I think the largest percent
22 of it is all very good, but there are some places in there
23 where we look like we have changed tracks and nobody knew
24 there was a switch coming.

25 DR. GLENN: Again, I heard some comments there

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 that bring in this idea of measurement of risk. You are
2 talking about having a clear decision basis. I think one of
3 the problems that we have as a staff in developing
4 regulations, in terms of the discussions with the
5 Commissioners in developing new regulations, is a good
6 measuring stick as to what the impact of what we are doing
7 will be, what are the consequences and the costs.

8 I wonder if this is the right place to have some
9 discussion about what kinds of measurements of effectiveness
10 we might incorporate into our program.

11 MR. GODWIN: Godwin again from Arizona.

12 It appears that one of the things that you have
13 not looked at -- but maybe you have, I am not real sure --
14 is that you would take the dose, for example, to do some
15 risk estimate as far as diagnostic procedures, and you say,
16 well, these are all not very risky.

17 That is fairly true when you look at the dose that
18 is coming out. However, it is not clear that you said,
19 well, okay, what about unnecessary exposure caused by, like
20 I say, inappropriately trained persons ordering exams that
21 are inappropriate for that diagnosis or that symptom group
22 that is being presented.

23 You have these radiation doses being given and
24 with no benefit to the patient, in fact. You can do a
25 similar thing relative to x-ray, and as we see in

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 particularly mammography, that there is a great emphasis
2 being made on making sure that the people who are reading
3 and have the equipment and everything is being checked, so
4 as to get the best optimal reading conditions for diagnosis,
5 to prevent the doses.

6 Now, admittedly, the doses are somewhat higher in
7 general for mammography, but we have a similar thing on the
8 road to me regarding fluoroscopy, where you have had 5
9 percent of fluoroscopic units cannot identify a single
10 phantom object.

11 You know when that gets going, you have a problem
12 coming down there because effectively you are giving people
13 exposure with no benefit to them.

14 I think you need to have some way of factoring
15 that into your equation before you decide on some of your
16 decisions not to have people necessarily trained.

17 DR. GLENN: Aubrey, you have raised some questions
18 that get right on this nub of the dividing line between what
19 the NRC should get into and what it shouldn't get into. I
20 think you right, that the major danger to patients,
21 probably in diagnostic procedures anyway, falls on the side
22 of the adequacy of the procedure rather than on the
23 radiation safety aspects of the risk, in other words, that
24 more harm comes from a misdiagnosis or from many people
25 receiving unnecessary exposure rather than from any

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 particular radiation risk.

2 I think, speaking for the staff, that the side we
3 have been coming down on recently is that we will regulate
4 the radiation safety aspects of that procedure, and not the
5 medical quality assurance issues associated with that, but I
6 would be interested in some comments from other states in
7 terms of in going in that direction, are we going the right
8 way.

9 MR. KULIKOWSKI: Bob Kulikowski, New York City.

10 First of all, I have a question for you, John,
11 relative to your last comment. How can you really
12 dissociate the two?

13 I think we are looking at a sheet of black on this
14 side and a sheet of white on this side, and where the two
15 pages meet, you would like to have this intersection of a
16 black plane and a white plane, but you really have this
17 fuzz, which we all can't get away from.

18 Just some other general comments. The States have
19 the added responsibility of applying -- and I know at least
20 in New York City -- we will have the added responsibility of
21 applying similar type regulations to machine-produced
22 radiation, as well.

23 Our administrative procedures people come down
24 pretty hard on us when we say we are going to do this for
25 one group, and a similar group that is doing something with

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 a similar risk we are going to do something different for.

2 New York State now has quality assurance for
3 diagnostic radiology, so we are going to have to be involved
4 in that, in nuclear medicine, as well.

5 The other comment that I want to make is the
6 policy statement is all well and good. I don't believe, to
7 the best of my knowledge, it is applicable to the Agreement
8 States.

9 I mean I think we have different enabling
10 legislation which may say things that are different than the
11 Atomic Energy Act does for you people, and we are right in
12 the middle of doing one of these right now,
13 accelerated-produced facilities, as well, which require
14 other special considerations.

15 So, I think basically, in summary, I think you
16 probably do need a Medical Policy Statement. I think the
17 questions that you need to ask are, one, not going to have
18 any answers, any clear answers, and to make them applicable
19 to the Agreement States, using the nasty "C" word,
20 compatibility, I think it is just not possible.

21 It is not a question that we don't want to be
22 compatible, but I have talked about, I am really
23 disappointed that the Commission did not act on the
24 compatibility paper in time for this meeting, because I
25 think it was very important that this be done because it

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 seems to me that as we go forward and even discuss
2 philosophically, these things are going to end up in
3 rulemakings, and as we heard this morning, there are a bunch
4 of rulemakings that are on the table now.

5 It seems rather absurd to me -- and I think that
6 is the appropriate term -- to try to go ahead with these
7 rulemakings without making a determination on the
8 compatibility.

9 My recommendation would be that you stop all
10 rulemakings, sit down and iron out the compatibility issue
11 now, once and for all, and then go ahead, so that the
12 rulemakings can be done in some semblance of sensibility.

13 Thanks.

14 DR. GLENN: I hear your thought there, I guess.
15 One thing, if you read the paper, you did notice we sort of
16 put a disclaimer in there that compatibility was not the
17 issue of this management plan because it is such a bigger
18 issue than this particular Issues paper.

19 MR. KULIKOWSKI: I know, but you can't really
20 divorce it, just like you can't divorce misadministrations
21 as part of radiation safety.

22 DR. GLENN: Again, all I can say is that my branch
23 will not in fact be the group that will develop the plan
24 that resolves the compatibility issues, but we hear you.

25 MS. ALDRICH: Rita Aldrich, New York State.

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 New York State, for information purposes, already
2 has a regulatory requirement for quality assurance in both
3 diagnostic x-ray and diagnostic nuclear medicine, and we
4 hope by the end of November to have the same in place for
5 radiation therapy.

6 There is a big difference in the focus. It is
7 largely focused on optimization and radiation safety. I
8 don't know that that is the jurisdiction of NRC, but it sort
9 of reinforces what everyone else has been saying, that the
10 risk to the patient has to be justified by the benefit. It
11 is like a basic tenet of radiation protection.

12 The error prevention part of diagnostic, we
13 consider to be rather low on the totem pole when you look at
14 the importance of the diagnostic quality of the results of
15 tests, especially with new cameras, complicated procedures
16 coming along.

17 So, what we have done is say that traditionally
18 what we have accepted in x-ray for ongoing oversight over
19 whether errors are being made, whether the wrong person is
20 getting a procedure -- and believe me, it happens are more
21 often in x-ray than it does in nuclear medicine -- is that
22 we have always accepted an ongoing analysis of retakes,
23 repeats, misadministrations, which in x-ray is typically
24 done by looking at your films on some kind of a regular
25 basis and sorting them and just doing it statistically.

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 We are doing the same thing with nuclear medicine.
2 We are treating it as the same sort of thing because it is
3 the same kind of a risk. It is a statistical population
4 exposure risk, it is not an individual risk item.

5 If anyone wanted a copy of the regulations that we
6 have, we would be happy to provide them to you.

7 DR. GLENN: The last two commenters I think have
8 raised a possible distinction between NRC and perhaps state
9 regulations in this area. Let me just throw this out.

10 It is possible that the NRC should draw the line,
11 and not get into medical quality assurance things, such as
12 the reproducibility of films, the ability of the camera to
13 detect artifacts, but that may in fact, by the nature of the
14 way medicine is regulated in this country, be more of a
15 state function.

16 Are there any comments on that?

17 MR. GODWIN: Godwin of Arizona.

18 I would draw the line at a different point perhaps
19 from where you did. I think from my understanding of the
20 Atomic Energy Act, that there are many areas that you would
21 indeed want to be involved in quality assurance. I don't
22 have that kind of difficulty.

23 But there are areas where probably you should not
24 be dealing in, and perhaps even at the state level, many of
25 our radiation programs should not be dealing in, and that is

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 where we deal directly in the physician-patient
2 relationship, particularly individual patients, not so much
3 as perhaps a group, but individual patients, I think that
4 probably looking, for example, at dosages, a strong case
5 could be made that you should not be looking so much at
6 dosages while some of our State Programs may.

7 On the other hand, qualifications of people
8 working might be an area that you would look at rather
9 closely, and I am just giving my sort of personal opinions
10 on this.

11 If there is a clear-cut function relative to the
12 overall program, I think that the case could be made in some
13 cases where you haven't a real function defined yet in your
14 regulations.

15 Once a physician is determined to be competent to
16 do the procedure, many of us probably need to step away and
17 let that relationship run as a strictly medical malpractice
18 relationship.

19 We cannot get into that kind of thing, the
20 physician malpracticing after we have evaluated and
21 determined he is a qualified individual prescribing it, that
22 is probably the way it should be handled in our current
23 regulatory process.

24 If he is determined to be malpracticing, we might
25 want to think whether we need to continue to authorize him

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 as a user, but that is another issue, too.

2 So, I think there are a lot of places where you
3 can look at that line and it is going to take some banging
4 around to determine where it goes, but I do not think that
5 we can interfere directly with the physician-patient
6 relationship, nor should we once it is established that they
7 are the qualified people.

8 MR. KULIKOWSKI: Kulikowski, New York City again.

9 Gee, John, has Carol Marcus gotten to you?

10 [Laughter.]

11 MR. KULIKOWSKI: Aubrey sort of said what I wanted
12 to say, and it seems like talking about that line between
13 black and white, it seems that that gray area becomes
14 narrowest when you focus in on the physician-patient, you
15 know, will the physician prescribe what he deems is best for
16 his patient, whether indeed that departs from the package
17 insert or what someone else may consider good medical
18 practice. That I think is clearly on the one side that we
19 don't have any authority to go into.

20 However, regardless of what the physician
21 prescribes, once that medical determination is made, then it
22 seems like we have the responsibility as the radiation
23 safety regulators to ensure that the delivery of the
24 prescription is done in an accurate fashion for the sake of
25 radiation safety.

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 DR. GLENN: Is that an endorsement for the Quality
2 Management rule?

3 [Laughter.]

4 MR. KULIKOWSKI: For the record, no, that was not.

5 [Laughter.]

6 DR. GLENN: That was a little bit facetious, but
7 in fact that was certainly the intent of the NRC staff with
8 the Quality Management rule was to just do exactly what you
9 said there, to assure that the prescribed dose is delivered.

10 MR. COLLINS: Steve Collins from Illinois.

11 To give a specific answer, at least in my personal
12 opinion, to the question you posed is I think where you draw
13 the line, as you stated it for NRC, is the proper place for
14 NRC to draw the line.

15 Some of us in our states have state statutes that
16 allow us to draw the line a little bit differently, but even
17 in those, we should realize, as health physicists, that we
18 are not experts in the practice of medicine and a lot of
19 times some of the things we have done should, instead of us
20 imposing direct restrictions on medical practice, we should
21 have provided our analysis of the situation to the proper
22 board that gives licenses to physicians or pharmacists, for
23 that matter, to do their practice and let them take the
24 appropriate action.

25 DR. GLENN: Dr. Pollycove, would you like to make

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters

1612 K. Street, N.W., Suite 300

Washington, D. C. 20006

(202, 293-3950)

1 any statements?

2 DR. POLLYCOVE: No, I would just concur with Steve
3 Collins. I think that the matter of competence should be
4 left to various bodies that are involved in competence, and
5 this ranges from the residency review committees to the
6 specialty certification boards, and also the state medical
7 boards.

8 I think the groups that are primarily concerned
9 with this are the ones that should deal with this, and the
10 NRC's primary concern is with radiation safety, and I think
11 that is its proper area.

12 DR. GLENN: Are there any more issues, questions
13 people would like to raise about the policy statement?

14 [No response.]

15 DR. GLENN: If not, I will pass the baton over to
16 Mr. Camper, and we will discuss the next topic.

17 MR. CAMPER: Next is Appendix B, which deals with
18 Part 35.

19 You might recall in 1983, the staff had proposed a
20 revision to Part 35, which was much more performance based
21 than the final regulation. After publication of that
22 proposed rule, the Commission directed the staff to redraft
23 the rule with much more specific prescriptive requirements
24 and to certainly a significant degree, that was at the
25 urging of some Agreement States' representatives who felt

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 that the Part 35 needed to be more prescriptive-based at
2 that time.

3 In doing this we tried to bring together a number
4 of branch technical positions, certain information that was
5 used in licensing guides, and so forth, to licensed medical
6 licensees, and put it into one document.

7 Part 35 is both prescriptive based and performance
8 based. These are relative terms. If you look at the recent
9 Quality Management Rule, that is clearly a performance-based
10 requirement, but yet we could go through a number of parts
11 of Part 35 or components of Part 35 that are quite
12 prescriptive, for example, leak test requirements, doing
13 certain types of surveys, incoming packages, these types of
14 things.

15 The question that come up then, the first question
16 that we are asking you under the Part 35 category is, are
17 there issues that should be incorporated into Part 35 or
18 added to the current rule that you would like to comment
19 on? When I say incorporated, I really don't necessarily mean
20 added, we are saying added, or, you know, in the context of
21 incorporated, we are saying perhaps modified, changed, or
22 added to.

23 Any comments on that?

24 MR. COLLINS: Steve Collins from Illinois.

25 I don't know that I want you to slow down the

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 current rulemaking for it, but things that we have discussed
2 in the Agreement State meeting that was completed yesterday,
3 that should be looked into for possible inclusion in the
4 future modification of the rule would be some standards for
5 gamma stereotactic units, for mobile high-dose rate remote
6 after-loaders, if in fact that application is allowed, and
7 for mobile nuclear medicine services.

8 MR. CAMPER: We did, in fact, discuss those, as
9 Steve will recall, at great length at the ACMUI meeting
10 under this concept of emerging technologies that we felt
11 needed to be addressed.

12 Those are the very ones, mobile nuclear medicine,
13 the HDR's, in particular mobile HDR's. One of the things
14 that the Advisory Committee said about this particular
15 question is they felt that there really should be more
16 emphasis upon performance standards.

17 Is there any general reaction to that?

18 MR. GODWIN: Godwin, Arizona.

19 As long as performance standards are something
20 that are definitive enough that you can hang your hat on if
21 you have to take an enforcement action. Unfortunately, many
22 times we come out with this nice, wonderful performance
23 standard, that whenever you get ready to do something, you
24 find out that it is subject to 15,000 interpretations.

25 If there is an important radiation safety function

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 there, it needs to be clear enough that we can indeed do
2 what we need to do to protect the public health and safety.
3 That would apply really to all these things you are
4 considering, not just this one subject.

5 Again, go back to our prior discussion. It is a
6 wonderful performance standard, but everybody has got a
7 different opinion on what it meant.

8 MR. CAMPER: That is a good point, Aubrey. I
9 think all of us who have been out there in the field have
10 seen, on one hand, there is merit to arguing in favor of
11 requirements of Part 35 and performance-based standards as
12 opposed to specific criteria, like we currently have in some
13 parts of Part 35.

14 The problem that you get into, as a practical
15 matter, is that in many cases licensees -- it certainly
16 makes it easier for licensees if you have prescriptive
17 requirements that are clearly black and white, very
18 task-specific, I know exactly what I have to do as a
19 licensee, and if I do those things, because you have made
20 them very clear in your regulations what it is that I must
21 do, and either as a physician, radiation safety officer, or
22 through the use of a consultant, if I do those things, if I
23 dot those i's and cross those t's, I can have a high degree
24 of confidence that my program will pass an inspection.

25 Similarly, for inspectors, NRC inspectors or state

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 inspectors, if you know exactly what to expect of a licensee
2 before you go in, it reduces to at least some degree the
3 amount of on-site judgment that has to take place, and
4 perhaps argues more for consistency amongst inspections.

5 So, while on one hand I think that
6 performance-based criteria, as I said has merit, there is
7 something to be said for prescriptive-based.

8 Now, what I would really like to find out from
9 those of you from the States, is generally speaking, this
10 idea of licensees finding it easier to deal with
11 prescriptive requirements as opposed to having to develop
12 performance-based standards, do you have observations on
13 that or thoughts on that from your own inspection processes?

14 MR. KULIKOWSKI: Bob Kulikowski, New York City.

15 Yes, and I would sort of like to make an overall
16 statement about the next three questions in Appendix B.
17 Being a largely medical program, we have a fair amount of
18 experience in this area.

19 First of all, I don't think it is possible to be
20 exclusively performance based or exclusively prescriptive,
21 and even within each category you are going to have them to
22 various degrees.

23 I mean there are some things that we definitely
24 want prescriptive - radiation safety officer, we want them
25 to have specific training, not just to say training or

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 adequate training.

2 Experience from inspectors in the field, it
3 depends, and we have medical facilities which range from
4 nuclear med docs in private offices to major broad licenses,
5 some of the largest in the country, and everything in
6 between for the large non-broad scopes.

7 I don't think there is a consensus. I think it
8 depends on the staff of the hospital, the radiation safety
9 staff of the hospital, how they want to deal with things. For
10 example, two very large hospitals may do things entirely
11 differently, arrive at the same end point, and I think we
12 need to -- and I am beginning to recognize this more and
13 more -- the people that I send out in the field have to have
14 the ability to make the judgment that not only is it
15 something that is performance-based, but something that is
16 prescriptive-based, as well, but be able to make the
17 determination does the licensee indeed fulfill the radiation
18 safety requirements, whether it is to the letter of the law
19 or whether it is not to the letter of the law.

20 I mean, you know, go back to the Merchant of
21 Venice, you know, can they take the pound of flesh, you
22 know, what the licensee is doing may vary a little bit from
23 what the regulation says in a very prescriptive sense, but
24 does it get the job done adequately with no compromise to
25 health and safety.

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 I don't think there is any answer to your question
2 that there is any one right way for somebody to do
3 something.

4 MR. CAMPER: Bob, if you had to come down either
5 way, is Part 35 too prescriptive currently as it exists?

6 MR. KULIKOWSKI: I don't know. I can't give you a
7 yes or no answer because for some of our licensees, yes, it
8 is too prescriptive; for other ones, no, it is not too
9 prescriptive.

10 MR. CAMPER: Any other thoughts?

11 MS. TEFFT: Diane Tefft, New Hampshire.

12 Just to say that regardless of what we think,
13 there are states in their interpretation of their
14 Administrative Procedures Act which are requiring very
15 prescriptive regulations.

16 What is happening -- New Hampshire may be a good
17 example -- is that when compatibility is an issue and we are
18 going in and trying to take the existing regulations, say,
19 NRC and the SSR's, and making them into prescriptive
20 regulations because that is what the State is requiring, we
21 in some cases are developing national policy in each of the
22 individual states.

23 So, in answer to your question, I personally may
24 not think that it is too prescriptive or not, but the State
25 is going to say I know that Part 35, along with many other

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 parts, is nowhere near prescriptive enough.

2 MR. CAMPER: That is a good point.

3 Aubrey?

4 MR. GODWIN: I was just going to say that your
5 question about is Part 35 too prescriptive or not, it is not
6 a very fair question because parts of it I would say yes to
7 both questions.

8 MR. CAMPER: Can you give me an example of what
9 you think is overly prescriptive and perhaps an example of
10 what you think is just about right?

11 MR. GODWIN: Well, trying to quickly from memory,
12 I am not sure when you try to balance the training
13 requirements for clinical use, and then you put in the
14 training requirements for the radiation safety for the
15 physicians, that a good balance has been struck there.

16 Will the radiation safety work be done by the
17 physician or will it be done by somebody else, will that
18 training be better placed somewhere else?

19 MR. CAMPER: We are going to explore that question
20 at great length, probably this afternoon.

21 MR. GODWIN: I think there is an inadequacy and it
22 doesn't clearly say what the authorized user is responsible
23 for, yet, the physician is authorized user, but there is
24 nothing that really says what is he supposed to be doing,
25 you know, and there are other sections that I think would be

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 better. Some of the duties for the RSO, for example, are
2 probably a better defined section than it had been in the
3 past particularly.

4 I would just have to go through it article by
5 article. I am just trying to do this off the top of my
6 head.

7 MR. CAMPER: Yes, I understand.

8 DR. GLENN: I have an example of one where perhaps
9 it is not that it is too prescriptive, but maybe it was
10 wrong-headed. In Part 35, we require that the check source
11 go with the instrument when it is sent to be calibrated.
12 Should we get that prescriptive about how you determine that
13 your instrument, when you check it, is working properly?

14 MR. FRAZEE: Terry Frazee from Washington.

15 Part 35 is a mixed bag, some are, some aren't. As
16 far as enforceability of a performance-based rule, in fact
17 we already went over one this morning earlier, talking about
18 the patient release criteria.

19 I would say that at least part of that is
20 performance-based, allowing the release of a patient if the
21 Total Effective Dose Equivalent is less than 500 millirem in
22 a year -- or 500 millirem. It doesn't tell you exactly how
23 you have got to calculate that or figure it out, and that in
24 fact could be the rule and just let it go at that.

25 Throwing it or leaving in the very prescriptive

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 part of it, saying 5 MR per hour, okay, that is very
2 prescriptive. Some licensees could figure out a different
3 way to do it.

4 So, I think that kind of a performance-based
5 concept, that doesn't tell you all the individual steps on
6 how to get there, but does give you something that is
7 enforceable at the end, a goal, a well-defined goal, 500
8 millirem, I mean I think we would agree that that is
9 something we could enforce to.

10 MR. CAMPER: Just to give you a comparison,
11 generally speaking, we heard the ACMUI saying to us that
12 Part 35 is overly prescriptive.

13 MS. ALLEN: Kathy Allen from Illinois.

14 I will give you an example of both.

15 MR. CAMPER: Good. Excellent.

16 MS. ALLEN: For brachytherapy, requiring a survey
17 after sources are removed to verify that the sources have
18 all been removed, I think is prescriptive and is very good.
19 The requirement that you use iridium sources only for
20 interstitial treatment of cancer is too prescriptive.

21 MR. CAMPER: We totally agree. We are trying to
22 change that, in the very near future as a matter of fact.

23 MR. KERR: Wayne Kerr, Illinois.

24 Bob Kulikowski made a point that Part 35 is too
25 prescriptive for some of his licensees, and not for others.

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 I think raises the question you probably have to regulate to
2 the lowest common denominator. That is sort of a general
3 philosophy. So, the good guys get hurt by it, and the regs
4 are written for the ones that aren't so good.

5 MR. CAMPER: I think that is a very good point.
6 One of the things that I constantly bring up in the advisory
7 committee meetings is that clearly we have, you know, an
8 excellent advisory committee that consists of physicians
9 that I think most of us would agree are the creme de la
10 creme, that come from very fine institutions.

11 They make suggestions. You can't help but make
12 suggestions and offer ideas that divorce yourself from where
13 you have been and what your own experiences are.

14 There are times when we do point out that believe
15 it or not, the standards for radiation protection and
16 radiation safety -- Dr. Pollycove is chuckling over there
17 because I think in the last year or so he has had sort of an
18 eye-opening experience -- there are some problems out there,
19 and your point, Wayne, about regulating to the lowest common
20 denominator is something I think that generally speaking, as
21 regulators, we do have to do and it is the right thing to
22 do.

23 I think, unfortunately, some people will look at
24 that as, well, you have got the bad apple complex, whereas,
25 we are really doing a great job over here and your rules are

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 inordinately overbearing, but we have to strike that balance
2 somewhere.

3 I think what I am really hearing on this question
4 is that the question on whether Part 35 is overly
5 prescriptive or not prescriptive enough or
6 performance-based, what I am hearing is you are saying it is
7 really a mixed bag, you are saying that we perhaps should
8 try to get to the lowest common denominator, and you are
9 really saying there are instances where it needs to be
10 prescriptive and there are instances where it needs to be
11 performance-based.

12 MR. BAILEY: Ed Bailey from California.

13 Before you take that as a consensus opinion that
14 we have to regulate to the lowest common denominator, I
15 would suggest that there should be levels of regulation.
16 There is absolutely no reason that I can see that a
17 cardiologist, for instance, has to have the same set of
18 rules that a board-certified nuclear medicine physician has
19 to have.

20 MR. CAMPER: Are you speaking of training, Ed?

21 MR. BAILEY: No, I am talking all the way through.

22 MR. CAMPER: The radiation safety program across
23 the board.

24 MR. BAILEY: Right. I mean they are totally
25 different programs. Likewise, a radium quack or iridium

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 quack, whichever one you want them to be, there is no reason
2 that I can see that they have to follow every single rule
3 that a full-fledged nuclear medicine program has to follow,
4 or maybe they have more rules, I am not coming down.

5 I don't think the rules have to be written, so
6 that everybody has to do each one of these steps just
7 because they fall under the guise of nuclear medicine.

8 MS. DICUS: Greta Dicus, State of Arkansas.

9 This is totally off the subject of the medical
10 rule, but I have got to go and I won't be here, and I did
11 want to make some general statements in order to have them
12 part of the public record.

13 We are aware of the very large number of rules
14 that are going through the system, and they impact every
15 Agreement State. I think in the past year or two, somewhere
16 between 25 to 30 rules are being worked on or currently
17 considered. The impact on the States, both in terms of time
18 and people and money, is significant.

19 The second point that I would like to make is that
20 most, if not all, of these rules, decisions have been made
21 on compatibility without in some cases consultation of the
22 States. Particularly, I think Part 21 has gone from, let's
23 see, from Division II to Division I. I don't know that we
24 were consulted, and that does impact some of our programs.

25 Also, as has already been pointed out, there is

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 not a clear set of criteria to define how, who, what, when,
2 and where the decisions on compatibility were made.

3 A third point, we are being required to implement
4 rules that are flawed. The examples particularly are the
5 decommissioning rule, Part 20, and the medical diagnostic
6 misadministration rule.

7 We would like for these rules to be clear and to
8 the point, and all the flaws in the rules corrected before
9 we are required to implement them.

10 Again, I know I am off the subject, you do not
11 have to comment, I just wanted it as part of the public
12 record.

13 Thank you.

14 DR. GLENN: Greta, I will just mention I don't
15 think it is off the topic because one thing we are talking
16 about here is the process and long-term planning, and
17 although I can't control all the regulations, certainly in
18 the medical area one output of this strategy session may be
19 that we say we are only going to have two rules a year or
20 one rule a year at most, and get the maximum effectiveness
21 out of that rulemaking.

22 MS. DICUS: Well, another point, again already
23 made, but we regulate x-ray machines, we regulate
24 non-byproduct material, we regulate accelerators, and here,
25 when we are talking about the medical licenses per se, I

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 have got approximately 60 in my state, but I have 2,900
2 x-ray registrants.

3 When I have to implement a rule that has some
4 risk-based option to it, particularly misadministration, I
5 have got to implement it across the board, and I have to
6 implement it for dentists, for chiropractors, and so
7 forth. You have got to take that into consideration and the
8 impact, because when we went to implement our diagnostic
9 misadministration rule, we went to public hearing on it, and
10 our people said, well, what about the dentists, what are you
11 going to do about this, the people who came to our public
12 hearing, and we said, well, we hadn't thought about that.

13 So, we had to go back, try to define a diagnostic
14 misadministration on an x-ray machine, what is it, and what
15 is going to be the impact, and where is the risk. So, it is
16 important that that be considered when we have to implement
17 these rules.

18 MR. CAMPER: Thank you for your comments.

19 Any other general comments about performance-based
20 versus prescriptive?

21 [No response.]

22 MR. CAMPER: If not, then I would ask the question
23 and perhaps just a show of hands is sufficient, and I think
24 I know the answer, but it is should the rule be entirely
25 performance-based, should Part 35 be entirely

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 performance-based? Let me see a show of hands that believe
2 that it should be.

3 [No response.]

4 MR. CAMPER: Let the record show that there are no
5 hands. Okay.

6 What techniques should NRC use to identify
7 potential new rulemaking endeavors? Let me just set that up
8 a little bit for you. One of the things we have tried to do
9 very clearly is to go to the Advisory Committee on the
10 Medical Uses of Isotopes earlier and earlier in the process.

11 Similarly, we are trying to come to the Agreement
12 States earlier and earlier in the process to talk to you
13 about there is an issue or we believe that there is an issue
14 and we think that something needs to be done about it.

15 Now, what needs to be done about it is something
16 we have to work through and find out. It may or may not be
17 a rulemaking. Other than the communication, the improvement
18 of the communication technique, are there other things that
19 we could do to identify potential new rulemaking endeavors?

20 MR. BAILEY: Ed Bailey from California.

21 I think there should be one basic tenet that
22 should be put above everybody's desk, and that is, if it
23 ain't broke, don't fix it.

24 I think there should be a clear procedure whereby
25 a problem must be identified before you write a regulation.

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 I think what we have seen, not only in radiation, but in all
2 areas of rulemaking, is that very bright people come up with
3 a hell of a lot of "what-if's," and the way to solve or
4 answer all those "what-if's" is to write a rule or
5 regulation, so that you don't have a "what-if."

6 I very much support the concept of having
7 rule-writing groups, I think as Ruth can attest to, but we
8 must sort of remember that it shouldn't be anybody's job to
9 write rules simply for the sake of writing rules.

10 This question about regulating medicine. The
11 impression -- and it is not just my impression -- but it is
12 things that are verbalized about a lot of people. There is
13 a lot of M.D. envy, and we all make jokes about the
14 M-deities, and there are at least one or two regulators who
15 feel that, okay, we are going to get even with them now
16 because I couldn't be a physician, for whatever reason, and
17 I dare anyone to challenge me that that is not true.

18 I grew up I guess in a different atmosphere. I
19 grew up in a hospital where my attitude was if I can't get a
20 decent job, I can always be a doctor.

21 [Laughter.]

22 MR. BAILEY: There were some things I guess that
23 would have prevented that. I think we have to try to really
24 identify problems, and I think we can give some very good
25 examples of where problems were identified and then rules

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 developed, and these really to some extent have come up from
2 the States because, generally speaking, States have smaller
3 staffs and have more interaction with people in their field.

4 I would point out the well logging regulations,
5 the two-man rule in radiography, the testing of
6 radiographers really to determine that they have been
7 trained, not that they could pass a test.

8 I think when NRC decides to do rulemaking, the
9 first thing up front should be here is the problem, and that
10 problem should have to be related to radiation safety or the
11 national defense, or whatever.

12 That is my idea.

13 MR. CAMPER: Any other thoughts or comments on
14 ways to identify potential new rulemaking endeavors?

15 MS. ALDRICH: Rita Aldrich, New York State Health
16 Department.

17 This is a little bit off the subject, but it is
18 along the lines of what Ed was saying really. I don't think
19 that NRC thinks in terms of the fact that states make rules
20 on their own, they are not always simply adopting an NRC
21 rule.

22 So, in addition to the burden of any rules you
23 might think are good for us to adopt, states have -- and we
24 have I think heard frequent mentions of it here today --
25 gone and done their own regulatory initiatives. NRC may

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 wish to look at those as possible models for some of the
2 things they are doing or planning or thinking about.

3 Also, once we have done a major rulemaking, as we
4 are doing with Part 16 and the sections that apply to
5 medical use, we don't intend to touch that for quite a
6 while, so we will have done what we are going to do before
7 you come up with whatever it is you are thinking of doing to
8 Part 35.

9 We are not going to go back and revisit that. We
10 have got, as Greta said, Part 20 to work on. That is going
11 to be a very intensive, not only rulemaking, but followed by
12 information programs for licensees and working on
13 interpretations. Shaking that all down is going to take an
14 enormous amount of time and effort.

15 There is a financial assurance rule which I, at
16 this point, don't know how we are going to adopt it given
17 all of the holes that exist, but we need to do something.
18 We need financial assurance, the waste crisis alone makes
19 that critical.

20 Those are two major rules that could eat up
21 enormous time. I mean even the New York State Health
22 Department, we do not have a big licensing program. I have
23 two full-time licensing staff plus me, and I do licensing in
24 addition to whatever else, you know, wash windows, clean
25 floors.

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 But I think that you should keep that in mind. I
2 don't think you are looking at the fact that the states
3 undertake rulemaking initiatives on their own, also address
4 and solve problems in ways other than rulemakings on their
5 own, and that having done that, not only do they not want to
6 turn around and adopt something or change something just
7 because NRC has decided that is a good idea, but the time
8 and the resources are not there.

9 MR. CAMPER: I appreciate that. Just a comment or
10 two about Part 35 again. We really don't have any plans to
11 do anything to Part 35 at this point about this particular
12 endeavor.

13 I mean we know that there are certain things in
14 Part 35 that need to be cleaned up because there are
15 inconsistencies between Part 35 and Reg Guide 10.8, and we
16 know that those things need to be addressed at some point.
17 We want to get to that sooner or later.

18 Assuming the Commission accepts the staff's
19 recommendation on the radiopharmacy rulemaking, there will
20 be a need there to make some adjustments in Part 35 because
21 it is going to change things rather significantly, but other
22 than that we have no preconceived idea at this point in time
23 to make any changes in Part 35 other than administrative
24 clean-up and what is necessary from rulemakings that are
25 currently under consideration.

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 I mean it could well be when we go through this
2 entire process and hold these meetings, and so forth, that
3 the conclusion is that the things we currently have underway
4 are sufficient at this point in time and that we should
5 revisit this at some point in the future. So, really, we
6 have no plan at this time.

7 MR. GODWIN: Godwin, Arizona again.

8 I am not sure it is on the record, but I think it
9 should be on the record, that regarding professional
10 qualifications of the physician, particularly in the
11 clinical area, I feel that the professional boards and
12 certification bodies of the physicians is probably one of
13 your better sources for determining that, and I think we
14 ought to support that strongly.

15 There may be a need to grandfather in those that
16 are currently practicing, and there is probably a need to
17 provide an alternate way for people to qualify, but I think
18 we ought to lean strongly toward the professional boards,
19 and even to the extent of where they adequately address
20 radiation safety as far as operations, we might look at
21 that, too, but I am not sure all of those boards currently
22 do that.

23 On the other hand, regarding quality assurance,
24 they probably set up good model programs, and they probably
25 do a lot of work, but for the most part they are not as

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 independent as I would desire, and I think that we need to
2 maintain our regulatory oversight and provide unannounced
3 independent reviews of what is going on.

4 Certainly, they can supplement and may justify
5 somewhat reduced inspection frequency, but I don't think you
6 can walk away from it and say just because they have an
7 independent quality review that you don't need to go in and
8 make an independent assessment.

9 Certainly, we ought to encourage them to develop
10 these things because I think their primary focus is
11 something that may not always be our ability to direct. For
12 example, I think they can do a much better job of improving
13 patient care, which may not totally be a radiation safety
14 issue, and I think that we ought to encourage that and, to
15 the extent possible, encourage them to push that with their
16 groups.

17 MR. KULIKOWSKI: Bob Kulikowski, New York City.

18 I would like to reiterate both what Aubrey and
19 Rita said. I, too, do licensing at home, I only have two
20 licensing people. Rulemaking is an onerous task for us.
21 There are a number of things that are coming down the pike
22 that we have to do.

23 I realize the "C" word is not part of this
24 discussion. However, just like Greta, I am going to sort of
25 break the rules. That is what rules are usually for -- not

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 for licensees, of course.

2 Especially with respect to rules that, as Greta
3 put them, are flawed, and we have to adopt them within the
4 three-year time frame flawed or not, or we get a finding of
5 perhaps adequate and not compatible, or a finding of
6 compatibility is withheld upon the program review -- and
7 this is a comment that I made in response to some Federal
8 Register Notice about a year ago -- it seems very strange to
9 me that you can find a program adequate but not compatible.

10 If the program is adequate, in my estimation
11 everything is there, that is in place, that makes it
12 compatible. I mean if you look at compatibility as being
13 compatible with the Commission's goal of protecting public
14 health and safety from radiation, if the program is found
15 adequate, I don't think you can make a finding of not
16 compatible.

17 MR. QUILLIN: Quillin, Colorado.

18 I have been around this business for 30-some years
19 now and I think that when you ask about the need for rules,
20 one of the observations I have to make is that sometimes I
21 wonder what prioritization the NRC uses in picking the
22 development of one rule over another.

23 Has the NRC ever gone through a process where they
24 have tried to prioritize the problem areas and then tried to
25 address their rulemaking process from that perspective?

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 DR. GLENN: I will just make a quick comment. We
2 do -- you may not agree with it -- but, in fact, Research is
3 required to submit to the Executive Director of Operations
4 on a periodic basis a listing of all rulemakings, what the
5 priorities are, which ones are being put off indefinitely,
6 and there is a little rationale for every one of them.

7 So, in fact, there is such a process.

8 MR. CAMPER: Interestingly enough, you know, we go
9 through a much similar process further down the scale, as
10 well. We take a look at things that are under
11 consideration, try to make some determination as to which of
12 these things might require rulemaking and which can be
13 handled in other ways.

14 Now, the two rulemakings that we are working on
15 right now, one results from a petition filed by -- actually,
16 there are three rulemakings -- two of them result from
17 petitions filed and the third, dealing with pregnancy and
18 breast-feeding, resulted from a number of incidents that
19 were occurring that had some fairly significant consequences
20 that we felt we needed to do something about.

21 Let us try to go back to focus on what we are
22 doing here. The next question was: What level of research
23 and analysis should be used to make the decision to forward
24 with rulemaking?

25 Just to kind of set the stage for the question,

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 when we asked this question to the Advisory Committee,
2 amongst the answers that we got was "the right amount."
3 That is hard to argue with.

4 Of course, things such as scientifically credible
5 arguments, trying to take a good look at risk, and comparing
6 the risk to the population as a whole or to certain elements
7 of the population.

8 Are there any other thoughts about what we can do
9 in terms of research and analysis that we could bring to
10 bear in decisionmaking as to whether or not to move forward
11 with the rulemaking process?

12 MR. BAILEY: That is a different question.

13 MR. CAMPER: Yes, it is.

14 MR. BAILEY: Bailey from California.

15 The phraseology used in the question orally was
16 different from what is written there. Do you want both of
17 them answered? I think they are different.

18 MR. CAMPER: Right. What level of research
19 analysis should be used to make the decision to forward with
20 rulemaking? That is the question. What level of research
21 and analysis?

22 MR. BAILEY: Well, certainly, there should be the
23 research that goes forward with the rulemaking, that
24 provided the basis of your deciding to do a rulemaking.
25 That is where I see the difference in the question.

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 You need to say why you decided to do this, what
2 compelled you or what -- sometimes it is very simple, a new
3 law passes, and we are told to write a rule, so that is a
4 pretty compelling reason.

5 For other rulemakings, I think there needs to be a
6 justification, and that may or may not involve research, but
7 it will always involve an analysis.

8 MS. MAUPIN: I am going to digress here and try to
9 respond to some of the issues concerning compatibility since
10 I have been the project manager on that for I guess over the
11 last three years now.

12 Basically, I know that without communication there
13 can be no progress, and I don't want you to think that you
14 are raising issues here on compatibility and no one is
15 hearing you. I am hearing you, and we have heard you.

16 It is kind of complex to make a finding that a
17 state is adequate and not compatible, but that happened over
18 the history of the program because initially, there were
19 basically three different types of findings: one, that a
20 program was adequate, could be adequate, but they could also
21 be compatible, but not in areas affecting public health and
22 safety.

23 Then, there was the finding, yes, you can be
24 inadequate, but compatible. So, I just want you to know
25 that this is a complex issue. I know that right now

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 compatibility is only held in regard to regulations, and we
2 know that there is concerns whether or not compatibility
3 should address the overall program areas.

4 We did make some responses back to the Commission.
5 As you know, we are awaiting their decision. There were
6 some complicated scheduling concerning the Commissioners
7 over the summer, and they were not able to respond back
8 concerning this issue.

9 But I want you to know that your concerns have not
10 fallen on deaf ears and that we are trying to respond, but
11 as I said, now it is in the Commissioner's hands.

12 MR. CAMPER: Thank you, Cardelia. I think we all
13 look forward to getting the compatibility question resolved.

14 Let me go to the next question on this particular
15 issue. Are there other provisions of Part 35 that we have
16 not discussed thus far, that interfere with effective
17 regulation of the medical licensees?

18 At the ACMUI we heard that Part 35 was generally
19 overly prescriptive. They felt that we perhaps should
20 revisit the data for the 1987 rulemaking, the last time we
21 implemented changes to Part 35.

22 They also felt that perhaps that there were
23 industry standards in existence today that might allow some
24 form of deregulation. Then, of course, I think the one that
25 they felt most strongly about was the ability for medical

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 licensees to procure radiopharmaceuticals with much more
2 flexibility than is currently allowed in the wording in Part
3 35.

4 We have, as I mentioned a while ago when giving
5 you the overview, the staff proposes to make a fairly
6 dramatic change, suggest a change in the language in Part
7 35, to open up and provide great flexibility to medical
8 licensees as to where they may procure radiopharmaceuticals.

9 So, we think we are going to address that
10 particular issue very thoroughly.

11 DR. GLENN: I don't mean to interrupt, but you
12 have just given me a very good opportunity to make an
13 announcement. That is, that John Telford has in fact
14 brought along copies of the draft rule language to address
15 the radiopharmacy petition, and those will be available for
16 you to pick up today. I just couldn't pass that up.

17 MR. CAMPER: That is good news. I think when you
18 read that language, you are going to see that it is (a) a
19 tremendous simplification as compared to what we have
20 discussed with you previously, and you are also going to
21 find that it is all about suggestions that came out of the
22 meeting in Atlanta with the Agreement States.

23 It was received very well by the Advisory
24 Committee, even including Dr. Marcus, who was the primary
25 author of the petition. So, we think it is constructive

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 changes in language, we think it does protect public health
2 and safety while providing flexibility to medical licensees,
3 and it does recognize the practice of radiopharmacy.

4 It has to undergo management review and
5 concurrence, OGC review and concurrence, as well as
6 Commission consideration, but the schedule for that is of
7 submitting the rule in December.

8 So, setting aside for a moment this question of
9 radiopharmaceutical procurement, the practice of
10 radiopharmacy, and flexibility, as it currently exists in
11 35.100, 200, 300, and so forth, are there any other
12 provisions of Part 35 that interfere with effective
13 regulation of medical licensees, interfere with effective
14 regulation of medical licensees?

15 [No response.]

16 MR. CAMPER: Seeing no expressions, hearing no
17 comments, we will assume that there are none.

18 [Laughter.]

19 MR. GODWIN: I guess since I don't have all of the
20 provisions of 35 that we have been trying to enforce, it
21 makes it a little tough to answer your question, but as I
22 recall, you all had certain flexibility relative to changing
23 procedures by the licensee.

24 I would guess that probably has caused you all
25 some problems relative to discussions between you and the

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1812 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 licensee as to whether the changes made by the licensee were
2 within the scope of authority of the rule. I would guess
3 that could be an impediment in some cases, but I don't know
4 since I don't have that provision.

5 DR. GLENN: I will make one comment. I think
6 probably the flexibility is not being exercised very much
7 because the licensees are afraid that they will make a
8 mistake and then we will cite them for it.

9 We haven't had too much of a problem with regard
10 to after the fact interpreting administrative changes if they
11 have been made, but my understanding in talking with certain
12 members of licensees is that they are very cautious in terms
13 of making administrative changes.

14 MR. CAMPER: Okay. The next question is one that
15 you may or may not be able to offer much specific
16 information on because it is not an item of compatibility
17 yet in terms of implementation in the Agreement States.

18 The question is: Is there evidence that either
19 the submittal of QM programs or the subsequent recordkeeping
20 requirements have posed an undue burden on medical
21 licensees?

22 It is still early in the game. It would be
23 difficult for us to answer this question, as well. We just
24 don't know yet. It is very early in the game. Clearly, for
25 you it is an item of compatibility, but not for

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 implementation as of yet.

2 The Advisory Committee also agreed that it was
3 still early in the game. They felt that perhaps some of the
4 estimates for burden were somewhat underestimated, and they
5 had some questions about the audit component itself.

6 But in the absence of evidence, given that it is
7 not effective in your states yet, and it is still early in
8 the game, are there any general thoughts that anyone would
9 like to express about whether or not the Quality Management
10 Program, the submittal of the Quality Management Program, or
11 the recordkeeping requirements pose an undue burden?

12 I know we have heard a lot of criticism about the
13 Quality Management rule -- I certainly sat through a lot of
14 that in its development -- but are there any additional
15 comments?

16 MR. RATLIFF: Richard Ratliff of Texas.

17 I think the main problem I see on any of those
18 recordkeeping requirements, you can relate back to
19 radiography where you see direct threats, is that if you put
20 too much emphasis on the records, the person makes records
21 and there are records there available to look at, but
22 whether they performed the survey or actually completed the
23 radiation safety task with that in mind rather than keeping
24 the record, I think you get derailed that way.

25 MS. HADEN: Robin Haden, North Carolina.

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 This is where I have to make one of those offhand
2 comments. Our licensees are already required to do almost
3 everything that is in the QM rule. They are already keeping
4 the documents, so no, there won't be any great impact on
5 them. They are already submitting the programs with their
6 license applications, and they are already keeping the
7 records.

8 However, the other side of that is we are still
9 looking at a compatibility rule that is going to require a
10 change to our regulations. It is a very intensive process
11 that we are already doing something that is equivalent.

12 No one has talked to us about it to this point.
13 No one has said if you have got something that is already
14 effective -- our policy is already as effective as the QM
15 rule in essence.

16 So, here we are getting around again to the "C"
17 word that nobody really wants to discuss and talk about, but
18 what some of the Agreement States are doing is already as
19 good or better than the NRC, and we need to take that to
20 task.

21 MR. KULIKOWSKI: Bob Kulikowski, New York City.

22 I just want to reiterate what Robin said, and I
23 think one of the operative words is "equivalent," does
24 compatibility -- again, we are going to beat this word to
25 death -- because we need to know whether compatibility means

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 verbatim, word for word, or whether it means equivalent.

2 I mean you can have something which is equivalent
3 to protect public health and safety, and it may not be a
4 regulation, it may be a license condition because it affects
5 only one of your licensees.

6 Just in the general tenor of regulation, I think
7 this gets back to the analysis question that you brought up
8 earlier, Larry. You know, rule-writing is not the panacea.
9 You know, it is appropriate in certain situations, it is not
10 appropriate in other situations to address an isolated
11 instance or even a few isolated instances or incidents.
12 There may be better ways to go about it.

13 I am not saying that a rule is not required, but I
14 am saying that sometimes something happens in the regulated
15 community does not warrant a rulemaking.

16 MS. ALDRICH: Rita Aldrich, New York State Health
17 Department.

18 You are probably asking the wrong people about
19 problems with Part 35, since I don't know about the other
20 states, but we don't deal much with Part 35. You know, we
21 haven't adopted much of it. You probably should be asking
22 your licensees instead. I don't think you should take our
23 silence for a statement that everything is okay. I just
24 think you may be asking the wrong people.

25 But on the other subject, as I said, we are

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 requiring Quality Assurance Programs -- it is not quality
2 management programs, quality assurance is a more extensive
3 type of program -- we are not requiring them to be submitted
4 any more than the other agencies within the State Health
5 Department that require quality assurance, such as the
6 Office of Health Systems Management, in the x-ray regulatory
7 program, require them to be submitted. They are matters of
8 inspection.

9 So, there again is an area where we have already
10 done something that is different from what you are doing,
11 but it certainly more than accomplishes the goal that you
12 intend, because after all, the Quality Management rule has a
13 very limited objective, to -- how should I put this -- to
14 minimize the likelihood of random error, whereas, our
15 quality assurance approach is, one, to optimize, and two, to
16 minimize the likelihood of both random and systematic error.

17 MR. BAILEY: Bailey from California.

18 I think one thing you could put in NRC rules --
19 because when I look back at our agreement with AEC, the
20 statement is, "The State will do its best to remain
21 compatible," and the next sentence says, "and the Commission
22 will do its best to remain compatible also."

23 I think the NRC should require in the Medical
24 Section, that in states, number one, that the nuclear
25 medicine physician be licensed to practice in that state and

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters

1612 K. Street, N.W., Suite 300

Washington, D. C. 20006

(202) 293-3950

1 because they do work on citizens of that state, and number
2 two, if that state requires licensed nuclear med techs, that
3 those people should have to be licensed by the state before
4 they are allowed to work in an NRC-licensed facility.

5 MR. CAMPER: We are going to tackle that
6 particular topic again this afternoon when we talk to this
7 overall question of supervision, but I appreciate your
8 comments.

9 I will move to the next question, then, and again
10 this is a question that -- well, not this one, but the
11 following question is one you may not have specific input on
12 -- this particular question is: Is there evidence that the
13 use of the term "misadministration" has had a negative
14 impact on the practice of medicine or directly resulted in
15 medical malpractice suits?

16 Is there evidence -- is there evidence that the
17 term "misadministration" has had a negative impact or
18 resulted in malpractice suits?

19 Ed is shaking his head in the affirmative.

20 MR. BAILEY: Yes. Ed from California.

21 MR. CAMPER: Do you have an example?

22 MR. BAILEY: Yes, HIV-positive patient. The
23 hospital has settled out of court with the patient. She
24 came back to the hospital with her lawyer because of
25 misadministration.

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 Interestingly enough, according to NRC rules, it
2 is not a misadministration.

3 DR. GLENN: Ed, I guess following up, is there any
4 evidence that the word --

5 MR. BAILEY: Yes, yes.

6 DR. GLENN: If it had just been reported, there
7 wouldn't have been the suit? That sounds like the one which
8 was just ready for malpractice all the way.

9 MR. BAILEY: I don't know if you can separate the
10 word from the action. I mean it implies you did something
11 wrong.

12 DR. GLENN: Maybe to put this question a little
13 more in context, I guess the reason we asked this question
14 is people have told us that just the word itself is damaging
15 because of the negative connotations and that what the NRC
16 is really interested in is learning about significant events
17 and evaluating them to see if there is something that needs
18 to be done. But you are still saying yes.

19 MR. BAILEY: Yes, it is definitely a negative
20 word. Now, I am not sure -- well, the interesting thing
21 about misadministrations is they are not illegal, which I
22 find weird, but you have to then be very careful on what you
23 call a misadministration if you are in fact going to make
24 them illegal.

25 On the other hand, if you deliver what the doctor

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 prescribed, it is not a misadministration. We have got a
2 doctor now in California that is beating us about the head
3 and shoulder. He said I made a mistake, I prescribed twice
4 as much dose as I should have. I made a mistake. I want to
5 report it.

6 We are saying it doesn't fit in the category. So,
7 that kind of thing needs to be corrected, too, and I think
8 that that doctor wanted people to have that information
9 available to learn from what he did wrong, and he wanted it
10 in the system to be counted, here is what is going wrong.

11 MR. CAMPER: Let me ask the question again. Just
12 a show of hands.

13 You might recall that the staff at one point had
14 suggested to the Commission that the term "reportable event"
15 be used to define or describe these events that occur as
16 opposed to the term "misadministration." In the final
17 analysis, the Commission chose to stay with the word
18 "misadministration."

19 Just by a show of hands, the word "reportable
20 event" versus "misadministration," could I see a show of
21 hands of the States' representatives that would favor the
22 use of the term "reportable event" rather than
23 "misadministration."

24 [No response.]

25 MR. CAMPER: Could I see a show of hands in favor

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 of the term "misadministration."

2 I see a couple of hands favoring
3 "misadministration," and I see no hands favoring the term
4 "reportable event," and I see a lot of abstentions. Okay.

5 MR. KULIKOWSKI: Bob Kulikowski, New York City.

6 Just to follow up on what Ed said, we actually had
7 a misadministration event that turned out to have
8 significant impact in that it caused regulatory changes from
9 another aspect at the State Department of Health level with
10 regard to blood banking.

11 That was we just didn't have a dirty needle used,
12 we actually had an Indian 111 white blood cell labeling that
13 was mixed up between an HIV-positive and an HIV-negative
14 person. It was reported to us because it was the wrong
15 patient.

16 However, the implication -- and I don't know what
17 all the legal follow-up has been with the licensee -- but it
18 is a severe -- it is a strange misadministration, if you
19 will, because from a radiological health aspect, the fact
20 that the person got -- he was going to get that much
21 radiation anyway, so in that sense it was not a radiological
22 misadministration, however, it certainly was a lethal
23 misadministration, if you will.

24 You have almost got to do it on a case-by-case
25 basis, it would seem. Obviously, there are some things that

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters

1612 K. Street, N.W., Suite 300

Washington, D. C. 20006

(202) 293-3950

1 are of relatively little significance in diagnostic. There
2 are other things where the basic procedure which you would
3 hope to have in place in the Quality Management-Quality
4 Assurance, what have you program, to ensure the safe
5 administration of that dosage, really probably would have
6 prevented this. This happened a few years ago.

7 I don't know whether there is any clear-cut answer
8 to your question, Larry. You are always going to find the
9 exception.

10 DR. GLENN: Since Steve Collins I guess had to
11 leave, I will mention I think, he raised at the Advisory
12 Committee meeting the possibility that you get more reports
13 if you don't call them misadministrations, that if it is
14 called a reportable event, that you will get better
15 compliance with the reporting requirement.

16 MR. CAMPER: Yes, and his comment was that you
17 lose nothing by calling it reportable event versus
18 misadministration, you get the very same data.

19 MR. KULIKOWSKI: Bob Kulikowski, New York City
20 again.

21 We have always called it a misadministration, and
22 don't seem to have any problems with our licensees. I have
23 not had any negative -- I have not had people call me up
24 screaming, saying I can't report it because it is a
25 misadministration.

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 MR. GODWIN: Godwin, Arizona, but at the time I am
2 fixing to talk about it was Alabama.

3 We had an event which was a misadministration or
4 should have been a misadministration, and the hospital
5 promptly turned it over to their risk management lawyer, who
6 promptly claimed it was -- or started off going to claim it
7 was a lawyer-client privilege and wasn't real gung ho to
8 report it. We had to lean on him a little bit about that,
9 but we thought we were going to have a real problem.

10 They came on through and reported it, but I wonder
11 if that has interfered or become an issue relative to any of
12 these rules.

13 DR. GLENN: I don't think there has been any legal
14 challenge to our right to require reporting.

15 MS. ALDRICH: Rita Aldrich, New York State Health
16 Department.

17 Again, in New York State, I believe that incident
18 with the mix-up of the blood cells came in through this
19 mechanism. The Office of Health Systems Management within
20 the Health Department has an incident reporting program that
21 is confidential. The initial reports are not subject to
22 FOIA.

23 It was set up that way by the legislature. That
24 encourages reporting, that the information won't be
25 disclosed unless a finding of deficiency is made against the

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 institution. At that point it can be disclosed.

2 The terminology appears to be unimportant. Once
3 it is reportable, it doesn't seem to matter what you call
4 it. It is the reportability that drives things. So, most
5 of the medical community we have talked to doesn't think it
6 matters, whatever term you use eventually become pejorative
7 because the connotation is it is a reportable error,
8 therefore, it is important and it is going to get us in
9 trouble from a legal perspective.

10 MS. ROTHSCHILD: Marjorie Rothschild from NRC,
11 Office of General Counsel.

12 John, I just wanted to make sure, did I hear you
13 right, you said there has been no legal challenge to our
14 right to require reporting?

15 DR. GLENN: Right, and I guess in the narrow sense
16 that it is a violation of doctor-patient relationships. I
17 know the QM rule was challenged in court, but that wasn't
18 the basis for it.

19 MS. ROTHSCHILD: Right. That is what I just
20 wanted the record to reflect, that the NRC was sued on the
21 QM rule, and I believe that included a challenge to the
22 revised misadministration reporting requirements in the
23 rule, and NRC's position on the rule was upheld completely
24 by the D.C. Circuit, and the suit was, in effect, thrown
25 out.

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 So, to that extent we were challenged and upheld.

2 MR. CAMPER: Okay. The final question in this
3 particular part is -- and again this is a question you
4 probably can't give much specific evidence of at this point
5 because it is early in the game, but again perhaps a general
6 comment about your thoughts on it -- the question is: Are
7 there any examples that the QM rule is an encroachment on
8 the practice of medicine? Any thoughts on that?

9 [No response.]

10 MR. CAMPER: Okay. I see no comments.

11 We are at a point, Vandy, where we could break for
12 lunch in terms of what we are doing. We will come back.
13 The next section that Dr. Glenn will cover is Inspection and
14 Enforcement. Also, Jim Lieberman, the Office Director for
15 Enforcement, will be here in case we have any tough
16 questions.

17 Then, we will be talking later on, after that,
18 about medical supervision including related training and
19 experience issues. That should be lively.

20 CHAIRMAN MILLER: Yes. I just want to emphasize
21 that we really need to get back promptly at 1 o'clock
22 because we must be out of this room by 4:00, not in the room
23 at 4:00, but out of it by 4:00, so we will need all the time
24 we can muster for the afternoon session.

25 We certainly want to give the panel this morning a

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 big hand for the morning session.

2 [Applause.]

3 [Luncheon recess taken at 11:51 a.m.]

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters

1612 K. Street, N.W., Suite 300

Washington, D. C. 20006

(202) 293-3950

AFTERNOON SESSION

[1:00 p.m.]

CHAIRMAN MILLER: We will ask that you give us your attention now as we kick off the afternoon portion of the Medical Issues Paper discussion.

In speaking with John Glenn, he feels that we are pretty much on schedule, and that means then that we will be able to clear this room by 4:00, and we continue to seek your spirited discussion on the issues that we are going to be laying out here for you.

Now, to kick it off for the afternoon, we have Dr. John Glenn, who will kick it off.

DR. GLENN: The next topic that is contained in the issues paper has to do with inspection and enforcement, and of course, I think that is sort of where the rubber meets the road with respect to the regulatory program.

I think a lot of the comments that were made in terms of the regulations relate to the fact that you want the regulations to be prescriptive enough that you can have an effective inspection and an enforcement program to achieve the objectives.

Certainly, we feel that the objectives of our inspection program are to be able to identify licensees who are not running safe programs, not complying with the radiation safety regulations, and the purpose of the

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters

1612 K. Street, N.W., Suite 300

Washington, D. C. 20006

(202) 293-3950

1 enforcement program is to assure corrective action is taken
2 and is hopefully lasting. We want to fix it now and keep it
3 fixed.

4 We are going to be exploring some questions about
5 how we do inspection and enforcement, seeking comments on
6 ways that they could be done differently, better, other
7 alternative methods to achieve our objectives, assuring that
8 there are safe programs being conducted out there.

9 I think one criticism we frequently hear from the
10 regulated community is that our inspectors focus in on the
11 nits, piling up violations, not looking really for safety,
12 but for the small items.

13 My experience has been that I think NRC and
14 Agreement States have very similar programs. So, I pose the
15 question: Do our current inspections focus on those aspects
16 of programs that are most important to radiation safety? Is
17 there any legitimate criticism that we focus too much on
18 records, paper, those kinds of compliance issues?

19 MR. FRAZEE: Terry Frazee from Washington.

20 I think it might be worthwhile if NRC did do an
21 audit of their inspectors and just take a look at what
22 percentage of time they do spend looking at records versus
23 observing operations, interviewing employees, and making
24 actual measurements.

25 A test case of one. One of my inspectors did

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 accompany an NRC inspector recently, and my inspector came
2 back fuming because there was too much time spent on the
3 records, and that is something that in my program and in my
4 opinion, you know, records are way, way down on the list. I
5 mean we do them in many cases because the NRC says we have
6 to.

7 My own philosophy is, you know, get out there and
8 like a politician, press the flesh, talk to people, find out
9 what is going on, you know, how are things happening, watch
10 what they are doing, yes, look at some records to make sure
11 that it looks like they following through on that end of it,
12 but that is not a high priority with me.

13 I think what I would like to see would be the
14 amount of time that you save by not doing inspection of
15 records, not reviewing records becomes time saved that can
16 be invested in doing additional inspections, and in fact,
17 coming back more often.

18 It is the frequency of visits that needs to be
19 improved even at the risk of doing something less on the
20 inspections. That increased frequency, you know, name
21 familiarity, you know them, they know you, there is
22 communication that is increased, the communications in a
23 sense of also being instructors.

24 Just talking with somebody you are instructing
25 them as to what you think ought to be going on in their

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 program, and I think that is a valuable tool in terms of
2 gaining compliance.

3 DR. GLENN: I certainly agree with you on the
4 audits. I guess one thing we do, in fact, make it sort of a
5 performance requirement on our supervisors in the regional
6 offices, that they do accompaniments of inspectors and
7 actually do some field audits of inspectors.

8 But we have never instituted any sort of
9 measurement process, some sort of objective measure to see
10 how the inspections are actually conducted, get feedback on
11 whether, in an objective manner, we can determine that
12 indeed the time is going where we want it, observing actual
13 operations, determining that people understand the
14 requirements, records to the point that they verify that
15 what somebody is doing when they know you are there is also
16 what they do when you are not there.

17 Let me just ask the question. In the Agreement
18 States, do any of you have an especially good way of
19 auditing inspector performance that we can maybe consider as
20 a good model?

21 MS. ALDRICH: Rita Aldrich, New York State.

22 We do annual accompaniments of each inspector. We
23 have a field supervisor who tries to ensure consistency
24 among inspectors. It is one of the biggest problems you
25 have with the regionalized program.

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 Everybody has their own personal approach to this.
2 We have at least one inspector who, left alone, would look
3 through records until she just got kicked out, you know, and
4 it is not terribly productive is our finding.

5 Also, from your original question, we sent out to
6 all of our licensees last year an audit form, and we said
7 they could use this or something of their own. Actually,
8 what we did was we took it out of that ALARA Medical
9 Institutions new reg. We took that and modified it to suit
10 ourselves.

11 Essentially, what we did was make a deal. We sent
12 it out with a notice to licensees that if they would do
13 these audits on a regular basis -- we suggested it
14 quarterly, but smaller licensees, you know, we told the
15 inspectors, encouraged them to call us if they want to make
16 it a longer interval because that is kind of frequent -- but
17 if they would audit their own records, when we come for
18 inspection, we will just spot-check. If the spot-check is
19 okay, we won't go any further.

20 We also modified our inspection form. We divided
21 it up into modules. Along the lines of what Terry was
22 saying, we have decided that the important thing is to get
23 there, and times are tight, money and staffing are problems,
24 we are going to get there. If we have to abbreviate the
25 inspection, we will.

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 So, we divided the form up into modules, ranked
2 them in order. The first one is waste management because it
3 is kind of important right now. Those first few have to be
4 done. After that, it is up to the discretion of the
5 inspector.

6 Our inspectors are very well trained, very
7 professional. We trust them to make those judgments based
8 on the past history of the licensee. We find that licensees
9 appreciate this. They don't like being hassled all the time
10 about records, and then get a letter that says we found one
11 day out of the last 365, we didn't do a moly breakthrough. It
12 is not productive, and I think the licensees decide in many
13 cases that we will make the record instead of doing the
14 action because we know that is not going to get us in
15 trouble. That is exactly where you don't want to go.

16 DR. GLENN: And you found that that has worked
17 rather well, people actually document they are doing the
18 audits?

19 MS. ALDRICH: Yes, it is working well. We wanted
20 them to be more familiar with their own program, not to use
21 us as an auditing function. I think a lot of what we do for
22 our licensees is giving them free health physics services
23 that we shouldn't be doing. I would rather have them do it.

24 Also, Ed Wright from Oregon -- I get the Wrights
25 mixed up -- whichever one works for Oregon, at the Atlanta

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 meeting this summer, mentioned a form designed for
2 hospitals, that one of their licensees was using. I asked
3 him to send me a copy of that.

4 We are modifying that. The other form could be
5 used. We have modified it, so you could use it in any kind
6 of a program. But this one is specifically directed towards
7 medical, and it includes a lot of QA, Joint Commission
8 oriented, which is what we have put in our regulations, and
9 might be more useful to them.

10 We have had one broad licensee submit their own
11 form that was excellent. We have also circulated that to
12 our licensees, and we did do one other thing. I don't know,
13 about a year or a year and a half ago, in the Health Physics
14 Journal, there was an article by an RSO at a large academic
15 institution.

16 It was about outside audits. I approve of outside
17 audits, everyone should have one. What they were doing was
18 he would have an RSO from a similar institution come in
19 every year and audit his program, and he would return the
20 favor. This was a good article on how his program worked.

21 We sent that out to all of our broad licensees and
22 our other larger licensees and suggested to them that they
23 could really improve their programs if they did this. So,
24 we are waiting to see whether or not they implement that
25 one.

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 MR. WHATLEY: Kirk Whatley from Alabama.

2 I think it is important, the attitude a licensee
3 takes towards an inspection and following rules is vital to
4 all of us. They need to want to follow rules, and they
5 don't need to follow them simply because they have to.

6 That is an attitude that we have tried to get our
7 licensees to use over the years. I think we contribute to
8 those attitudes the licensees have. Let me give you an
9 example.

10 A few weeks ago, we got a new employee in our
11 office, that has actually been working in public health for
12 an excess of 20 years, but he has switched over to our
13 department. He accompanied one of our inspectors.

14 They went out and did a long inspection of a
15 pretty good-sized hospital. In the closeout interview, the
16 inspector sat down with the administrator, and literally
17 bragged on the program about all the good things that were
18 going on and what a good program they had.

19 But there was one little, small item on
20 noncompliance, and we came back. The inspector drafted his
21 letter, and it was reviewed by this new employee. He came
22 into my office, and he said, "Is this the way we write our
23 letters?"

24 I took a look at it, and I really hadn't looked at
25 it before, and basically what it said was your program is in

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 bad shape, you know, you have got one item of noncompliance.
2 It never reflected all the good things that had gone on.

3 It said you have got to post this thing on your
4 wall, you have got to reply within 30 days, and all of this
5 stuff. You know, we are going to change that. I went back
6 and asked our inspectors where that came from, and they said
7 that is the way NRC said do it in our inspection course.

8 I don't whether that is right or not. I am just
9 telling you what was said. I think we need to emphasize
10 some good things people do, too, and not just dwell on one
11 little, small bad area sometimes. I think we can contribute
12 to improving things by changing some things, such as that.

13 MR. CAMPER: Just to follow Rita or Terry or Kirk,
14 for that matter, I hear you saying that you use an audit
15 function, a sampling, if you will, of records, and you place
16 a review of records per se, for the sake of reviewing
17 records, sort of down the list of priorities in your
18 inspection.

19 I assume that in each of your states, your
20 licensees commit, they send in a program, they say they are
21 going to do certain things, they are going to keep certain
22 records, they give you examples of those records, and so
23 forth.

24 But then when your inspectors go out, you are
25 looking at your regulatory requirements and you are also

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 looking at the commitments the licensees make.

2 Now, in the process of looking at the commitments
3 the licensees make, you sample some records. I guess what I
4 would like to know is at what point -- let's say, for
5 example, you are sampling and you find two or three
6 dose-calibrator constancy checks that were not done on
7 certain days, what do you do then?

8 Do you then delve more deeply into the records?
9 Do you simply say that, well, we observed that there were
10 two or three things that were not recorded, but we chose not
11 to go any further? Do you cite them when you uncover
12 through your random process that this hasn't been done?

13 I guess I am trying to understand what is your
14 threshold for determining that there is a need to look more
15 closely at the records, perhaps cite for having not done
16 these things or at least not recording them.

17 How does that work for you, generally speaking?
18 As you answer, how much discretion do your inspectors have
19 in the field versus what management -- in other words,
20 management can set the tone for your inspectors.

21 You can let them have a great deal of discretion
22 or you can set up a scenario where inspectors feel like if
23 they miss anything, they are in trouble, or if some
24 inspector follows them later, it is going to be viewed badly
25 if they overlook something. Just generally, how do you

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 handle that?

2 MR. FRAZEE: Terry Frazee from Washington.

3 You asked too many questions. I can't handle them
4 all at the same time.

5 As far as records are concerned, we do the
6 sampling of records in cross-check with other similar
7 records or interrelated records, sort of get a feel for what
8 was happening during a period of time.

9 If the inspector starts to see gaps in the
10 records, they will start -- a couple of options -- they can
11 start looking even further and making a big case, if you
12 will, because they missed records or they can just say, hey,
13 look, based on some sampling it appears that you are not
14 doing such a good job on keeping up with records.

15 It depends on whether it is current history or
16 ancient history. You know, you go back and you sample, and
17 you may pick out 10 months ago and pull it, and, you know,
18 so there are a few that they are missing back then. I mean
19 that is not as significant as if, when you walk in today,
20 and yesterday's records are not complete.

21 To jump into one of your later questions, it is
22 quite a bit inspector judgment, you know, how does this
23 inspector feel about this licensee based upon his
24 observations and interviews with the licensee.

25 That will have a great influence upon whether he

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 really starts digging and creating a big case, and sending
2 out the letter that Kirk was talking about, or whether it is
3 a little bit more low key.

4 You still cite them, but there is different
5 approaches, how big is the stick you are going to hit him
6 with, you know, what are you trying to accomplish here. We
7 are trying to accomplish compliance, and we are trying to
8 accomplish the attitude on the licensee's part that, you
9 know, we want to comply, we want to get on with doing
10 business here. They don't feel good when you beat them over
11 the head.

12 MS. ALDRICH: Rita Aldrich, New York State Health.

13 First of all, they look to see have the internal
14 audits been done. They will check some of the records that
15 were checked during those audits. If they don't check out,
16 we obviously have a problem.

17 Now, the first problem is you said you audited
18 this, I am looking at the same records. Is it falsification
19 or you just don't know what you are doing, you know, is this
20 an education problem, is this a training problem?

21 The inspectors have a great deal of discretion.
22 As I said, they are very well trained. They are good health
23 physicists. The inspection form, the summary part of it we
24 realized a few years ago we had just sort of left a blank
25 space summary, let the inspector write a summary.

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 That turned out to be largely editorializing, in
2 some cases slander. So, we decided that these things were
3 all fallible, and especially when incidents come up, medical
4 misadministrations or low level waste incidents, people all
5 of a sudden calling from newspapers and want every
6 inspection done in that area at a large generator, and this
7 inspection report says something slanderous about the RSO.

8 We took NRC's indicators that you came up with for
9 slides and program performance, and used those instead, and
10 parenthetically, we also listed prompts for the inspector of
11 things that they might wish to cover, so they are very
12 specific.

13 One of the problems that we found, that again you
14 have to keep prodding people to correct, is the tendency to
15 look at the trees, and not the forest, and count nits, and
16 look at records, records, records, and not notice that the
17 person, you know, who is doing the dose calibrator check
18 doesn't know what the actual limit is and can't convert from
19 CPM to DPM. It is much more important to concentrate on
20 those things.

21 One of the other problems that we found -- I can't
22 remember, maybe it will come back -- but we found that it
23 was very important to go out with them periodically and
24 actually watch what they were doing.

25 That, I think is really critical. If you don't

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 know what your inspectors are doing in the field, you have
2 got a problem.

3 We also ask for feedback from the licensees, and
4 we found that having regional meetings, we encourage them to
5 invite us to meetings. Mallinkrodt has put on a couple of
6 regional meetings for us.

7 One was precipitated by an enforcement action.
8 Everybody in the particular region got panicked. NRC had
9 taken an enforcement action of a VA hospital in the same
10 area, and they sort of thought there was something going on.

11 We brought everybody. I brought my licensing
12 staff and our field supervisor, and they got to ask all the
13 questions they wanted. It was a big meeting. We had about
14 55 people there. We actually got physicians, which is very
15 unusual at an evening meeting.

16 What they wanted to know is what we wanted to
17 demonstrate compliance. We had another one recently in the
18 Buffalo region. We had the Long Island Society of Nuclear
19 Medicine Technologists. I went to their annual meeting last
20 year.

21 It is very important to communicate to them what
22 it is your inspectors are going to want to see when they
23 come, and it is also important to encourage them to give you
24 feedback in case the inspectors come in and do something
25 other than what they were led to believe they were going to

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 do, but a lot depends on the quality of your inspectors.

2 MR. CAMPER: Rita, do you cite them? Let's say,
3 for example, you are doing a random sampling. Let's pick
4 dose calibrator linearity, for example. Let's say you find
5 that it is not done twice. Would you cite that?

6 MS. ALDRICH: Yes. Again, we would look and see,
7 did you check this record. You know, it is among the things
8 that we had on here to be checked. If you did check this
9 record, didn't you notice it wasn't there. It kind of
10 flows, it is kind of obviously really.

11 We don't find that much of a problem with people
12 making records of things that are fictitious, but what we do
13 see is a tendency to focus on making the record, and not
14 seeing the implication of what you are writing down. You
15 are not comparing it to the action level. That is one of
16 the biggest problems that we see.

17 MR. LEVIN: Stuart Levin, Pennsylvania.

18 We are a non-Agreement State, but we do actively
19 license norm and do all the inspections and everything.

20 In response to your question about how good your
21 inspections are, of course, we get all your correspondence,
22 and I have it all on the mainframe computer, so I can always
23 go and check your statistics if I want.

24 However, it is a matter of philosophy in one way.
25 When I came to work in Pennsylvania, the first thing I was

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 told I was I am a health physicist, and not a policeman. If
2 your inspectors go out and act like policemen, you are going
3 to have a hard time because once you leave the place, and
4 your back is turned, if you haven't sold them on radiation
5 protection, they are not going to do it.

6 So, we use the health physics philosophy. The
7 regulations we consider as minimal health physics protection
8 type activities, and hopefully leave them with a good
9 feeling, help them a little if they need it, cite them when
10 they are supposed to be cited.

11 One of the problems that you have, and we have,
12 and probably everybody has, is part of the effectiveness of
13 that inspector is on how much experience he has. Prescriptive
14 regulations are not only good for licensees, but they seem
15 to work well for brand-new inspectors, because they can read
16 it and get a yes or a no, but the more experience the guy
17 gets or the woman gets, the more they can pick out what is
18 important and what isn't.

19 Our experienced people will not cite if they
20 forgot to post a notice to employees. If that was the only
21 thing that was missing, they get a nice letter from us, and
22 they put the notice up while we are there, and that takes
23 care of the problem.

24 MR. FRAZEE: Terry Frazee from Washington.

25 Back to differences in inspectors, I have got, for

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 instance, two inspectors. One acts like a new inspector. I
2 mean looks at lots of details, goes over records, I mean
3 really is thorough, and at the same time I am fairly
4 confident he does a good health and safety inspection.

5 I have another inspector who is more typical of
6 the old hat. He walks in the door, records aren't that
7 important -- records are important, I don't mean to say that
8 -- but that is not his focus.

9 I mean he is talking to people, he is
10 concentrating on health and safety issues. I tend to see a
11 whole lot more citations out of the "newer" inspector than I
12 do out of the older inspector, which is fine.

13 From my perspective as the manager, that is okay.
14 I take advantage of that in rotating him through licensees,
15 through the same licensee basically.

16 Occasionally, I get comments back from the
17 licensees, but both of those inspectors, as part of their
18 spiel, talk about the other inspector, saying, hey, look,
19 you know, I am looking at a certain set of things, my eyes
20 are different than the next guy's eyes, and the whole
21 purpose here is to make sure that the whole program is
22 improved with time.

23 Dr. Glenn, you asked an earlier question which
24 sort of led this off, and I think I interpreted your
25 question as being how would we audit our own inspectors with

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 reference to records.

2 What I have been doing is it is kind of like
3 timing them, you know, get out the stop-watch, and how much
4 time do you spend looking at records versus interviewing
5 people versus measurements.

6 That is difficult to do because most of my
7 inspectors are just going 50 million miles in different
8 directions all at the same time, so you have got to sort of
9 make some judgment on my part as to how much time they are
10 spending.

11 But I use that as a rough handle on are they
12 spending too much time on records or versus some other
13 category. It is not that there is a goal in mind or, you
14 know, if you spend more than 25 percent of your time, that
15 is a gig, I am not doing that, but it is a point that in
16 closing with that inspector, I can say, gee, you spent a lot
17 of time on records here, you know, why did you do that, was
18 there some reason for it.

19 Sometimes there is. If they were finding
20 something and looking for something specific, that is
21 probably okay. But I think that is kind of a tool that you
22 might consider, you know, clocking them, how much time is
23 being spent.

24 MR. GODWIN: Godwin, Arizona.

25 In looking at the record situation, it is going to

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 be focusing primarily on the nuclear medicine. I would
2 expect an inspector to go in and sort of look at the size of
3 the program and pull a representative sample of records.

4 If they look all right, he would probably pass on
5 to some more records. He would look pretty much in depth at
6 things like exposure records, and things of that nature,
7 because having x-ray, as well as this, we would like to know
8 about over-exposures either place.

9 If he found a single record not complete, I would
10 expect him to look a little more in depth and try to
11 establish is that a single violation, if you will, or is
12 that a pattern, and I expect him to look particularly at
13 such things as weekends.

14 Over time, particularly while I was in Alabama, we
15 discovered that technicians for some reason don't associate
16 quality control with weekend work. I have never quite
17 understood that, but we look for the weekend records, and
18 match, you know, did they do a patient, did they do the
19 quality control, that kind of stuff.

20 In looking at the overall program, if he goes
21 through and finds a single record or an occasional leak test
22 that is one or two days late, that would lower our
23 evaluation as to how serious the violation is. It will
24 still be cited, but it will be a Category 5 rather than a 4,
25 something like that.

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 On the other hand, if there is an indication that
2 it is a well-established pattern at the facility, reflective
3 of management lack of interest, then it would go up in
4 categories, as well as perhaps bring on more serious
5 considerations of management meetings. So, we use it that
6 way.

7 In evaluating our inspectors, I try to discuss,
8 not all, but a lot of our inspections with the inspector
9 before I sign off a determination of a violation. My key
10 reason for discussing it with the inspector is to determine
11 does he understand what they are doing, does he really
12 understand the problems that are at that institution.

13 If he does, and the report reflects it, obviously,
14 I have a better feel for the violations and their
15 significance and can determine what category they should
16 fall into.

17 If he doesn't, I may not accept his violations
18 until we have documented it a little more clearly and we
19 understand really what they are doing there. If they didn't
20 have records, yes, they get cited, but you really need to
21 know how significant that relates to the overall program
22 operation to determine the category of significance.

23 That is really important, and I see that as
24 something that a lot of the Society inspectional operations
25 are not in a position to do.

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 DR. GLENN: We have sort of moved into a topic
2 that comes up a little bit later, and I think maybe I will
3 skip over and come back to another question.

4 One thing that we have been doing in the last few
5 years in the NRC is to try to encourage licensee
6 self-identification, you know, correcting their actions, and
7 this sort of thing, is by saying, hey, there is going to be
8 a category of violations that we are going to call non-cited
9 violations, and basically, either it is of low significance,
10 rare occurrence, and the licensee agrees to take corrective
11 action right on the spot, or it is something where they, in
12 fact, in an audit program identified it themselves, took
13 corrective action, and appeared to have fixed the problem.

14 We are encouraging our inspectors to treat those
15 as yes, you were in violation, however, we are not going to
16 cite it. We do -- and I think our inspectors get a little
17 mad at us in Management -- because we do require them to
18 document all those, but again I think that is part of the
19 feedback process, so that we know what our inspectors are
20 finding, what kind of judgments they are exercising.

21 I that is probably a plus, you know, on the side
22 of eliminating unnecessary paperwork, review, and sending
23 the right message to licensees. One thing it does do,
24 though, is say that NRC inspectors can now exercise this
25 discretion in the field prior to coming back and exiting

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 with their supervisor.

2 I was just wondering, any comments on that
3 particular way of dealing with this question of proper focus
4 priorities?

5 [No response.]

6 DR. GLENN: Does anybody think it is a bad idea?

7 [No response.]

8 DR. GLENN: Okay. I will go back to the question
9 I skipped, then. The NRC a couple of years ago changed
10 their unannounced inspection policy for reactor licensees,
11 and now most of the regional-based inspections at reactors
12 are, in fact, announced inspections.

13 One reason that the NRC felt they could do that,
14 of course, is that they have resident inspectors at reactor
15 sites, so essentially you have got unannounced inspections
16 going on continuously as the resident happens to wander
17 around the facility.

18 We get complaints from licensees that the
19 unannounced inspection policy is disruptive to them and
20 unfair. I was just wondering, what are your comments about
21 the policy for materials licensees which the NRC still has,
22 unless there is a reason not to announce it, all inspections
23 are unannounced?

24 MR. LEVIN: Stuart Levin, Pennsylvania.

25 I used to accompany NRC inspectors when I was

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 doing those inspections. As a matter of fact, I even
2 accompanied them when they used to be called AEC inspectors.

3 We find in our state experience that for large
4 facilities, it is more economical to make an appointment.
5 You are spending a lot of time there. Especially if you are
6 traveling a long distance, if they are not there, you have
7 really wasted time.

8 On the other hand, on our x-ray program, for
9 instance, when you have got a load of dentists and
10 chiropractors, and whatever, we never make appointments with
11 them unless they have some unusual hours. You can usually
12 walk in their office unannounced, get the thing done, go on
13 to the next one.

14 There were times I accompanied NRC inspectors, we
15 got in the car and rode for two hours, got down to the site,
16 and they weren't doing radiography that day. He didn't have
17 an alternative place to inspect sometimes. When you are
18 flying out of the regional office, this is all time and
19 money.

20 We have found that for the most part when we have
21 made appointments, we have still found items of
22 noncompliance, which kind of suggested that even though they
23 knew we were coming, they didn't seem to do anything
24 extraordinary to see if they had anything wrong.

25 I just realized while I was sitting here, in the

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 old days, occasionally I would accompany an NRC inspector,
2 and we would sit in the little outer office of whoever we
3 had to go and see in the plant for an hour cooling our
4 heels. I realize now they were probably running around in
5 the plant trying to get something fixed up in a hurry.

6 MS. ALDRICH: Rita Aldrich, New York State Health.

7 When I first took my present position, we were
8 announcing inspections. We found that with a couple of
9 consultants we had some problems when inspections were
10 announced with any kind of lead time, that committee minutes
11 would appear all written in the same hand, in the same ink
12 color, so we switched over to an unannounced.

13 Since that time, we have been having to have
14 inspectors in one region in the state do inspection in other
15 regions, for various reasons, short staffing, also there is
16 an ethics law in New York State that makes us try to rotate
17 inspectors, so you don't have the same person going to the
18 same place. Also, it improves the quality of the
19 inspections and it is better for the licensees because they
20 don't get personally regulated by an individual forever.

21 But those inspections are announced a few days in
22 advance to make sure there is going to be somebody there, if
23 it is a place like a private office.

24 A hospital, there is always going to be somebody
25 around, and besides, you want to get there when they are not

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters

1612 K. Street, N.W., Suite 300

Washington, D. C. 20006

(202) 293-3950

1 expecting you, because we all know what goes on in
2 hospitals. We have a physician also and a tech, and if
3 there is nobody there minding the shop, and they are still
4 doing nuclear medicine, you want to see what happens in the
5 absence of the person you have on record as RSO.

6 Universities, you are going to have to have the
7 RSO to be able to function, so you had better announce
8 those. So, I think logic and common sense really dictate.

9 We also don't want the licensees to spend two
10 weeks getting ready for us. That is counterproductive. I
11 wish NRC would do our reviews unannounced.

12 [Laughter.]

13 MR. KULIKOWSKI: Bob Kulikowski, New York City.

14 A couple of things. I think what Rita has said,
15 and what other people have said, are that inspections, just
16 to summarize, you need to do everything on a case-by-case
17 basis because what works in one situation isn't going to
18 work in the next.

19 We have had a little experience with announced
20 versus unannounced inspections. Now, we don't have the
21 geographical problems that most places have because I can
22 get somebody out on five minutes' notice basically.

23 However, the past couple of program reviews, we
24 have been beaten over the head -- not so much this past one,
25 but the one before especially -- that we weren't doing

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 unannounced inspections because of an historical reason.
2 One of our former Commissioners about 10 years ago made a
3 pact with the Greater New York Hospital Association
4 especially with respect to x-ray facilities, that they would
5 do announced inspections.

6 I agree with Rita that hospitals are not really
7 that much of a problem because if you miss the administrator
8 on the entrance meeting, it is not such a big deal. You can
9 go and see what they are doing, catch them for a few
10 minutes, the entrance is not that big a deal. Usually, you
11 are there a day or two, so you catch the administrator on
12 the exit, which we always do.

13 It is a problem sometimes for small offices to do
14 an unannounced inspection because you may have a radiologist
15 who has a small nuclear medicine practice and a radiology
16 practice, and he has got, you know 30 women lined up to do
17 mammographies that day, and you come in and you say, well,
18 we need the machine, and you know, what is he supposed to
19 do, so that does present a logistical problem.

20 We have facilities that are sort of targeted, that
21 we know that we don't want to give them -- if we do announce
22 and make an appointment, we don't give them a lot of lead
23 time. There are other ones that we know that have a good
24 inspection history, that we can say, okay, we are coming
25 next month and things won't really change very much.

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 So, I think, not only how you perform the
2 inspection, but whether you announce it or not has really
3 got to be pretty much on a case-by-case basis, depending on
4 how well you know your licensees.

5 MR. BAILEY: Ed Bailey from California.

6 We hold the right to do unannounced inspections,
7 and I think that that is maybe a key to it. I would agree
8 with most of what people have said except that I think the
9 impact on smaller facilities is often bigger than on the
10 large ones, so I would agree with Bob.

11 For the most part, our medical inspections are
12 announced, and by "announced," that means usually the day
13 before or two days before they are given a call. It doesn't
14 mean that they are told weeks in advance.

15 Now, if we have people traveling to Northern
16 California, say, to do x-ray inspections, they may be
17 scheduled a week or two in advance because you are going to
18 hit a bunch of small towns or something.

19 HCFA, on the other hand, for mammography, is being
20 pretty insistent that those inspections be totally
21 unannounced, and at this point we have got agreement from
22 them that we can announce them two days in advance.

23 I think the concept of unannounced inspections is
24 very important. We recently had a doctor complain that in
25 27 years of being inspected he had never been treated like

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 the Gestapo coming in unannounced to inspect his program.
2 So, I think it is important that everybody realize that, you
3 have the right to do that, and I think periodically you need
4 to do it, you need to work it into the system.

5 I would comment, too, on rotating the inspectors.
6 I think for the most part the managers know which inspectors
7 are not the good inspectors. I can remember one time when
8 we exchanged a regional inspector who always came up with
9 two or three or less violations, and a new inspector went to
10 the region, and everybody was getting 12 or 14.

11 So, I think you need to rotate the inspectors, and
12 you need to look at, not only accompanying them each year,
13 but then taking a sampling of their inspections and trying
14 to confirm what they did, so that you don't get a high
15 percentage of wind chill inspections.

16 I mean you can do an inspection if you have got a
17 good file without ever going to the facility. You can fill
18 out a form well.

19 MR. GODWIN: Godwin, Arizona.

20 Arizona, I think is operating pretty much like we
21 did in Alabama. It looks like it from what I can tell so
22 far. Virtually all are unannounced. Occasionally, you run
23 into a situation where somebody is not there, let's face it.
24 If you have an extra folder with you, you can do another
25 unannounced. Fortunately, in Arizona, most of our

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 inspections are in Phoenix, too. That is another little
2 easy thing, somewhat like New York City in that regard.

3 But generally speaking, I found in Alabama, and it
4 looks like it is working the same way in Phoenix, that
5 unannounced inspections are not that unproductive. You go
6 in there and you know some things that you just will have to
7 do.

8 For medical, in particular, you have got to
9 understand when you make the inspection that the patient is
10 going to come first, and anybody who is an inspector that
11 doesn't understand that, trying to do medicals, is in deep
12 trouble right off the bat.

13 It is just a matter of when you get there, indeed,
14 if they are too busy to be inspected at that time, I would
15 have someone leave, then come back later, but that doesn't
16 happen very often, they don't have to wait terribly long to
17 get in for the most part. Occasionally, you will have to
18 wait an hour, but generally it is less than that.

19 Know that when you go into a hospital, you are
20 better to go in the afternoon, for example. Most nuclear
21 medicines and most radiology departments are busy as heck in
22 the morning. If you go in the afternoon, you have a lot
23 better luck. Get there at late lunch, a good time to hit.
24 Those kind of tricks do a whole lot of good.

25 Approach it with the idea of learning what they

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 are doing. It really works out quite well.

2 Industrial radiography is another ball game,
3 trying to find where they are working is real tricky, but
4 that is not what we are here for. Get a good microammeter
5 and ride around the industrial area is where you will find
6 them.

7 MS. ALLEN: Kathy Alien, Illinois.

8 Illinois does mostly unannounced inspections. In
9 a previous life, I worked for a broad-scope licensee, and we
10 had been inspected by NRC and Illinois, and most of our
11 inspections were announced, some were unannounced.

12 We didn't really see a problem from a licensee
13 standpoint either way. If we knew the day before, we
14 usually stayed to make sure that all the records were
15 actually put in the proper files and whatever, and if they
16 just showed up that day and said we were being inspected,
17 then we would have to say, well, here is our file and here
18 is a bunch of stuff that hasn't filed yet, and here you go.

19 We didn't mind it either way. It seemed like it
20 was just a snapshot of what you do. If we had a problem,
21 for example, if you couldn't keep up with the backlog of
22 wipe tests or something like that, it was almost better
23 unannounced because then it showed management what the true
24 situation was in health physics, not necessarily staying up
25 all night to put all the documents in order, but this is the

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 way it is, guys, and that is why we need the help.

2 DR. GLENN: I think there is a little bit of
3 variety in opinion, but it sounds like everybody agrees that
4 the right to unannounced inspections is important, some
5 percentage should be unannounced.

6 What that percentage is and which licensees is
7 perhaps somewhat variable, but an appropriate mix of
8 announced and unannounced is what I hear, some of you
9 leaning towards most of them being unannounced and some
10 would say most being announced.

11 Another issue that frequently comes up -- and I
12 have talked before about how we could take low severity
13 level violations that are identified and corrected by the
14 licensee and make them non-cited violations or on-the-spot
15 simply giving what we call a 501 form -- I think many of the
16 enforcement cases that the NRC has had in the last 10 years
17 have involved situations where we have had multiple severity
18 level 4, maybe even some 5 violations.

19 What we do is to sometimes aggregate, say if we
20 see a problem in this part of your program, we see another
21 problem over here, it indicates to us that your program
22 isn't working. So, although any individual problem that we
23 found is not very significant, looking at the thing as a
24 whole, we think that it constitutes a management breakdown,
25 which we will classify as a severity level 3.

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1512 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 So, many of our enforcement conferences at medical
2 facilities involve that kind of conclusion. I would say
3 most of the events that I have seen that result in
4 enforcement conferences in medical are either what we call
5 program breakdown, aggregation of smaller items, or else
6 events that involved a serious misadministration. Those
7 tend to be the kinds of things that bring us into the strong
8 enforcement category.

9 Any comments on this system of aggregating minor
10 violations and calling them a serious problem in aggregate?

11 [No response.]

12 DR. GLENN: Everybody thinks that is the
13 appropriate way to do it. Okay. Good.

14 One question has to do with are programs being
15 effective in identifying and correcting safety concerns,
16 and, if so, what aspects are most effective in identifying
17 and correcting safety concerns.

18 We have fairly frequent civil penalties within the
19 NRC, and so I think maybe throw that out as one tool we have
20 to trying to assure that people focus on problems.

21 MR. FRAZEE: Terry Frazee from Washington.

22 Actually, before we get too far away from the
23 unannounced inspection, it occurred to me that unannounced
24 inspections are extremely important if you are concentrating
25 on records. Announced inspections, the worst thing that an

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 announced inspection is going to do without respect to
2 records is that the licensee is going to scurry around,
3 getting his act together, training his workers, making sure
4 that they know the right answers, and so we walk in and they
5 have got the right answers, then we walk out, and we are
6 happy, they have been trained.

7 So, from that perspective, you know, maybe
8 unannounced inspections aren't really that critical, but
9 then again, there is the radiographer, so --

10 [Laughter.]

11 MR. FRAZEE: The last issue was civil penalties,
12 and we don't have civil penalties. We seem to be getting
13 pretty good compliance without them. We do carry the
14 ultimate big stick, which is you just jerk the license, and
15 so I think that is an important tool that is there for
16 threatening them.

17 As far as aspects of the inspection enforcement
18 program that is most effective, again, I am going to go back
19 to it is the observations, it is the interviews, talking to
20 these people, training them.

21 DR. GLENN: So, mere regulatory presence by an
22 intelligent inspector is your most effective tool.

23 MR. FRAZEE: Yes.

24 MR. KULIKOWSKI: Bob Kulikowski, New York City.

25 Yes, I agree a lot with what Terry said. We don't

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 issue a lot of monetary penalties. We have found that
2 enforcement conferences are very effective.

3 As far as the one thing that I have had the most
4 positive feedback on with respect to the actual inspection
5 protocol itself, is the exit interview where we insist that
6 management be present.

7 What we do is usually have a technical closeout
8 with the RSO or somebody from the radiation safety staff
9 before we go in, so the radiation safety staff doesn't get
10 any punches pulled on them, and present it in a positive
11 light to be constructive for the health physics people, and
12 telling the management that this is really, you know, it is
13 either a good program, it is a bad program, and if it is
14 bad, where can you patch it up, fix it, make it better, and
15 give the radiation safety people adequate support.

16 MR. TEDFORD: Tedford, Alaska.

17 There are a couple of observation points that I
18 have made over a period of years. One, that the attitude of
19 the upper level management in a hospital is directly
20 proportional to the quality of the program that you are
21 going to see.

22 I think that is true also with reactors and any
23 other field that you are in. If upper level management
24 desires that there be a good program, and the attitude is
25 correct, that is going to be reflected all the way down

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 through the program.

2 Now, upper level management needs to know what the
3 program is. I think several states have conducted excellent
4 forums in this area. Texas has had meetings with their
5 licensees and told them what the problems are.

6 I think there are other mechanisms that we have
7 had available. In my case, where I had medical newsletters
8 available to me -- and I have always had those available --
9 I have told the licensees what the main problems are, and
10 they are pretty uniform throughout the NRC and the states.

11 The number one problem with regard to medical
12 licensees is the Medical Isotope Committee or the Radiation
13 Safety Committee, as the case may be, and not meeting and
14 not governing and not looking at the program.

15 On the other hand, you can flip over to X-ray, and
16 its non-beam alignment, half-value layers, film batches in
17 some instances, but if you tell the people what their
18 principal problems are and the ones that need to be
19 corrected, if you have any good administrators or good
20 management, they will look at that, they will see, and they
21 will correct it.

22 So, I think it is an approach and telling people
23 what the problems are, and being up front about it before
24 you go to inspect them.

25 MR. GODWIN: Again, Godwin from Arizona.

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 I think it is imperative that the inspector
2 understand what is going on at that facility, and not asking
3 leading questions when he learns what is going on. The
4 typical example that we see with a new inspector is, you
5 know, you take wipes. Well, what is a good answer? You
6 have told him the answer.

7 But if you ask him for his wipe records first, and
8 he has got them, then you can say show me how you do the
9 wipes, well, he doesn't have a clue, and you have got a
10 pretty good idea of whether he really knows and is serious
11 about the program.

12 You have to go through and talk their language.
13 One of the most difficult problems we have is getting the
14 inspector to ask the question in a language they
15 understand. Some of the records in radiography are not -- you
16 ask them for a utilization log, and in a lot of places you
17 are going to get "what," but you ask them for show me how
18 you keep records of where this thing is located, "oh, yes, I
19 got that one right there."

20 So, you have to talk their language, but you also
21 have to understand how they do it without leading them to
22 the answers. The last part of it is, as you go through,
23 find out if they understand why that is important, not
24 because it is a rule, but that it represents something to
25 protect them or their patients or some interest that they

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 have. That keeps them motivated to keep doing it.

2 MS. HADEN: Haden from North Carolina.

3 Going back for quality programs, I think Rita's
4 idea of internal audits is a very good idea. North Carolina
5 does cite noncompliance items even if they are discovered by
6 the radiation protection staff, but we use almost a
7 non-cited approach by removing them from noncompliance as a
8 result of whatever action was taken.

9 Aubrey made some very good points about speaking
10 somebody's language. We do mostly announced inspections
11 based on our budgetary crisis right now. If you find out
12 how to talk to a technologist and you start out with tell me
13 what you do during a normal day, they will tell you honestly
14 and openly what they have been trained to do, and you can
15 solve those problems.

16 But what we have started with our licensees now is
17 we hand-deliver new licenses as much as possible. You get
18 upper management involved, you get the radiation safety
19 officer involved, you get the authorized users involved,
20 explain to them up front what their license conditions mean,
21 what our expectations are, and particularly in cases where
22 they have consultant-prepared applications, make sure they
23 understand what they have committed to.

24 We have found that the first inspections following
25 those deliveries are better than they would have been before

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters

1612 K. Street, N.W., Suite 300

Washington, D. C. 20006

(202) 293-3950

1 they were delivered, they are not operating for a year, six
2 months or a year or two years without any oversight. That
3 has been very effective.

4 Oh, industrial radiography. In North Carolina,
5 they have to report all temporary job sites to us.

6 DR. GLENN: Just a quick follow-up question. Does
7 the hand delivery of new licenses, does that cause you any
8 scheduling problems in terms of usually when people are
9 getting a new license, they are eager to get it as quickly
10 as possible?

11 MS. HADEN: Generally not. What we do is if it is
12 far enough away in the state -- we have one office centrally
13 located, and the farthest point takes about five hours to
14 get there -- we may send them their copy in the mail and
15 schedule a week or two later a follow-up if we have got
16 somebody in the area, but we prioritize at least within the
17 first six months that they must be reviewed initially to do
18 that management review of a new license.

19 MR. MARSHALL: Stan Marshall of Nevada. She stole
20 a little of my thunder, so I will just expand on her comment
21 about hand delivery of licenses.

22 Really, the inspection enforcement loop begins
23 with that first communication to the licensee. We have
24 found that, yes, that hand delivery and that 30-minute
25 discussion with the licensee management saves at least that

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 30 minutes to a half a day on that first inspection, plus
2 you have cultivated some continuity in that licensee's
3 impression toward you as a licensing agency.

4 We have found this to work well. We only began
5 hand delivery of major licenses in the last couple of years,
6 so I can give you a comparison, a recent comparison.

7 It works for new licenses, and yes, you have got
8 the problem in Nevada where some of our people are 400 miles
9 from either of our inspection offices, but that scheduled
10 hand delivery sets the stage for the unannounced first
11 inspection.

12 It also works for renewals or the circumstances
13 where you have a private physician at a hospital who moves
14 to Montana, and the hospital suddenly recognizes they now
15 have no program and must get an institutional license. You
16 have set the stage for hand delivery and a better first
17 inspection for them.

18 MR. TRUMP: Carl Trump from Maryland.

19 We have recently adopted the new frequency or the
20 frequency schedule of the NRC, whereby the gauges have been
21 kicked from a 5 priority to a 4, and likewise up the scale.

22 I think on initial visits to such as a gauge
23 program, we find that in most cases everything under the sun
24 is wrong with these programs, anywhere from the licensee not
25 having the regulations, to posting, labeling, what is

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 required, what is going on.

2 I know I maybe stepped on some toes, but I have
3 talked it over with our management and also Charlie Flynn in
4 Licensing here, that I think that it is really crucial that
5 somehow we would increase -- not only giving licenses out,
6 maybe on a new license -- but the pre-licensing visits, not
7 only for the 1's or 2's, but sometimes down to 5's.

8 I think if only one visit were to be made to those
9 programs out there, they wouldn't be in the sad state of
10 affairs they would be in when we get to them. Then,
11 obviously, we always call it the initial discussion, this is
12 kind of your trial run, so to speak, and you don't do too
13 much to them other than they have got to respond in a
14 compliance letter within 20 days.

15 But the second time around -- and they may be put
16 on what we call the hit list -- maybe a year later, and they
17 have got the same problems wrong, and it is centering around
18 management control, then we are likely to take a severe
19 action, such as a conference and/or civil penalties, and we
20 do have a lot of civil penalties.

21 We do travel across the state, and you know
22 Maryland is quite wide. It is about 175 to 200 miles
23 across. So, when even our reciprocity friends come in,
24 because a lot of our radiographers, we have more
25 radiographers come from out of state than we have in state,

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 and we do require that they notify us three days in advance
2 of the personnel they have, cameras, vehicle, and
3 everything, and any changes that occur, they have to notify
4 us, plus the fact they notify us of the times, so that when
5 we are riding out to Western Maryland, we are not going to
6 take a ride in the sun when they finish up early or they
7 don't work that day.

8 So, we put that in, and all these go out in a
9 letter form prior to reciprocity even being started.

10 DR. GLENN: I will ask a question. How many of
11 the states have something like this hand delivery of
12 licenses?

13 [No response.]

14 DR. GLENN: Do all of those people feel that it is
15 an effective way to get the program started?

16 [No response.]

17 DR. GLENN: I will ask a slightly different
18 question on the enforcement options and then move into what
19 may be a fairly long discussion on voluntary programs.

20 Do any of you find that you lack the tools you
21 need in order to correct certain kinds of problems? Is
22 there any lack of having enforcement tools available in
23 order to solve problems?

24 MR. BAILEY: Ed Bailey from California.

25 Yes, I think that administrative penalties, as we

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters

1612 K. Street, N.W., Suite 300

Washington, D. C. 20006

(202) 293-3950

1 would call them, the lack of having them is detrimental to
2 our program.

3 DR. GLENN: Your administrative penalties are
4 similar to our, what we call civil penalties?

5 MR. BAILEY: Right.

6 DR. GLENN: The agency itself without involving
7 the legal system.

8 MR. BAILEY: Right, without involving the court
9 system. The court system just takes too long, at least in
10 California, to get a case from the time something occurs.
11 Number one, you have got to get either the Attorney General
12 or the District Attorney to think that it is important
13 enough to do in the face of murders and other cases.

14 So, we tried this past session to get
15 administrative penalties, and the California Medical
16 Association was successful in getting that struck out, so we
17 will be going back again sometime, but right now our
18 department is saying they don't want to fight the medical
19 association until we correct some things, many of which are
20 related to the Medical Guide. So, we will do that.

21 I had one question that I wanted to ask about the
22 previous topic. Of those states that deliver their
23 licenses, do you deliver them by licensing personnel or
24 inspection personnel, or both?

25 MR. GODWIN: Godwin of Arizona. There seems to be

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 a great mass of people coming up to answer that question.
2 In the interim, we would like to mention one little quirk
3 regarding enforcement. You all broached on it I guess it
4 was yesterday or the day before.

5 If you are using self-inspectors that are coming
6 in, you may have difficulty using their inspections as an
7 enforcement action. You should be very cautious of that.
8 Again, I am well aware that these people, when they go
9 through and impose these programs on the State Programs,
10 they announce it to the legislature as third-party
11 inspections, but they are actually hired and paid for by the
12 institution that is being inspected, and that makes it
13 self-inspection in my book.

14 But you need to be aware that you may have trouble
15 taking enforcement actions even if it is found that they are
16 doing all sorts of weird things.

17 MR. FRAZEE: Terry Frazee from Washington.

18 In our case, it is the license reviewer that is
19 hand-delivering the license. I should also point that the
20 license reviewer is also responsible for doing compliance
21 inspections, alternating with our compliance program, so
22 they have got a first-hand feel for what is going on out in
23 the field.

24 The reason I came up, though, we don't have civil
25 penalties, but we do have something that is perhaps a little

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 innovative. It is called the fee for additional service.

2 We have defined follow-up inspections and when we
3 crank in follow-up inspections, then we can charge them an
4 hourly rate for our time on site. So, they don't want us to
5 come in a second time.

6 MR. MARSHALL: Stan Marshall, Nevada.

7 To answer Ed's question, I will qualify it because
8 we all recognize there is a world of difference between
9 Nevada and California, so I will set up the scenario.

10 We have got a licensee in Nevada who is getting a
11 license, and I have got staff in Carson City and Las Vegas
12 that are involved with both activities. Who do I send? I
13 am more likely to send a primary inspector who may or may
14 not have had any element of license review activity because
15 it helps to put a face with a name of the first one in the
16 door to do the inspection.

17 The guys in our ivory tower who might only do 5
18 percent of their time in inspections anywhere, may not
19 handle those administrative questions, especially if they
20 line up their techs and everyone who is familiar with the
21 process.

22 MR. TEDFORD: Tedford, Alaska.

23 I would just like to make a comment about what Ed
24 Bailey stated earlier. I have functioned in both states,
25 have enjoyed the advantages and disadvantages of both

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 systems. One is the Medical Department system where, like
2 Ed said, you have to kill somebody to get an action taken,
3 and the other is where you have administrative penalties or
4 you have civil penalties. There is day and night difference
5 between the two.

6 Where I used to write letters until I was blue in
7 the face, in the state that had the Medical Department
8 situation, and when I then was able to operate under civil
9 or administrative penalties, I never had to look for them.
10 They got the answer back once there was money associated
11 with it.

12 MS. HADEN: Robin Haden, North Carolina.

13 We don't have civil penalties, so we just use our
14 administrative conferences or follow-up enforcement
15 conferences where we bring the licensee into our office to
16 discuss what we consider to be the bottom-line problem with
17 their program, and that is generally pretty effective so
18 far.

19 To answer Ed's question as far as license delivery
20 goes, the license delivery is performed by one of our
21 license reviewers that happens to also be my inspection
22 compliance staff, and we don't make any rules as to whether
23 it was the initial license reviewer or not. If it is not,
24 all the better, it gets one more good read-through to make
25 sure that it is complete and accurate before it goes out.

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 MR. GODWIN: Godwin, Arizona.

2 Just a suggestion to our good friends with NRC,
3 whenever you increase your inspection frequency because of a
4 weak history, shall we say, that increased frequency might
5 should be considered a non-routine inspection because it is
6 not at the routine interval.

7 I don't think it makes that much difference in the
8 medical end, but it sure does in the radiography end. We
9 did this for a while in Alabama until we discovered you all
10 weren't doing it, and since we were trying to track you all,
11 we had to drop off doing that, but you would be amazed about
12 how you get there and you have to pay for an extra
13 inspection every six months in radiography, particularly
14 when it jumps up about 25 percent, that tends to get their
15 attention.

16 MR. BAILEY: Bailey from California.

17 We use the enforcement conferences. One of the
18 things that we quite often negotiate in the enforcement
19 conference is an outside review, and we try to be very
20 careful that it is not a brother-in-law review.

21 I think you have to insist on who that reviewer is
22 going to be. You don't get the guy that came and looked at
23 your program last year, who is across the street. You find
24 somebody that you know has a good program or does a good
25 review of a facility, and you get them to come in.

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 We found that that has been pretty darn effective,
2 particularly in medical facilities where the administration,
3 and rightfully so, will tend to support the medical staff
4 against the regulators, and then they get somebody to come
5 in and say, well, your medical staff is not doing it the
6 same way we would do it at our facility. It lends a little
7 more credibility to it.

8 DR. GLENN: I will make one observation. I have
9 found that quite often the threat of a civil penalty is a
10 very effective tool for getting corrective action.
11 Sometimes when you actually impose it, then they dig in
12 their heels and start fighting and some of the costs
13 associated with the hearing process begin to make you wonder
14 whether it was worth it or not, but many times the threat of
15 the penalty is an extremely effective tool.

16 MR. TRUMP: Trump from Maryland.

17 We have both the administrative penalty and civil
18 penalties in our statute. These can result from inspections
19 or investigations where the licensee has definitely fouled
20 up either procedurally, the safety system, or personal
21 monitoring, things of that nature they were not wearing it.

22 We choose mostly to call them in for an
23 enforcement conference, management conference, and at the
24 time we think we are going to be pursuing a penalty,
25 administrative penalty, we will tell them at the time we are

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 still going to pursue a penalty after all the corrective
2 actions have been discussed at the table and what measures
3 they are going to take in the future, and any other material
4 that we need to be sent to us to determine that they are
5 going to be in compliance.

6 A letter will usually go out within probably 10
7 days to two weeks following that of our decision. Now, we
8 can charge up to \$1,000 a day up to \$50,000 for
9 administrative penalties without going to court. We don't
10 have to go to court.

11 Over 10,000 of the civil penalty, we can only seek
12 it through the court system. So, therefore, our Attorney
13 General's Office has advised us to go the admin way and,
14 say, take half a loaf and swim with it and move on rather
15 than seek higher penalties, but that is not to say that we
16 can't pursue that. In fact, we have got one case now that
17 is coming up I guess with Neutron Products.

18 But the thing is that with these type of
19 penalties, they do have the appeal period in which to appeal
20 this, and of course, it is with the ability to pay, and so
21 forth.

22 DR. GLENN: I would like to move to -- and Aubrey
23 has already brought it up a couple of times -- to the next
24 subject for discussion in terms of inspection and
25 enforcement.

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 That relates to the fact that we did receive a
2 request from the American College of Nuclear Physicians
3 during the period when the Commission was considering the
4 override of the Office of Management and Budget's denial of
5 the information collection part of our rule.

6 That letter said we have a voluntary program that
7 inspects for quality assurance in nuclear medicine. We
8 would like to meet with you, Commission, and see if there
9 are some aspects of our program that match up with your
10 program and whether you could give some sort of recognition
11 to our program.

12 We had an informational meeting with the ACNP in
13 September. They described their audit program to us. It is
14 clear from that discussion that what they are looking for is
15 what they called "deemed status," which would essentially
16 mean if someone voluntarily participates in this program,
17 then some aspect of the NRC's program would be waived for
18 that part of the radiation safety program.

19 Now, this is something that we have not done
20 before. Certainly, we recognize credentialing by the boards
21 in medicine as far as training is concerned. We are in the
22 process of the radiography certification program,
23 recognizing again training certification by an independent
24 body.

25 We have never recognized the audit in lieu of

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 inspection aspect before, but we certainly are going to
2 approach this with an open mind and discuss it with them,
3 but we would like your input on what we should be looking
4 for.

5 Aubrey has already pointed out, can we use the
6 finding of a voluntary audit program for enforcement
7 purposes. Something we have to explore with them is whether
8 they are willing to have sufficient disclosure for us to
9 feel comfortable that if a problem is identified, that we
10 will learn about it and be able to independently judge the
11 corrective action.

12 But at this point there are several programs out
13 there that could be recognized. Certainly, the ACNP is the
14 only one who has approached us, but in developing the
15 Quality Management rule, a lot of consideration was given to
16 whether the JCHO audits could cover the inspection of the
17 Quality Assurance Program.

18 But, anyway, should the NRC recognize voluntary
19 programs, and if so, what aspects?

20 MR. GODWIN: Godwin, Arizona.

21 Having broached it, I will charge forward. If you
22 recall my comments relative to industrial radiography,
23 ditto. The problems, as I see it, first of all, there might
24 be a small administrative problem with you all, but since
25 you charge fees based upon, in part, services rendered, ala

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 the inspection, well, obviously, if you are not doing the
2 inspections, you need to reduce your manpower and reduce
3 your fees, so that is just sort of one of the administrative
4 things that will be kicking along.

5 It seems to me the first question of can you use
6 the inspections for enforcement is an issue that you would
7 want to address, and how are you assured that their
8 inspections are addressing the same issues that you have
9 identified as a radiation safety issue, and how will they
10 take their enforcement action, what kind of sanctions will
11 they do.

12 For example, I could see a real problem if they
13 said they walked into a facility, Dr. Jones' office, and
14 announced that we are here to do our deemed inspection, and
15 said, "Nope," so we will decertify you, and they walk out
16 and don't tell anybody, you are stuck with a facility you
17 haven't inspected, nobody has inspected, and how long will
18 that condition before you find out.

19 Interpretive matters relative to the regulations
20 might be an issue that you need to look at, and how will
21 they ensure that their inspection interpretations will be
22 consistent with yours, will the inspections be unannounced,
23 will a certain portion of them be unannounced.

24 Again, suppose they sanction someone who you would
25 have revoked the license, will they allow that information

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 to be circulated to other jurisdictions, so that we may not
2 want that individual or organization, whichever it may be --
3 a person I guess would be the best way to describe it --
4 operating in our jurisdiction.

5 Falsification of records being submitted as part
6 of the inspection might be an item of interest. What
7 happens with complaints, who is going to be responsible for
8 investigating complaints, particularly employee complaints,
9 and the list sort of goes on and on. I think that will do
10 for a start.

11 MR. KULIKOWSKI: Bob Kulikowski, New York City
12 again.

13 A couple of comments, and these have to do with
14 our machine radiation programs. The American College of
15 Radiology has a Mammography Certification Program. We have
16 on several instances gone to "certified" facilities and they
17 have not only had violations, they have been issued stop
18 orders because they are in such bad compliance.

19 I personally would be very hesitant to substitute
20 a voluntary protocol for something that we normally have the
21 authority and right to inspect. We are also under extreme
22 pressure from our mayor's tennis partner's lobbying firm to
23 have third-party inspections of dental facilities.

24 We have run into a lot of the same questions that
25 Aubrey has brought up about if someone goes out and does an

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 inspection, and one, if they find a severe violation, how do
2 they communicate that to us; two, can we use their
3 inspection documents to proceed with escalated enforcement,
4 and the questions go on and on from there.

5 I, for one, am very uncomfortable with this sort
6 of thing.

7 DR. GLENN: Bob, one follow-up. In terms of this
8 mammography inspection, were these in areas where what you
9 looked at overlap? What I am trying to figure out is that
10 they covered the same thing, but they didn't see the
11 problem, or was it you were just looking at different
12 things?

13 MR. KULIKOWSKI: No, it was things that are
14 covered by the ACR in the QA certification, and actually
15 what we are doing is exploring right now with the ACR and
16 our lawyers whether we can indeed legally notify the ACR
17 when one of their accredited facilities is not able to pass
18 one of our inspections.

19 MR. FRAZEE: Frazee from Washington.

20 Voluntary audits should not be the basis for a
21 compliance action on our part. Another one of your
22 questions deals with whether we would reduce or change our
23 inspection frequency, and the answer is no, if we are going
24 to do anything, we ought to increase the inspection
25 frequency, certainly never decrease it.

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 If we are aware of the audit findings, that is
2 fine. Their goal should be basically looking at the same
3 goal or end point that would be looking at, and we can make
4 that assessment ourselves, and we don't have to base it upon
5 their findings, and certainly would not want to do so. It
6 should be something that we find, we see ourselves.

7 MR. GODWIN: Now, to present perhaps another part
8 of the thing. I feel that, particularly in the medical
9 field, that the professional certifications and all are very
10 important.

11 There are areas that are being addressed that are
12 vital to our overall interest, that are not something we
13 perhaps should get ourselves into. For example, the
14 training, they are probably in a much better position to
15 evaluate someone's training.

16 They are in a much better position to look at the
17 overall end product quality of the work. We are interested
18 in that. I would like to see us do that, but I think they
19 would be in a much better position to say this particular
20 patient was really treated well, and we really don't have
21 any business to get individual patients.






22 They have that unique ability that is important
23 and should be taken care of. I think we need to encourage
24 the professional groups to get in and work. They can make
25 our jobs so much easier, and they can really help.

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950






1

IMAGE EVALUATION TEST TARGET (MT-3)







1

IMAGE EVALUATION TEST TARGET (MT-3)









1

IMAGE EVALUATION TEST TARGET (MT-3)



1

IMAGE EVALUATION TEST TARGET (MT-3)



1 So, I think we need to do something to encourage
2 the professional associations to participate and work with
3 us as partners rather than an adversarial relationship. I
4 think it is very important that we bring them on-board.

5 DR. GLENN: I guess a follow-up. Do you see some
6 area where we could actually give them something back in
7 return? I agree, I have drawn VENN diagrams of ACNP's
8 Quality Assurance Program and our Quality Management
9 Program, and theirs is a much bigger program. However, it
10 doesn't really overlap that much with ours.

11 But when it gets into is the patient getting good
12 treatment, their program answers that question a lot better
13 than the NRC's inspection program does.

14 MR. GODWIN: I think there are aspects that we can
15 give them credit. Obviously, I would think that we could
16 give them credit for the training review. If someone is
17 certified by an appropriate organization, we can give them
18 credit for that, assuming -- well, if it is a valid
19 certification, let's put it that way.

20 Where they have established an example or some
21 sort of quality control program overall, that encompasses
22 all or part of what we would need, I would think that we
23 could make our inspection only touch briefly on those areas,
24 just enough to spot-check to make sure that the facility is
25 indeed following the program that they have committed to.

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters

1612 K. Street, N.W., Suite 300

Washington, D. C. 20006

(202) 293-3950

1 We wouldn't have to go into depth.

2 You could touch on things and shorten up your
3 inspection to the degree that maybe you only look at their
4 reports where their people have come in for certain aspects
5 of it.

6 I don't think we can totally duck the issue of
7 doing unannounced inspections at some frequency. If we have
8 a facility that had some decent inspection history, and was
9 using that, I personally feel we ought to recognize their
10 program and lengthen the inspection interval.

11 I disagree with my colleague from Washington to
12 some degree, and that is all right, too. I mean, you know,
13 you have got to look at it. But I think there are things
14 that we can do that would give them credit, and since the
15 NRC is charging fees for their inspections, lengthening the
16 interval translates into saving money.

17 MS. ALLEN: Allen, Illinois.

18 I am not really clear whether or not -- I
19 understand third-party inspection -- but I am not really
20 clear whether or not you would accept a licensee's statement
21 that they will participate in a JCHO type of QM program in
22 lieu of submitting another program for us to evaluate for
23 licensing purposes.

24 DR. GLENN: That is the question, should we. If
25 we have established that it achieves the same objectives as

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 our program, would we recognize. They would perhaps not
2 have to submit a program, and perhaps we would at least
3 waive some part of the inspection.

4 MS. ALLEN: But I can see where they would be
5 independent of each other, yes, we will accept your QM
6 program, but we are still going to inspect you according to
7 our regulations to see if you still meet those requirements
8 without even looking at the inspection, even just a
9 statement saying that we were inspected annually or
10 whatever, because licensees may have a problem with you
11 looking at actual inspection reports, but a statement signed
12 by management may be acceptable enough.

13 The question is -- and I think you are going to
14 address it at your November meeting -- which one of these
15 programs meets the requirements of the QM rule, and is there
16 going to be some sort of list where licensees can say we are
17 going to do this one and therefore we don't need to submit
18 it.

19 MS. ALDRICH: Rita Aldrich, New York State Health.

20 I think I can give you one parallel for the kind
21 of thing you are looking for. What we are proposing for the
22 therapy QA requirements, which we hope to get adopted, as I
23 said, by the end of November, is our inspectors will inspect
24 for the presence of a QA program.

25 We are requiring outside audits to look at the

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 efficacy of the program. We have on our Medical Advisory
2 Committee a member of the ACR's practice accreditation
3 review for therapy, and he keeps telling me that they don't
4 look for QA programs when they go in to do these reviews. The
5 data that they get from these reviews are used in the --
6 good heavens, what is the name of the program that the
7 American College of Radiology runs -- Patterns of Care
8 Study, which they go back, all that information feeds into
9 establishing parameters for particular types of cancer
10 treatment, particular sites, upper and lower dose levels,
11 and other things that seem to, in their effectiveness,
12 increase the likelihood of control of the tumor.

13 He keeps telling me this, we don't look. In fact,
14 he says he is not even sure it is a question, do you have a
15 QA program. They don't care. What they care is what is the
16 quality, not what you have on paper, but what do you have in
17 reality.

18 They look at five treatment sites in the practice
19 accreditation review, and they look at the patient treatment
20 data and the follow-up on the patient, how the patient does,
21 and that is what they are looking at, the effectiveness of
22 the Quality Assurance program.

23 So, what we are saying is that our inspectors will
24 inspect for the presence of a QA program, but we want
25 outside audits to look at the effectiveness of the program.

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 Again, it is one of those things, as I said before, that
2 there are things that we can't and shouldn't do for our
3 licensees, but that they do need to do for themselves to
4 close the loop on quality assurance.

5 I don't know about the importance of these kinds
6 of things for diagnostic, but we have used a requirement for
7 an outside audit for diagnostic programs where we had severe
8 problems.

9 Partly that is because we are in the Health
10 Department, we have another part of the Health Department
11 that is the Office of Health Systems Management. They will
12 sometimes go in and do a review and find clinical problems,
13 and then we might take a joint enforcement action, and this
14 has in the past included a practice accreditation review by
15 the American College of Nuclear Physicians.

16 I agree with you that their inspection report -- I
17 have a copy, and it is far more detailed and much better
18 suited to evaluation of a quality assurance program for
19 diagnostic than anything that we could ever do.

20 I don't know about requiring it. I think if you
21 looked at it the same way, that you would look for the
22 presence of a QA program, that we have in our regulations
23 specified certain minimums -- which essentially are the
24 Joint Commission's requirements, we are not trying to invent
25 anything -- and then look for something like this to close

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 the loop and fill in the rest of it, because our inspectors
2 are not going to be able to look at treatment plans for
3 patients and find errors.

4 DR. GLENN: I guess one thing we did already
5 mention to the ACNP is that, as currently constituted, their
6 audit program does not include the use of written
7 directives, and without that definition being in there,
8 there is almost no overlap with the NRC's Quality Management
9 Program.

10 So, there would be some things clearly that they
11 would have to change about their program before we could see
12 any comparability at all.

13 One thing I heard is that there is a possibility,
14 not so much of waiving inspection programs, but of waiving
15 certain aspects of the inspection program. In other words,
16 the regulatory agency would be responsible to see that a
17 program exists, that a program has been implemented, that
18 audits are performed, but in terms of whether the program is
19 working, that could be judged by an independent authority,
20 at least in some cases.

21 I believe it is 2:30. My understanding is that at
22 2:30 we have coffee service.

23 Why don't we take a 15-minute break.

24 [Recess taken from 2:34 p.m. to 2:55 p.m.]

25 DR. GLENN: There was another paragraph of

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters

1612 K. Street, N.W., Suite 300

Washington, D. C. 20006

(202) 293-3950

1 questions relating to inspection and enforcement. In
2 looking those over, I think we pretty well covered all the
3 topics, and so I think the next area is another very large
4 and important area.

5 I would like to move on and Mr. Camper will lead
6 the discussion having to do with Training and Supervision.

7 MR. CAMPER: In the interest of time, I am going
8 to try to just hit some of the high points, Appendix D in
9 your Medical Issues Paper.

10 What it is really saying is that Medical Use
11 licensees are somewhat unique in the sense that the
12 justification for the use of radioactive materials in the
13 practice of medicine must be done at the direction of a
14 physician, and that historically, physician-authorized users
15 have occupied a very unique place in our licensing scenario.

16 If one goes back to the early days of AEC and the
17 development of nuclear medicine, the authorized user I think
18 most of us would agree meant something. They were typically
19 at the forefront of developing radiopharmaceuticals.

20 They were the most knowledgeable individuals to
21 deal with, not only medicine and the practice of medicine in
22 terms of using radioactive materials in the practice of
23 medicine, but also in terms of radiation safety
24 requirements, handling procedures, and so forth.

25 Well, over time some other specialties have come

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 along, other individuals who know a lot about
2 radiopharmaceuticals and how radiation safety programs
3 should be conducted.

4 We have nuclear med techs, we have radiation
5 therapy technologists, we have radiopharmacists, and we have
6 other physicians that have come along that want to use
7 radioactive materials in the practice of medicine.

8 Now, if you use that as a backdrop, and you also
9 consider that the day-to-day supervision of the actual
10 handling and use of materials in many facilities is being
11 done by someone than an authorized user, there are literally
12 scenarios which exist where the authorized user is not on
13 site for some prolonged periods of time.

14 When we revised Part 35 in 1987. we did try to set
15 up specifically some flexibility on this question of
16 supervision. You might recall historically, there was a
17 time when we wanted to see authorized users being available
18 within 15 minutes, and then it was an hour, but then in
19 1987, we realized that it really is case-by-case specific
20 and the need for the degree of supervision was left in the
21 hands of the authorized user.

22 Similarly, the question of training and
23 experience, what is the adequate amount of training and
24 experience for a physician that wants to use radioactive
25 materials in the practice of medicine.

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 I think most of us would agree that board
2 certifications, of course, are a very good standard, but
3 there is also this "or" category. We can't rely strictly
4 upon board certifications. That would be restraint of
5 trade. So, we have the "or" category that says a physician
6 may come in, and as you know, if you demonstrate 200 hours
7 of didactic training, 500 hours of types and quantity, 500
8 hours of clinical -- those two may be done concurrently --
9 in some minimum time frame you can match the "or" category.

10 Well, this question of training and experience,
11 you know, tends to bubble to the surface periodically. It
12 has been there recently. Dr. Myron Pollycove has been
13 leading a task force to take a look at some training and
14 experience criteria for us to see what might be done to
15 change that.

16 So, with that as sort of a backdrop, what you find
17 in Appendix D is a series of questions that is designed to
18 say that, look, if we were to take a look at this question
19 of the authorized user and what he or she is or is not in
20 terms of today's practice, some interesting questions and
21 concepts come to mind.

22 For example, the first question is should training
23 and experience requirements be general or should they be
24 more specific to the user's intended use of licensed
25 material.

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 As you know, right now, on one hand, we look for
2 200 hours of didactic training. We are looking for
3 instrumentation and physics, radiochemistry, mathematics,
4 and so forth, of a general nature, radiation safety across
5 of the board of a general nature.

6 Is that appropriate or should there be some
7 adjustments in that level of training or the content of the
8 training or the breakdown in training for, say,
9 cardiologists as compared to somebody who wants to do a
10 broader spectrum of nuclear medicine?

11 Should it remain general in nature or should it be
12 more specific to the practice intended? That is the first
13 question.

14 MR. FRAZEE: Frazee from Washington.

15 In my opinion, the training and experience
16 requirements for radiation safety handling should be put on
17 the radiation safety officer and that responsibility. The
18 list of authorized users does not need to have that listing
19 in there for a couple of reasons.

20 MR. CAMPER: You are saying authorized users,
21 physicians would not necessarily need to be listed?

22 MR. FRAZEE: Right, the list of authorized -- you
23 can cite it better than I can -- but the different
24 categories of use that are listed in the back of Part 35,
25 whether it is diagnostic or therapy or whatever.

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 There are two reasons for that, for not bothering
2 to put that in there. One, in terms of Aubrey's question
3 the other day about what is the function, what is the
4 purpose of having an authorized user on the list or on the
5 license.

6 I interpret the authorized user as being that
7 individual who is responsible for directing the application
8 of radioactive materials to humans. That is the
9 responsibility end of it there.

10 It would be through many of the things that are
11 already listed in there, you know, establishing the criteria
12 for patient acceptance, writing a clinical procedures manual
13 for the diagnostic realm, writing the actual order that
14 causes an application of radioactivity to be administered to
15 a patient, but that is their function, that is their role.
16 They have the professional competence to do that sort of
17 thing.

18 With all due respect to your comments about
19 interfering with free trade or whatever, you know, I would
20 be happy to just say if you want to be an authorized user,
21 you have to be board certified, that's it. I mean that is
22 your professional group has determined that you have a level
23 of competence that we will accept that allows you to apply
24 radioactive materials to humans.

25 MR. CAMPER: You have an "or" category currently

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 in the State of Washington.

2 MR. FRAZEE: Oh, sure. The outcome would have to
3 be some sort of a grandfathering of people that are already
4 there, but by a date certain, you know, two years, three
5 years in the future, it is like that is it, you would have
6 to have board certification to be "the authorized user."

7 The flip side is that the radiation safety aspect,
8 which we are all saying, I mean that is what our role is, to
9 ensure radiation safety, well, it is the handling of the
10 materials, and the first thing to do would be to beef up the
11 training and experience requirements for radiation safety
12 officer.

13 What does it mean to be a radiation safety
14 officer? You know, the list starts out with certified
15 health physicist. All right. So, you have got some
16 high-powered individual who has a lot of specific radiation
17 safety training.

18 Then, it goes through and it lists some "or"
19 categories, and that would be an appropriate place to stick
20 in the training and experience types of considerations that
21 you would want to have for an authorized user who is
22 authorized to administer or cause the administration of
23 materials to patients, to at that point define, if you want
24 to be the radiation safety officer, which the license would
25 have to have one, you would have to have such-and-such

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 training

2 Now, it may be the stuff that you have just pulled
3 out of the individual areas, but the emphasis is the
4 radiation safety officer is that person who is responsible
5 for making sure that radiation safety is handled
6 appropriately and that anyone working under that license,
7 tech, janitor, whatever, has appropriate training.

8 That is already in the list of duties of radiation
9 safety officer. So, a lot of the things that we would be
10 concerned about are actually covered in other areas.

11 MR. CAMPER: Terry, let just interrupt you there.
12 You are answering a lot of questions.

13 MR. FRAZEE: Yes, I know.

14 MR. CAMPER: But with regard to this question
15 about general training versus training that is specific to
16 the intended use by that particular applicant, which way do
17 you tend to come down on that?

18 DR. GLENN: Make it more specific, a person who
19 does one organ imaging, does he require the same amount of
20 certified training as someone who does imaging --

21 MR. FRAZEE: If there is the distinction in the
22 handling of the material, then yes, it should be
23 appropriate, the radiation safety training should be
24 appropriate to the type of handling of the material that you
25 handle. Iodine is different than technetium, but if you

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 just dealing with a bunch of different technetium isotopes,
2 I mean it is all the same, whether it is cardiologist or
3 nuclear medicine clinic where they are only doing
4 technetium. It doesn't matter. I mean it is the same thing
5 that is going on. You are dealing with spills, you are
6 dealing with some exposure.

7 Therapy, of course, you have got larger dose
8 rates, so you have got to have maybe a little bit more
9 emphasis on shielding, and so forth. So, yes, there would
10 be some specific additional training, but it would be for
11 the handling of the material, nothing to do with the
12 clinical aspects or anything like that.

13 DR. GLENN: Where I am having a little difficulty
14 with this concept is if we went to board certification, but
15 let's say that a cardiologist is board-certified in internal
16 medicine, would that qualify them to direct the application
17 of radioactive material to a human being?

18 MR. FRAZEE: Right, it depends on what is in the
19 board certification, but I guess from my perspective that is
20 not my problem, that is the medical community's problem.

21 DR. GLENN: But if we have a regulation that
22 requires a certification, how do I determine which
23 certifications to put on that, that is my question.

24 MR. CAMPER: It is our problem because we are the
25 ones who grant the authorization to possess and use

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 radioactive materials, so it is our problem.

2 MR. GODWIN: Godwin, Arizona.

3 I am going to approach pretty much the same thing
4 and see if the two of us can't get together on our answer
5 here. I tend to think that particularly for the clinical
6 part of it, it should be the boards. The boards ought to be
7 the ones primarily doing it.

8 Legally, we may have to have an "or" in there, but
9 I would hope in actual fact the boards are primarily the
10 ones that are doing it. I would have no problem, say, if
11 there is a board of cardiology, as a part of that board they
12 required a certain amount of nuclear safety -- or clinical
13 work I should say. That makes sense.

14 To the extent that they may have to use or deal
15 with leaking connections and things in the administration of
16 the material to the patient, there should be enough
17 information in that certification to handle that part of the
18 issue, or as sort of an alternative we may have to have like
19 a 40- or 50-hour training course as opposed to the 200 that
20 we are talking about now.

21 Certainly, the physician would have a lot less
22 unless he is going to be the radiation safety officer. If
23 the physician is the radiation safety officer, he would need
24 an appreciable amount. He needs to learn all the regs, know
25 what all is going on.

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 It seems to me that we may want to put on the
2 licenses the radiation safety officer as a separate unit,
3 and we may want to redefine away from authorized user and go
4 more to prescribing physicians, list a radiation safety
5 officer, and list the technicians more as authorized users
6 with regard to preparing and handling individual doses.

7 He would be an authorized user to the extent that
8 he is drawing up the doses into needles and perhaps actually
9 injecting into the patient, but not the authorized user as
10 far as a prescription.

11 That would be strictly a function of the
12 prescribing physicians, and those physicians who are charged
13 with that responsibility are the ones we have got the
14 training records on, not every physician who happens to
15 refer somebody down there. They would have some
16 responsibility to look it over to make sure that it is
17 appropriate.

18 I think that will address most of the questions
19 you have looked at, in that we are looking at board
20 certification to generally qualify the prescribing
21 physicians, perhaps with a supplemental training of somewhat
22 of a minimal nature, with a rather extended course for the
23 radiation safety officers, and that could either be the
24 physician or an appropriately trained technician could serve
25 as a radiation safety officer, and then have our

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 technicians, who would have the appropriate board
2 certification for them.

3 I think it is important that they would be
4 appropriately board-certified to be the practicing
5 technician.

6 DR. GLENN: I think maybe it is appropriate at
7 this point, so that we can weigh the two solutions, let me
8 try to describe for you what the ACMUI recommended to us.

9 What they recommended was that a physician should
10 have clinical experience with patients that have radioactive
11 material in them, and that there should be some sort of
12 preceptoring process, somewhat similar to what we have now,
13 but this preceptorship would serve as a ticket to an
14 examination.

15 Now, this examination could be part of the board
16 certifications that we already recognize or it could be an
17 independent exam, and they informed us that we could have
18 the Board of Medical Examiners develop a test that we
19 approve.

20 So essentially, they were suggesting what we do is
21 have a requirement about how much training a person has to
22 go through, what topics, and that someone signs off that
23 this person is ready to treat humans with isotopes, and that
24 then is their ticket to take this exam. If they pass the
25 exam, then they are qualified as a prescribing physician.

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 MR. GODWIN: I had envisioned perhaps a little
2 less government involvement. I would have the
3 certification, I would have successful completion and have
4 the preceptor sign off that they successfully completed it.

5 It sounds like a modification of the Texas
6 radiography type situation. Quite frankly, you know,
7 philosophically, you may have a tough time dealing with the
8 fact that we are requiring people to have an elaborate
9 training program and pass an exam before they can expose
10 radiation to p pe, but we don't do the same thing for
11 humans. So, there is some thought there you need to think
12 about.

13 MR. TEDFORD: Tedford, Alaska.

14 I would just like to share some experiences with
15 you and past visitations in the field. Most of the nuclear
16 medicine physicians trained in this country today, initially
17 were trained at the National Naval Medical Center at
18 Bethesda, the key individuals who have resulted in people
19 who are now board-certified nuclear physicians, if you
20 will. This went on over a number of years. I don't know
21 whether the course is still ongoing now, but the course
22 encompassed four weeks, and in the course they were taught
23 mathematics because they had a very poor understanding of
24 mathematics initially when they came in.

25 They were taught radiobiology, they were taught

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 biophysics, they were taught dosimetry, they were taught
2 safety, they were taught shielding, they were taught all the
3 general aspects, and they also are required to have a
4 preceptorship, a preceptorship for the particular types of
5 patients that they desire to be involved in afterward, and
6 that preceptorship had to be under an individual who had
7 done these tests and who had been accepted by the boards in
8 paths qualified to do so.

9 So what you have is a melange or a mixture, if you
10 will, of the general aspects that you have spoken to and the
11 specific training that is involved. You have four
12 specialties involved in this field principally. You have
13 cardiologists who have come in recently. Initially, you had
14 radiologists, you had pathologists, and you had internists.

15 The radiologist started off in the field
16 initially. They brought the internists in because of their
17 diagnostic capability, and there have been boards that have
18 been established all the way down this line.

19 What Aubrey said is to the heart of the matter,
20 let the people who are in the specialties tell you what it
21 is that they need to know, because regardless of what you
22 sit on the boards, they are going to ask these radiation
23 safety questions, they are going to ask about dosimetry,
24 they are going to ascertain that these physicians know what
25 they are doing.

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters

1612 K. Street, N.W., Suite 300

Washington, D. C. 20006

(202) 293-3950

1 It is this other side group that you are looking
2 at that you are going to bring in. and the final judgment in
3 this case, in all cases, is a group of physicians who can
4 sit and look at the qualifications of individuals you have
5 questions on, and they will tell you the truth, believe me.

6 The qualifications for the pathologists were not
7 nearly as great or as restrictive because they were dealing
8 mainly in in-vitro type situations, and so they had a much
9 reduced schema.

10 In summation, they need to know the whole field to
11 a certain extent because the boards are going to ask these
12 questions of them.

13 MR. GODWIN: Godwin again to expand a little bit
14 on my answer.

15 When you look at therapy, you will have to have a
16 much closer coordination to make sure that they do get all
17 of the brachytherapy, teletherapy, and radiopharmaceutical
18 therapies appropriate in their internship or whatever to
19 qualify for the boards and make sure that is either to get a
20 full certification, you know, for everything, that is one
21 thing, to get a limited -- we might have to recognize some
22 sort of limited certification, for example, where they are
23 using strontium-90 for eye for the ophthalmologists.

24 Those kind of certifications we can probably get
25 with the boards and get them out, but I think it would be

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 best if we can work through a board in some way.

2 MR. CAMPER: The next question was very much of a
3 related question, but yet somewhat different, and that is,
4 are the current criteria necessary, that being -- let's
5 focus upon the "or," the 200 to 500, and the 500, given that
6 board certification I think most of us would agree is very
7 positive and good.

8 Are the current criteria necessary if the
9 physician does not bear the primary responsibility for
10 radiation safety? If needed, could the training and
11 experience requirements for a physician user not seeking
12 authorization to supervise radiation safety programs be less
13 than the current criteria?

14 In other words, if you want to be an authorized
15 physician user, but you don't want to be the radiation
16 safety officer or to be responsible for the radiation safety
17 supervision, could the training criteria be less, could the
18 200 to 500, and the 500 be less under that scenario?

19 MR. FRAZEE: Is that for a certified?

20 MR. CAMPER: No, no.

21 MR. FRAZEE: A non-boarded individual?

22 MR. CAMPER: Right, non-boarded, may be boarded in
23 something other than nuclear medicine or one of the board
24 certifications currently listed in Part 35, could be
25 board-certified in cardiology, for example, or neurology,

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters

1612 K. Street, N.W., Suite 300

Washington, D. C. 20006

(202) 293-3950

1 but the point is they want to be an authorized user, but
2 they are not going to be responsible for radiation safety
3 supervision.

4 Could the training be less than the current
5 criteria?

6 MR. BAILEY: Yes.

7 MR. CAMPEP: There is a firm answer.

8 MR. BAILEY: I will give you the example of a guy
9 who is a certified health physicist, who didn't have that
10 criteria, who went back to medical school, and I would hope
11 to heck that he could be an RSO when he got out of medical
12 school at a small hospital.

13 I am agreeing with the people that say that the
14 RSO duties probably should be looked at separately from the
15 clinical duties. I think most of our problems with hospital
16 health physics programs have been where the physician was
17 the RSO and the program was a little bit too big for him to
18 manage, and not big enough to have a professional health
19 physics staff, if it is a small program, yes.

20 But honest to gosh, it is really a waste of talent
21 in my opinion to have a board-certified nuclear medicine
22 physician doing film batch reports and all this other stuff.
23 I mean you can hire us a lot cheaper, and probably we are
24 more interested in it than the physician.

25 I mean they like people, some of them, and let's

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 get them to doing what they have spent most of their lives
2 trying to learn how to do, and that is be a doctor, and
3 concentrate on putting requirements for the RSO, and if they
4 come together, fine, if they don't, fine.

5 MR. FRAZEE: Frazee again.

6 If the State Board of Medicine in their judgment
7 allows a physician to do nuclear medicine activities, then
8 far be it from me to tell them that he can't.

9 DR. GLENN: Okay. That's any physician.

10 MR. FRAZEE: Okay, but this is the State Board of
11 Medicine.

12 MR. CAMPER: But they license them to practice
13 medicine, Terry, they don't license them to practice nuclear
14 medicine.

15 MR. BAILEY: Bailey from California.

16 I think this may be the crux of why we are having
17 problems. We are licensing them to possess and use
18 radioactive materials. Now, they have to get a license from
19 us to do that. That is in addition to whatever medical
20 license. It is not unlike their whatchamacallit license --
21 narcotics license. There is a separate license for that.
22 It is a hazardous material sort of and so is this.

23 I can't agree that we just let them go.

24 DR. GLENN: I think the real question is for a
25 person who is going to direct the application of radioactive

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 material to a human being, is there some minimum amount of
2 radiation training they need. I see Ed saying yes.

3 MR. FRAZEE: That sounds pretty good. I guess
4 back to the philosophical aspect of this whole thing, we
5 have issued a license to an institution, and they have got a
6 qualified radiation safety officer, and this authorized user
7 that we are now talking about isn't going to touch
8 radioactive materials, not going to handle it at all.

9 The only thing he is going to do is select the
10 patient, prescribe, direct that radioactive materials be
11 administered to a human, and I am not sure that that is not
12 so far out of line.

13 MS. MILLER: And interpret the scans.

14 MR. FRAZEE: Oh, yes, and interpret the scans. I
15 mean, okay, he does all those great things that we say they
16 do.

17 DR. GLENN: I think it focuses better if you think
18 about a brachytherapy program.

19 MR. GODWIN: It seems to me that indeed, as I
20 discussed earlier, that we do have a certain responsibility
21 ala the patient for the patient's radiation safety, and
22 there is a little glitch relative to comparing it with other
23 sources of radiation where there is no one that has that
24 direct responsibility at the federal level.

25 Because of that, yes, I would say that NRC had

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 some responsibility to assure that there is some reasonable
2 degree that the material is given at the proper time, at the
3 proper set of conditions, which implies that, yes, they need
4 some minimal training to determine what those are.

5 There may be some procedures in the future that
6 use such a very minimal dose that you may say that that is
7 such a minimal risk that you might want to go back to a
8 general license, so that any physician can do it, as you had
9 with this other general license that you ended up with
10 nobody producing the drugs for.

11 Therefore, I would not want to be on the record
12 that from now on that you would have to be board-certified
13 in something, but I do think that it might be appropriate to
14 at least have the concept available that at some point,
15 where the dose is below some level, perhaps you would want
16 to consult with FDA on what an appropriate level is, or EPA,
17 or somebody like that, that you might make procedures of
18 that type open to any physician.

19 But, in general, from what I know about the doses
20 currently, the procedures currently, I would say board
21 certification would be the appropriate way to go.

22 MR. BAILEY: Ed Bailey from California.

23 We do test doctors and certify doctors to use
24 x-ray equipment. You must have a permit from the state if
25 you are an M.D. to operate or supervise the operation of an

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 x-ray machine, and that involves a safety test which they
2 just take on radiation safety and the regulations.

3 The only people that sort of duck out of that are
4 board-certified radiologists. So, you can always set up
5 some system that addresses the problem, and if you get the
6 board to handle the questions, then you don't have a
7 problem.

8 MR. CAMPER: Let me ask a question, then, and
9 respond by a show of hands.

10 If an authorized physician user is not going to
11 have responsibility for radiation safety supervision, how
12 many of you, by a show of hands, would agree that the
13 training could be less than our current requirements?

14 MR. GODWIN: What part of the current training?

15 MR. CAMPER: Two hundred, 500, and 500 in no less
16 than six months.

17 MR. GODWIN: The 200 could be less, but I am not
18 sure about the others.

19 [A show of hands.]

20 MR. CAMPER: I am seeing eight hands.

21 How many feel the current training is sufficient,
22 it is appropriate?

23 [A show of hands.]

24 MR. CAMPER: Four hands.

25 MS. ALDRICH: Rita Aldrich, New York State.

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters

1612 K. Street, N.W., Suite 300

Washington, D. C. 20006

(202) 293-3950

1 One of the things upcoming is the changes to the
2 pharmacy type regulations. Now, as I understand it, you are
3 going to be allowing deviations from the package insert.

4 MR. CAMPER: Yes.

5 MS. ALDRICH: That to me seems that we need to go
6 in the direction of more training, not less. I don't care
7 whether this person is a radiation safety officer or not, to
8 make judgments in that area, they certainly need some
9 minimal amount of training in the physics concepts. If they
10 change the route of administration, they can't rely on the
11 package insert for dosimetry.

12 The other thing that seems to be complicating this
13 is the RSO function. In hospitals that don't have health
14 physics staff, only techs and doctors, we require that it
15 has to be an M.D. who is the RSO. It is a question of
16 authority. A technician can't tell a doctor what to do.

17 The doctor can delegate everything, but remains
18 responsible for seeing that these things get done. The main
19 problem we see with small programs that are not effective is
20 they don't purchase enough consulting physics support, and I
21 really think that that is where the problem is.

22 One of the things we have done with hospitals
23 where performance is really bad is require them to get a
24 consultant in to set up their program for them -- we are not
25 going to do it -- and then to maintain an adequate level of

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 consultant support after that.

2 We don't do that alone, of course, because the
3 Joint Commission requires the same thing, so again there is
4 more than one agency pushing toward the same goal.

5 MR. CAMPER: I think we have done as much as we
6 can do on that one.

7 The next one is, is the training and experience of
8 an authorized user physician sufficient to qualify him or
9 her to be an RSO? Again, we are talking about the "or"
10 category, the 200 to 500, and 500.

11 Is it sufficient to qualify them as an RSO? Any
12 thoughts on that?

13 MR. GODWIN: Godwin, Arizona.

14 I think the question there turns upon the quality
15 of the 200 hours. Two hundred hours spent somewhere going
16 and playing golf is a lot different than 200 hours in
17 laboratory class, classroom work, and things like that.

18 I think the real crux of our problem is I don't
19 know of anyone who really knows what they get for sure in
20 the 200 hours or where good, approved courses are. So, with
21 that in mind, I think we need to look at the quality and
22 subjects covered before we can make an informed decision.

23 DR. GLENN: Again, one of the suggestions of the
24 ACMUI was the exam, which sort of says, okay, we can't be
25 there every time they give the course, but if the course

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 included these topics and these people say they took the
2 course work and they can pass the exam, that is sufficient.

3 MR. GODWIN: Well, I prefer the exam over existing
4 for a year or two and then taking over.

5 MR. CAMPER: They also suggested to us that we
6 might look at existing licenses and status of the RSO's to
7 determine whether or not there really is a problem.

8 MR. GODWIN: Getting out or approving courses may
9 be another way, and have a required exam, and then
10 occasionally having someone sit in on that might be a good
11 way to do it. There are all sorts of alternatives to this
12 system that may not be quite as expensive as giving an exam
13 and proctoring exams.

14 MR. CAMPER: Right. You have led us right into
15 the next question. It has your footprints all over it,
16 Aubrey.

17 Should NRC become involved in monitoring the
18 adequacy of consultant radiation safety courses, these
19 200-hour programs, residency programs, and board
20 certification courses as they relate to radiation safety?
21 Should we monitor them or, in fact, with regards to the
22 200-hour courses, should we put in place some approval
23 mechanism for them?

24 Any thoughts on that? I think we know where
25 Aubrey stands on that. Any other opinions or thoughts on

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 that?

2 [No response.]

3 MR. CAMPER: We often hear of these 200-hour
4 programs, particularly the ones provided by consultants.
5 There are a number of people who criticize them.

6 I think they raise questions like do they really
7 spend 50 hours in a weekend doing this, what is the quality
8 and caliber of the instructors, is there any feedback
9 mechanism in place to determine that the physicians, in
10 fact, completed the course satisfactorily, is there testing,
11 for example.

12 We have some of the same kinds of concerns, and we
13 have had some thoughts about going out and perhaps
14 monitoring some of these courses, and we would probably also
15 monitor some of the residency programs by using Dr.
16 Pollycove in particular to help us with that.

17 Any other thoughts other than what Aubrey has
18 already expressed about this?

19 MR. FRAZEE: It is kind of like the bottom line
20 is, you know, is it working, is there really a problem, how
21 are all the physicians doing once they are really out in the
22 field as far as whether or not their training has been
23 adequate or not.

24 If you do get into monitoring -- and I agree that
25 would probably be a nice thing to do -- you need to have

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 some way to get it into a national database, so we would all
2 have access to it and perhaps other states could monitor
3 programs in our own states and add to that database.

4 It would certainly avoid some duplication of
5 effort and streamline the evaluation process by the license
6 reviewer, wouldn't have to go through line-by-line their
7 training experience if there was this database.

8 I am not firmly convinced that we have to monitor
9 these programs, but if we do, provide the information
10 because we probably could make use of it.

11 MS. ALLEN: Allen, Illinois.

12 Isn't there an STIS database already for training?

13 DR. GLENN: That is correct. We have been very
14 careful, though, to always say that that is not an approval
15 process, in other words, that that means at one point in
16 time a reviewer has reviewed the course syllabus and the
17 method that the teaching group uses to ascertain the
18 effectiveness, and has found that acceptable for licensing
19 purposes, but there is no warranty that that program has
20 remained the same, there is no periodic checking, so I would
21 not call it an approval process.

22 MS. ALLEN: Well, we have been inundated with
23 requests from consultants with videotapes and disks that
24 expire on a certain date, and all kinds of things, looking
25 for approval for these training courses, for everyone from

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3930

1 hospital security to physicians. Maybe we need some sort of
2 uniform guidance document.

3 DR. GLENN: That is why we are asking these
4 questions. I think technology is going to say that if you
5 don't require that the training be received in a residency
6 program and through board certification, the number of
7 different ways that people are going to be able to get
8 training is going to be immense.

9 MS. ALLEN: Well, maybe it can be patterned after
10 like the sealed source and device evaluation. There is
11 uniform guides for evaluating whether or not they are any
12 good, they go on a database, they can pay -- I don't know --
13 some annual fee or some sort of an annual review, whether or
14 not they have been changed or updated.

15 They can be charged a fee for our evaluation time.

16 DR. GLENN: I have to admit my bias. My bias is
17 towards this exam because it gets us out of that business,
18 and I would rather say that there is an examining
19 organization, I know the quality of the exam they give, and
20 I don't have to worry about the quality of everybody who
21 trains someone to take that exam. It is easier.

22 MR. CAMPER: We have some more questions about
23 physician training and experience, but I think, in view of
24 our time, we will jump to another area of training to try to
25 get some of this on the record, as well.

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 Since technologists perform the majority of
2 isotope handling, should there be a minimum level of
3 training and experience requirement for technologists who
4 use byproduct material for diagnostic and/or therapeutic
5 procedures? Your thoughts, please.

6 MR. BAILEY: Yes, sir. There should be a
7 certified nuclear med tech licensed by the state.

8 MR. CAMPER: Let's say they are not -- now, we are
9 the regulators -- what would be that minimum level of
10 training that they should have, that we would require them
11 to have?

12 MR. BAILEY: Equivalent training to that.

13 MR. CAMPER: Equivalent training to that. Other
14 thoughts?

15 DR. GLENN: Again, I will mention that the ACMUI
16 advised. It was very similar. They said state registration
17 or certification. However, in a state that does not
18 register technologists, they told us to keep out of it.

19 MR. CAMPER: Right, they did.

20 MS. ALDRICH: Rita Aldrich, New York State Health.

21 A few years ago we amended our code because we
22 knew all the nuclear med techs were out there injecting, and
23 we had always said they couldn't. State Education said they
24 couldn't, but State Education didn't want to license them.

25 So, we amended the code to say that only techs

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 with certain qualifications could inject because that was
2 sort of an end run to beef-up their qualifications, and it
3 is board certification -- well, yes, it is called board
4 certification -- the AART or the NMTCB, or completion of a
5 CAHEA-approved program, which really boils down to
6 completing a program licensed by the New York State
7 Education Department.

8 They need not necessarily take boards, but they
9 are foolish if they don't, but either one of those
10 mechanisms allow them to inject.

11 What we are doing now is expanding that in
12 licensing to say if you have a generator, you are not going
13 to use unit doses, also has to be a certified tech, and if
14 you are going to use PET pharmaceuticals, things that are of
15 greater hazard, in the licensing process we are requiring
16 that those same qualifications apply.

17 MR. CAMPER: As I understand it, there are some
18 states that require that there be a certified technologist
19 licensed by the state in the states that do do licensing, or
20 if they have an individual that has not met that criteria,
21 that training has to be considered on a case-by-case basis.

22 Are there other states that have that requirement,
23 in other words, either you must be a certified and licensed
24 technologist, and if you do not meet that criteria, then you
25 must have some training and experience which is reviewed by

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 the state? There are other states, I understand, Arizona or
2 Alabama?

3 MR. GODWIN: Arizona.

4 MR. CAMPER: Arizona. Okay. Any others?

5 MR. FRAZEE: State of Washington. We have a
6 voluntary certification for technologists, so therefore, no,
7 we don't have a requirement for registered techs.

8 I am going back to what I think I was proposing
9 earlier. The emphasis should be on the radiation safety
10 officer and Part 19. You have to provide adequate training
11 for your workers.

12 Now, what constitutes adequate training may come
13 into play here, but again, that is why it is important to
14 have really adequate training for the radiation safety
15 officer, one of which should be how to train his
16 technologists.

17 MR. CAMPER: During our meeting in Atlanta there
18 was a fair amount of talk, and there were some suggestions
19 that perhaps this idea of having an authorized user listed
20 on the license and being only a physician is something we
21 should consider abandoning, and that perhaps we should have
22 physician-authorized users, as well as other authorized
23 users, for example, technologists, if you will, who are
24 handling the materials as a matter of routine.

25 In answering these questions, what are your

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 thoughts about that, as well, in terms of listing the
2 authorized user under a certain category, physician user,
3 and/or listing technologists as yet a distinct and different
4 category of authorized user?

5 MR. TEDFORD: Tedford, Alaska.

6 I wasn't going to speak to that question, but as
7 long as I am up here, I will.

8 MR. CAMPER: Okay.

9 MR. TEDFORD: I think, if you look, authorized
10 user has to be a physician.

11 MR. CAMPER: That is correct.

12 MR. TEDFORD: You might get into the problem of
13 practicing medicine in particular states, the way they may
14 interpret the law. That is my comment on it, for what it is
15 worth.

16 I would like to digress for a moment on these
17 courses that are given for qualification of individuals who
18 are not board-certified to practice nuclear medicine, if you
19 will, and some of the courses are given across the country.

20 Some of these programs in various states who
21 certify x-ray technicians, nuclear medicine technicians,
22 look at qualifications, et cetera, also have other
23 categories of qualified individuals, like practical
24 technologists.

25 To do that, they must establish a course or a

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 criteria for that course, a certain number of hours that the
2 subjects will be given, et cetera. They usually will send
3 their people from a board to go out and to visit and to
4 check on these schools to see what they are actually giving
5 and that they do meet these criteria.

6 I think that is what is needed in the case of your
7 people who are nuclear medicine, as well. Some sort of
8 check should be performed to ascertain the quality, the
9 quantity, and what is actually being given in some sort of
10 an established criteria course.

11 MR. BAILEY: Bailey from California.

12 I would suggest exploring the use condition that
13 says by or under the supervision of Dr. so-and-so, or I
14 would say in our case, by or under the supervision of Dr.
15 so-and-so, users under the supervision must be certified
16 technologists, or whatever, very similar to what you do in
17 some of the broad-scale licenses or big licenses that are
18 not true broad licenses with 3 to 83, and all that, where
19 you allow people to work under the supervision of somebody.
20 Otherwise, you are going to be adding names all the time.

21 MR. GODWIN: Godwin from Arizona.

22 I made a suggestion a while ago, I would stick by
23 it. It is not unanimously agreed to by the states around,
24 but I think it is one approach.

25 An alternative may be to put the criteria in the

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 regulations and say that people who meet those criteria are
2 indeed authorized users, so you wouldn't have to put names
3 on the license, and the inspector would simply have to check
4 to see if everybody meets that qualification.

5 However, then you run into the little problem of
6 what happens if they have lost their certification or what
7 happens if they have malpractice, and all those kinds of
8 ramifications. There are several approaches to it.

9 But I think it would be good to clearly have the
10 radiation safety officer spelled out on the license. I
11 personally like the idea of the physicians being listed as a
12 prescribing physician -- I think that is more in line with
13 what he actually does -- and the technologist listed as a
14 user, authorized user, preparing user, or whatever you want
15 to call it, because that is more in line with what they do.

16 The comment could be made if you go that route
17 that, well, you have taken away the responsibility of the
18 physician for the overall operation of a radiation safety
19 program in the hospital.

20 There are a fair number of hospitals where the
21 physician is technically an independent contractor, is not
22 an employee of the hospital, and really has no legal
23 association with the employees except by whatever the
24 hospital assigns to him, so hospitals are responsible
25 anyway, so I don't see where that would make a whole lot of

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 difference.

2 If it is a private physician operation, he will be
3 the named licensee, and the licensee is responsible. So, I
4 think you can at least explore that some. I am sure there
5 are some other legal questions that should be raised about
6 that.

7 MS. ALLEN: I have a bunch of answers for you.

8 MR. CAMPER: Great.

9 MS. ALLEN: First of all is yes. Second, we have
10 technologist accreditation in our state. If you don't keep
11 your accreditation up to date, you are fined.

12 DR. GLENN: A clarification on that. You have it
13 in your state. If NRC licenses users in a state that does
14 not do that, should we assume that function?

15 MS. ALLEN: Okay. The problem is what you should
16 do is contact other states that do have technologist
17 accreditation rules, see what they are, see if there is any
18 common ground, see if you can come up with a commonality
19 before you delve into that, because I don't know if every
20 state would want to do what we do, because we cover both
21 x-ray and materials, and you guys of course don't believe in
22 x-ray -- I mean recognize x-ray, sorry.

23 If you have someone other than a physician as an
24 authorized user, I have to bring up Rita's point again. You
25 are already going to potentially authorize deviations from

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 the package insert with approval by an authorized user.
2 Does the technologist at that point have the experience to
3 be able to deviate?

4 DR. GLENN: We would be sure not to do that. I
5 mean if we changed definition of authorized user, then we
6 wouldn't allow authorized users to prepare or compound or
7 whatever you want to call it. We have to make sure we are
8 consistent there.

9 MS. ALLEN: And something to keep in the back of
10 your mind, not all RSO's live at the hospital. Some are
11 consultant RSO's that travel across many miles, some are
12 just a physician or so that share between many hospitals,
13 and some of the things that I have heard don't really jibe
14 with consultant RSO's or physician RSO's shared among many
15 facilities.

16 MR. CAMPER: Let me see if I can try to wrap this
17 particular one up. What I think I am hearing is something
18 like the following. I think most of us would agree that
19 certified technologists is optimal, licensure by states is
20 optimal, but in those cases, from a public health and safety
21 standpoints, as regulators charged with protecting public
22 health and safety from the use of radiation, we would tend
23 to agree that there should be some minimum level of training
24 and experience, absent licensure or certification by the
25 state, for technologists that are handling radioactive

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 materials for diagnostic or therapeutic uses.

2 Is that fair, yes?

3 [A show of hands.]

4 MR. CAMPER: I see a few hands. Okay. Does
5 anyone disagree with that? Rita?

6 MS. ALDRICH: What I said before is we are tying
7 it to the function. What do you mean by handling? If you
8 have a private office where you have nothing but unit doses,
9 and the physician does the injections, and you have a tech,
10 but the tech doesn't do very much, maybe calibrates, there
11 aren't enough of these people to go around. There aren't
12 enough certified techs to do this.

13 We thought about trying to factor this in, and we
14 decided we would start with generators because nobody should
15 be handling a 2-curie generator without some demonstrated
16 training and experience that has been tested. I think
17 certification is the only way to go on that.

18 I don't think there is anything much else besides
19 certification that we would want to do on a state level. We
20 already have basic requirements, as was said before, for
21 training of employees. I think you can get into a lot of
22 trouble about just what it is this person does that requires
23 some level of training and experience.

24 The reason the State Education Department hasn't
25 licensed nuclear medicine technologists is the fear that

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 there would not be enough people to go around. What we are
2 encouraging those techs to do is to get certified, you know,
3 cross-trained x-ray techs that are licensed. New York State
4 does license x-ray techs, get certified, you know, be
5 prepared, because it is in essence rationing, but there has
6 got to be a point at which you would say no, this person
7 doesn't need it, you know, I mean what exactly are they
8 doing. You use unit doses, I mean what is this person
9 involved in.

10 MR. TELFORD: Telford, NRC.

11 I would just to provide a clarification for the
12 record. In the draft rule language that we gave out at
13 noontime today, under 35.100, 35.200, and 35.300, for those
14 persons that would either be doing or authorize a departure
15 from the package inserts, as Kathy and Rita alluded to,
16 would be two types of persons.

17 One would be the authorized nuclear pharmacist,
18 and the second would be a physician who is an authorized
19 user, who also meets the training requirements of 35.920.
20 That is the requirements that Larry has been talking about
21 today, of the 200, 500, and 500 hours.

22 It is only that physician, not the physician that
23 qualifies under 35.100 or 35.300 -- I am sorry -- 35.910,
24 35.930. Only the physician that qualifies under or meets
25 the requirements of 35.920 would be allowed to make the

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 departures or direct the departures.

2 Therefore, as Dr. Glenn has pointed out, if we
3 make a change in definition of authorized user, we would be
4 sure to carry that through.

5 MR. CAMPER: Thank you, John.

6 A little bit different type of question. Should
7 the NRC require the physical presence of a qualified
8 radiation supervisor, that being a physician, a physicist, a
9 pharmacist, or a technician or a technologist, at all times
10 when byproduct material is being used?

11 I see Aubrey nodding in the affirmative. I think
12 Ed is nodding in the affirmative. Any other thoughts or
13 feelings about it?

14 DR. GLENN: Any negatives?

15 MR. GODWIN: I think you need to stress that any
16 one of those present would be adequate. I do not see a need
17 for necessarily a physician to always be present, and I
18 would limit the definition of use, that after a patient has
19 received a dose by injection, that going back to the room
20 would not be part of it, spending the night, for example,
21 and things like that, would be under normal hospital care or
22 with special instructions if it is a therapeutic dose.

23 MR. BAILEY: I would agree with what Aubrey said
24 with one exception, that physician, user physician,
25 authorized physician should be present in the room when

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 therapeutic doses of liquid iodine or therapeutic doses of
2 iodine are administered orally over 30 millicuries.

3 MR. CAMPER: Any other thoughts? Rita, did you
4 have a thought?

5 MS. ALDRICH: I am not sure I understand the
6 question directly. Are we talking about supervision from a
7 radiation safety standpoint, RSO-type functions? We made a
8 change to our regulations last fall that defined radiation
9 safety officer qualifications for both x-ray and nuclear
10 medicine, because they hadn't been really clear before.

11 We put in there a requirement that for radioactive
12 materials programs, the radiation safety officer has to be
13 present 50 percent of the time when materials are in use,
14 but the way we are interpreting that is in nuclear medicine,
15 during the period, the time of the day when doses are being
16 prepared and/or administered, because under -- I digress --
17 but under our allowance for technicians to inject, there is
18 a supervision requirement.

19 It is under the supervision of the physician on
20 the premises, doesn't have to be in the room, but has to be
21 on the premises.

22 With the rising problems, we have blood-borne
23 disease transmission, we are falling back on that more and
24 more. The physician has to be present anyway, so if it is a
25 one-man office, you know, we have pretty much tied him to

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 the premises if the technician is injecting, at least while
2 the technician is injecting.

3 If we are only talking about the radiation safety
4 officer, whether that is the physician or it isn't, the
5 person has to be present 50 percent of the time when
6 materials are in use, because our approach is that if that
7 person is responsible for radiation safety during handling,
8 they have to be there when the handling is going on or they
9 are not going to know whether or not people are complying
10 with procedures.

11 DR. GLENN: I think this question was probably
12 more generated by what I will call the circuit-rider
13 syndrome, where in a fairly remote area there will be a
14 group of physicians and maybe actual presence at the
15 facility by the physician is one day a week, and the
16 question would be, well, it is unreasonable to say the
17 physician has to be physically present, but should we have
18 some person, be it an RSO or a technologist who has received
19 a certain amount of training, always present whenever
20 material is being used with the qualifiers that Aubrey has
21 suggested.

22 MR. CAMPER: We have very little time left. As
23 Vandy pointed out, we need to be out of here by 4 o'clock,
24 so let me ask just one more question. I am sorry.

25 MR. GODWIN: If I could expand just a little bit.

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 MR. CAMPER: Absolutely.

2 MR. GODWIN: There is a corollary question that
3 wasn't asked, do you want to require the nuclear medicine
4 physician or the authorized user physician to be within some
5 travel time from the hospital or wherever it is being
6 administered.

7 We had at one time physicians in Texas prescribing
8 in Alabama. They were legitimate licensed Alabama
9 physicians, but they lived in Texas. That did cause us a
10 little problem.

11 It seems to me you would want them within an hour
12 or so of the facility in the event something happened, some
13 sort of reaction happened where the other physician could
14 probably take care of the reaction, but you would like for
15 them to work with any radiation-related problems.

16 However, if they are not the radiation safety
17 officer, you maybe can get away from that, so you ought to
18 consider that as part of your work-up.

19 MR. CAMPER: Assuming the medical institutions
20 were following the criteria in Part 35 for physician
21 training and experience, should NRC rely upon medical
22 institutions to review the training and experience of
23 physician, authorized user, or applicants, and make that
24 determination without notifying NRC?

25 In other words, we know that currently broad-scope

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 licensees can in fact review the training and experience
2 credentials of physicians, applicants who want to be
3 authorized users, and they maintain records that they have
4 conducted this review process within the Radiation Safety
5 Committee minutes, or something of the sort.

6 Should limited specific licensees, medical
7 institutions be able to do the same thing?

8 MR. GODWIN: Godwin of Arizona.

9 I can give you Alabama's answer. The Medical
10 Advisory Committee in Alabama said no, they want to review
11 the first time a physician came in to practice in Alabama,
12 after that, then the hospitals could review the limited
13 scope, but absolutely the first time they got licensed in
14 Alabama, they had to be reviewed by the medical committee.

15 MR. CAMPER: I see Vandy moving around back there,
16 and I know we are getting close to the time, so I think I
17 will stop asking questions, but I would like to make just
18 one more question of a general nature.

19 Is there some issue that we have not discussed
20 thus far or that you thought of in looking through the
21 Medical Issues Paper that you would like to put on the
22 floor, that you view as being very important, so we can
23 consider it further? Yes, sir.

24 MR. KASYK: George Kasyk, Department of Labor.

25 This is not only for medical, but for all the

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 other applications. If we require somebody to be present,
2 it does not necessarily mean he will see the application. I
3 think it should be clarified that he should witness the
4 operation, not just be present. He can be in another room
5 for a whole year, and never see anything.

6 MR. CAMPER: Okay. Any other general thoughts
7 about issues of importance?

8 MR. ZALOUDEK: Yes. David Zaloudek with
9 Louisiana.

10 I was wanting to make sure we are filling in all
11 the gaps, if there are any. You all may be familiar with
12 the task force on RSO's, and I was wondering if you could
13 give us a status report on where that stands for medical
14 facilities.

15 DR. GLENN: We plan to initiate that. It has,
16 unfortunately, been put on hold simply because the resources
17 of the Medical Section, Mr. Camper's section, have been
18 overstressed to the breaking point this fall.

19 We hope in the spring to actually activate that
20 task force and get that moving. The end product we hope
21 will be a new reg that will help answer some of those
22 questions that institutions are always asking us, well, how
23 many people should we have the radiation staff, how should a
24 radiation safety committee function.

25 We hope to do a rather in-depth look at that.

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 MR. CAMPER: Yes. I would only agree that we
2 think that is very important, and the new reg, when we
3 ultimately develop it, we think will answer a lot of the
4 questions about resources and duties and responsibilities,
5 and we are going to get back to that, we really are.

6 I do want to say one more thing, Vandy, if I may.
7 I think all of you know that Steve Collins has been serving
8 on our Advisory Committee for the Medical Uses of Isotopes
9 as the States' representative.

10 The staff recommended, and the Commission agreed,
11 that we should rotate Steve from the ACMUI, so as to allow
12 maximum participation by as many Agreement States as
13 possible, and the Commission agreed with that.

14 Consequently, we have out currently, published on
15 the 16th of October, a Federal Register Notice calling for
16 nominations of new members to the Advisory Committee on the
17 Medical Uses of Isotopes. It is calling for a States'
18 representative, a regulator, or someone with a states'
19 perspective on regulation.

20 I would encourage you, if any of you are
21 interested, to self-nominate or through your organizations,
22 to nominate individuals, so we may consider them for
23 participation on the ACMUI.

24 Steve has done an excellent job, giving us the
25 States' perspective, but we do really feel, and the

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 Commission feels, that we should try to get maximum
2 participation, so please bear that in mind, that the
3 nominations are open right now. I have extra copies of the
4 FRN if anyone would like to see it.

5 CHAIRMAN MILLER: It is now time for us to draw
6 this public meeting to a close. I had one program director
7 say to me that he has been in a program in one of our states
8 for over 30 years, and this is the first time NRC has ever
9 asked him for his opinion on something.

10 So, I certainly think we ought to salute Dr. Glenn
11 and his fine staff here today in this public meeting for
12 asking your opinions on a lot of different subject matters
13 today, and you certainly have given them some good input,
14 and you have not heard the end of any of these topics, I
15 will assure you, because I was just watching them writing
16 down these fabulous notes, but we have a good court recorder
17 over here to my right, so if they missed something, they
18 certainly can get it out of the record, and I am sure that
19 they are going to take all of your comments to heart.

20 I do want to further say, though, that this has
21 been a rather long week and some of the States have departed
22 already, so whenever you are getting these counts, just
23 remember that we did not have all 29 States raising their
24 hands on each of your questions. Keep that in mind.

25 Of course, we had some usual ones every time, and,

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 Aubrey, I certainly want to thank you for being right in on
2 everything that was asked here today.

3 [Laughter.]

4 CHAIRMAN MILLER: And your colleague, Ed Bailey,
5 Terry Frazee. I can depend on you all. I told them that
6 you all would definitely stay to the end, and you certainly
7 have done that, and I want to salute you for being able to
8 do that.

9 Now, I do have a couple of other comments to make.
10 During this week, we received a letter from the State of
11 Oklahoma, from the Governor, saying that they would like to
12 seek Agreement States status, and that is the kind of thing
13 we like to hear.

14 In fact, Oklahoma was here this week, at this All
15 Agreement States meeting, and we normally try to invite
16 those non-Agreement States to the meetings who have shown
17 some interest in becoming an Agreement State.

18 So, we found out that this is happening this week.
19 The letter is on the way.

20 There is also an announcement concerning the FFE3
21 meeting that was scheduled. That is the full-field
22 exercise. That has been canceled. You can appreciate all
23 the problems that FEMA is being faced with at this time,
24 such as the steel problems with the hurricane out of Miami,
25 Florida, et cetera, so they have their hands full, and they

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 didn't say when this is going to be rescheduled, but right
2 now it is off.

3 Now, I want to take this time to thank the various
4 program officials of NRC, especially NMSS and Research, for
5 their contributions to this public meeting today and for
6 their contributions in the two and a-half day All Agreement
7 States meeting, because without the other program offices'
8 support, this meeting would not have been as successful as
9 it was.

10 Certainly, I can't say enough about the Agreements
11 States themselves who really made a tremendous contribution
12 to the All Agreement States meeting, and you certainly added
13 immensely to this public meeting today.

14 I opened the meeting up this morning saying I made
15 a little boo-boo yesterday, and that was because I did not
16 mention Wayne Kerr as the new Chair for the Organization of
17 Agreement States. This morning I was trying to find him in
18 the audience, and he slipped my vision, and I didn't get a
19 chance to focus on him, so I said I would just deal with
20 this later.

21 So, that is what I really wanted to tell you, but
22 I certainly did not mean to slight Wayne Kerr yesterday when
23 I was talking about the relationship with the Agreement
24 States organization and talking about Dr. Mary Clark coming
25 in as the new Chair-Elect, but we have got a Chair already

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 that has got to perform for at least one year before she
2 moves in for her year. She is still here with us right now,
3 too, by the way.

4 I also want to again thank the State of Maryland,
5 Roland Fletcher, and his in-house staff. He is the only one
6 that is not here, but I see all of his staff members still
7 here. We are just delighted about that.

8 You certainly have been a great host for us for
9 this week, starting out on Monday and going right through to
10 the final hour of Thursday, and we thank the State for
11 hosting the annual meeting and this public meeting.

12 I would be remiss if I didn't say a few kind
13 remarks about the hotel, because the Sheraton of North
14 Baltimore here has really put on a good professional
15 atmosphere for us here at this hotel.

16 I can't think of anything that we can complain
17 about. The rooms were very nice, the people that are on the
18 staff did everything they could to make your stay very
19 wholesome, and we certainly want to commend this hotel for
20 making our week very successful.

21 Then, too, we have had two recorders, two court
22 recorders here this week, and you know, they work the
23 hardest because they must document everything that takes
24 place, and certainly I would like to thank the young lady
25 here to my right, and she can also pass that on to her

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters
1612 K. Street, N.W., Suite 300
Washington, D. C. 20006
(202) 293-3950

1 colleague who she replaced in the middle of the week. I
2 just want to say one word to them, we will certainly be
3 looking forward to the final report.

4 I think now that I have covered about everything
5 that I really wanted to cover, and the report of these
6 proceedings, both the All Agreements States meeting and the
7 public meeting today, will be placed in the U.S. Nuclear
8 Regulatory Commission public docket room for public access.

9 Now, before I close, there is always somebody that
10 needs to say one last word.

11 Is there someone that would like to say the last
12 word?

13 [No response.]

14 CHAIRMAN MILLER: If not, then, again let's give
15 this distinguished panel a big hand.

16 [Applause.]

17 CHAIRMAN MILLER: We call the public meeting to a
18 close at this time. It is now four minutes after 4:00.

19 [Whereupon, the Public meeting concluded at 4:04
20 p.m.]

21

22

23

24

25

ANN RILEY & ASSOCIATES, Ltd.

Court Reporters

1612 K. Street, N.W., Suite 300

Washington, D. C. 20006

(202) 293-3950

REPORTER'S CERTIFICATE

This is to certify that the attached proceedings before
the United States Nuclear Regulatory Commission

In the Matter of:

NAME OF PROCEEDING: Medical Issues Paper and Other
Regulation Issues

DOCKET NUMBER:

PLACE OF PROCEEDING: Towson, Maryland

were held as herein appears, and that this is the
original transcript thereof for the file of the United
States Nuclear Regulatory Commission taken by me and
thereafter reduced to typewriting by me or under the
direction of the court reporting company, and that the
transcript is a true and accurate record of the
foregoing proceedings.

Debbie Tallman

Official Reporter
Ann Riley & Associates, Ltd.